data_2mmt_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mmt _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.7 0 N-CA-C 110.608 -0.997 . . . . 71.3 110.608 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -160.69 8.01 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-O 118.63 -1.095 . . . . 63.13 111.88 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -113.02 40.91 2.2 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 117.9 0.85 . . . . 54.51 109.907 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.13 -146.93 4.46 Favored Glycine 0 C--N 1.354 1.533 0 CA-C-O 118.55 -1.139 . . . . 74.12 112.928 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -113.82 -22.98 9.89 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-N 117.559 0.68 . . . . 74.23 110.848 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -110.15 135.69 20.54 Favored Pre-proline 0 C--N 1.361 1.108 0 O-C-N 119.145 -2.222 . . . . 72.1 106.865 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.54 151.58 70.31 Favored 'Trans proline' 0 C--N 1.358 1.064 0 CA-C-N 123.709 2.36 . . . . 73.33 112.75 -174.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -83.39 -42.15 17.35 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 118.673 -0.68 . . . . 71.03 109.667 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -143.6 173.4 11.68 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.876 -1.059 . . . . 74.35 109.416 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -132.32 137.64 47.5 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-O 117.062 -1.447 . . . . 73.21 109.778 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.466 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -103.22 164.9 3.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-N 119.231 0.923 . . . . 73.41 111.172 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtp85 -76.74 29.51 0.13 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 75.14 110.911 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.65 4.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.743 -0.741 . . . . 70.21 112.463 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -116.11 -76.1 0.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 74.23 110.849 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -116.95 156.42 48.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.632 0.729 . . . . 74.43 110.915 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.79 178.26 7.48 Favored 'Trans proline' 0 C--N 1.365 1.428 0 O-C-N 118.133 -1.562 . . . . 74.04 110.238 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.5 mm -110.78 -57.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.909 0 CA-C-O 118.126 -0.94 . . . . 75.35 112.158 -172.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.1 p -100.86 176.31 5.33 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-O 117.79 -1.1 . . . . 62.43 110.017 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -140.3 -178.62 5.57 Favored 'General case' 0 C--N 1.358 0.948 0 CA-C-N 118.992 0.815 . . . . 73.21 112.178 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -70.15 -177.31 1.35 Allowed 'General case' 0 C--N 1.354 0.768 0 CA-C-N 118.587 0.63 . . . . 71.32 110.793 -168.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 109.986 -1.245 . . . . 70.24 109.986 175.584 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.662 0 N-CA-C 110.383 -1.087 . . . . 73.31 110.383 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.83 -164.56 5.56 Favored Glycine 0 C--N 1.354 1.541 0 C-N-CA 120.243 -0.979 . . . . 74.01 111.619 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.2 41.67 1.93 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 117.784 0.792 . . . . 75.01 109.367 178.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.09 -144.91 4.26 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.333 -1.26 . . . . 50.31 112.218 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.3 m80 -115.45 -22.33 9.36 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-N 117.781 0.79 . . . . 75.34 110.905 -170.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.7 t -110.14 136.87 20.45 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.175 -2.203 . . . . 74.51 106.872 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -70.05 150.54 66.59 Favored 'Trans proline' 0 C--N 1.356 0.964 0 CA-C-N 123.802 2.393 . . . . 74.32 112.743 -175.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -82.52 -41.03 20.2 Favored 'General case' 0 C--N 1.356 0.857 0 CA-C-O 118.68 -0.676 . . . . 74.54 109.771 177.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -144.79 173.98 11.38 Favored 'General case' 0 C--N 1.353 0.728 0 CA-C-O 117.869 -1.062 . . . . 74.33 109.417 -177.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -132.51 137.04 47.04 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-O 117.16 -1.4 . . . . 74.1 109.702 -178.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.465 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -102.57 164.91 3.1 Favored 'Isoleucine or valine' 0 C--N 1.357 0.928 0 CA-C-N 119.191 0.905 . . . . 73.43 111.096 175.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.9 mtm180 -76.92 29.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 73.31 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.85 -115.51 4.08 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.709 -0.757 . . . . 74.04 112.473 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.96 -76.24 0.58 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.868 0.366 . . . . 74.1 110.873 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -116.97 156.02 48.67 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.638 0.732 . . . . 75.41 110.903 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -78.79 174.46 12.22 Favored 'Trans proline' 0 C--N 1.366 1.466 0 O-C-N 118.524 -1.356 . . . . 65.43 110.561 -178.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 mp -103.1 -64.41 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.911 0 CA-C-O 118.456 -0.783 . . . . 73.21 110.112 -172.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.0 p -98.15 178.36 5.1 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-O 117.75 -1.119 . . . . 73.02 110.606 -170.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -137.7 179.45 6.41 Favored 'General case' 0 C--N 1.36 1.037 0 CA-C-N 118.847 0.749 . . . . 74.32 112.053 -175.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.2 176.61 3.17 Favored 'General case' 0 C--N 1.354 0.767 0 CA-C-O 118.648 -0.692 . . . . 75.54 110.237 -169.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.82 0 CA-C-O 118.182 -1.344 . . . . 54.12 110.048 177.747 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.983 -1.247 . . . . 60.5 109.983 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.15 -161.03 12.52 Favored Glycine 0 C--N 1.354 1.557 0 CA-C-O 118.758 -1.023 . . . . 53.12 111.373 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.2 42.04 1.44 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 117.751 0.775 . . . . 75.32 109.938 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.56 -149.56 4.51 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-O 118.711 -1.049 . . . . 63.22 112.723 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -113.76 -22.41 10.21 Favored 'General case' 0 C--N 1.359 0.989 0 C-N-CA 123.235 0.614 . . . . 75.41 110.893 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.1 t -109.86 135.53 20.45 Favored Pre-proline 0 C--N 1.361 1.079 0 O-C-N 119.183 -2.198 . . . . 73.55 106.893 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.89 149.09 65.62 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.726 2.367 . . . . 71.42 112.49 -175.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -80.24 -44.8 19.08 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.715 -0.66 . . . . 63.3 109.542 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.4 p90 -140.98 173.93 11.0 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.973 -1.013 . . . . 72.11 109.41 -175.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -133.4 135.74 44.84 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.165 -1.398 . . . . 75.45 109.574 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.465 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.1 t -101.89 164.85 2.95 Favored 'Isoleucine or valine' 0 C--N 1.357 0.912 0 CA-C-N 119.2 0.909 . . . . 75.4 111.119 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.2 mtp85 -76.83 29.91 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 72.52 110.887 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -104.04 -115.4 4.07 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.78 -0.724 . . . . 73.23 112.504 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -116.26 -75.34 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.856 0.36 . . . . 71.52 110.868 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -118.16 155.87 51.07 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.642 0.734 . . . . 73.32 110.855 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -79.49 174.29 12.05 Favored 'Trans proline' 0 C--N 1.366 1.489 0 O-C-N 118.403 -1.419 . . . . 70.31 110.883 -177.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.86 -64.54 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.904 0 CA-C-O 118.389 -0.815 . . . . 73.4 110.072 -172.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.1 p -98.26 176.22 5.79 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 117.792 -1.099 . . . . 75.34 110.866 -170.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -137.82 178.51 7.06 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.79 0.723 . . . . 74.01 112.125 -176.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -69.39 -178.36 1.36 Allowed 'General case' 0 C--N 1.353 0.723 0 CA-C-N 118.502 0.592 . . . . 74.14 110.571 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 110.029 -1.228 . . . . 62.22 110.029 176.048 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.61 0 N-CA-C 109.968 -1.253 . . . . 50.42 109.968 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.27 -162.18 8.47 Favored Glycine 0 C--N 1.353 1.509 0 C-N-CA 120.344 -0.932 . . . . 64.55 111.268 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.61 43.49 1.24 Allowed 'General case' 0 C--N 1.357 0.891 0 CA-C-N 117.823 0.811 . . . . 73.22 109.135 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.13 -148.73 3.77 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.611 -1.105 . . . . 60.31 112.177 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -114.07 -23.06 9.72 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 117.437 0.619 . . . . 73.24 110.84 -172.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.7 t -108.79 136.12 20.03 Favored Pre-proline 0 C--N 1.361 1.091 0 O-C-N 119.145 -2.222 . . . . 73.22 106.607 -172.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.56 148.45 59.95 Favored 'Trans proline' 0 C--N 1.357 1.023 0 CA-C-N 123.663 2.344 . . . . 75.1 112.265 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -80.08 -42.05 24.42 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.539 -0.743 . . . . 73.53 109.514 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -142.58 174.54 10.54 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 118.017 -0.992 . . . . 73.54 109.662 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -133.25 136.9 45.84 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 117.14 -1.409 . . . . 73.24 109.62 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.463 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -102.56 164.86 3.11 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 CA-C-N 119.174 0.897 . . . . 74.15 111.145 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -77.06 29.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 73.05 110.85 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.463 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.92 -115.32 4.06 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.766 -0.73 . . . . 64.45 112.483 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -116.1 -75.74 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.85 0.357 . . . . 74.32 110.884 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -117.55 155.74 50.05 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.676 0.751 . . . . 74.34 110.891 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.16 173.51 13.29 Favored 'Trans proline' 0 C--N 1.366 1.484 0 O-C-N 118.508 -1.364 . . . . 72.33 111.009 -176.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.39 -64.88 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-O 118.39 -0.814 . . . . 73.21 110.004 -172.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.6 p -95.25 175.65 6.52 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.0 -1.0 . . . . 70.23 110.842 -170.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -136.6 177.8 7.57 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-O 118.661 -0.685 . . . . 74.1 111.542 -177.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -66.95 177.86 1.57 Allowed 'General case' 0 C--N 1.353 0.759 0 CA-C-N 118.824 0.738 . . . . 70.3 110.702 -169.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.775 0 CA-C-O 118.214 -1.326 . . . . 61.54 109.874 179.28 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.691 0 N-CA-C 110.429 -1.068 . . . . 42.4 110.429 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -156.11 5.02 Favored Glycine 0 C--N 1.353 1.511 0 CA-C-O 118.581 -1.122 . . . . 74.21 111.293 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -120.1 42.17 3.01 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 118.225 1.013 . . . . 72.23 109.541 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.09 -143.74 3.23 Favored Glycine 0 C--N 1.353 1.522 0 CA-C-O 118.233 -1.315 . . . . 73.5 111.916 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 -114.63 -22.42 9.76 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-N 117.934 0.867 . . . . 73.12 110.817 -170.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -109.76 136.82 20.31 Favored Pre-proline 0 C--N 1.361 1.089 0 O-C-N 119.465 -2.022 . . . . 74.15 106.474 -172.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -72.07 150.91 55.06 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.677 2.349 . . . . 74.52 112.498 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -81.8 -39.76 23.57 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.603 -0.713 . . . . 72.35 109.637 178.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 p90 -145.78 175.71 10.2 Favored 'General case' 0 C--N 1.353 0.726 0 CA-C-O 117.491 -1.243 . . . . 73.23 109.385 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -130.14 145.29 51.69 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-O 118.106 -0.95 . . . . 74.54 110.929 177.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.464 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -105.47 164.99 3.92 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.159 0.912 . . . . 71.31 111.109 177.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.4 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 26.1 mtt85 -77.23 25.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.456 . . . . 63.01 110.893 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.464 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.08 -115.81 4.11 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.742 -0.742 . . . . 71.43 112.474 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -116.06 -76.43 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.35 . . . . 75.5 110.863 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.6 m-85 -113.44 155.91 44.05 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.634 0.73 . . . . 73.24 110.876 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -78.74 173.56 13.45 Favored 'Trans proline' 0 C--N 1.364 1.384 0 O-C-N 118.609 -1.311 . . . . 72.34 110.542 -177.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 mp -102.07 -64.69 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-O 118.62 -0.705 . . . . 72.53 109.75 -173.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.0 p -90.75 177.6 6.28 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 118.058 -0.972 . . . . 73.34 111.076 -170.279 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -137.51 177.14 8.1 Favored 'General case' 0 C--N 1.358 0.955 0 CA-C-O 118.64 -0.695 . . . . 74.41 111.495 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -71.57 169.35 15.69 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.87 0.759 . . . . 75.23 111.098 -168.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.811 0 C-N-CA 119.858 -1.163 . . . . 61.41 111.404 174.281 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 110.577 -1.009 . . . . 71.34 110.577 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.5 -158.36 6.02 Favored Glycine 0 C--N 1.353 1.497 0 CA-C-O 118.662 -1.077 . . . . 55.43 111.557 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.87 41.8 2.64 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.032 0.916 . . . . 72.51 109.644 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.99 -144.4 3.38 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 118.323 -1.265 . . . . 72.31 112.111 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -114.92 -23.02 9.31 Favored 'General case' 0 C--N 1.358 0.973 0 CA-C-N 117.83 0.815 . . . . 71.12 110.872 -170.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.5 t -109.64 136.8 20.27 Favored Pre-proline 0 C--N 1.362 1.117 0 O-C-N 119.325 -2.109 . . . . 70.1 106.612 -172.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.1 151.31 61.29 Favored 'Trans proline' 0 C--N 1.357 1.019 0 CA-C-N 123.6 2.321 . . . . 72.42 112.643 -175.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.89 -41.68 17.17 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-O 118.765 -0.636 . . . . 74.15 109.728 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -145.27 174.71 10.86 Favored 'General case' 0 C--N 1.353 0.736 0 CA-C-O 117.502 -1.237 . . . . 71.22 109.196 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -130.24 145.09 51.71 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 118.139 -0.934 . . . . 63.33 110.927 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.465 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -104.98 165.03 3.74 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 O-C-N 124.212 0.945 . . . . 74.11 111.125 177.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.402 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 41.1 mtp85 -76.97 26.23 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 72.1 110.89 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.37 -116.02 4.14 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 60.13 112.519 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -116.27 -76.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.8 0.334 . . . . 75.15 110.908 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -113.93 156.1 44.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.634 0.731 . . . . 75.22 110.911 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -79.7 174.48 11.67 Favored 'Trans proline' 0 C--N 1.365 1.441 0 O-C-N 117.96 -1.653 . . . . 74.52 110.602 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.64 -63.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.913 0 CA-C-O 118.632 -0.699 . . . . 72.24 110.058 -172.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 28.0 p -98.46 177.22 5.41 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 117.941 -1.028 . . . . 72.43 110.802 -169.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -136.16 -179.64 5.79 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.649 -0.691 . . . . 75.24 111.73 -175.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -70.24 171.08 10.4 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 118.828 0.74 . . . . 71.01 111.357 -168.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.741 0 CA-C-O 117.989 -1.451 . . . . 61.24 111.386 176.245 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.644 0 N-CA-C 110.101 -1.2 . . . . 63.2 110.101 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.7 -164.73 15.87 Favored Glycine 0 C--N 1.353 1.52 0 C-N-CA 120.342 -0.932 . . . . 71.4 111.652 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -105.2 45.44 0.96 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 117.559 0.68 . . . . 61.34 109.712 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -84.78 -150.0 11.49 Favored Glycine 0 C--N 1.354 1.54 0 CA-C-O 118.469 -1.184 . . . . 75.55 113.077 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 45.3 m170 -113.3 -23.27 10.0 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.46 0.63 . . . . 73.12 110.862 -173.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 91.9 t -111.15 132.24 21.81 Favored Pre-proline 0 C--N 1.362 1.139 0 O-C-N 119.08 -2.263 . . . . 75.33 106.988 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -68.96 153.17 72.97 Favored 'Trans proline' 0 C--N 1.356 0.965 0 CA-C-N 123.631 2.333 . . . . 65.34 112.9 -172.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -83.46 -46.87 11.99 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 118.82 -0.61 . . . . 74.5 109.429 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 p90 -141.66 168.29 20.11 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 117.669 -1.158 . . . . 75.42 109.09 -177.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -123.92 144.87 49.52 Favored 'General case' 0 C--N 1.356 0.885 0 CA-C-O 118.257 -0.878 . . . . 74.34 110.49 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.461 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -105.31 164.98 3.87 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 O-C-N 124.237 0.961 . . . . 73.34 111.138 177.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.402 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 22.5 mtp180 -77.16 25.68 0.16 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 72.01 110.918 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.28 -115.83 4.12 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 52.22 112.525 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -116.18 -76.22 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 65.42 110.88 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -113.7 156.27 43.86 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.681 0.753 . . . . 74.51 110.845 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -77.85 -177.72 4.07 Favored 'Trans proline' 0 C--N 1.366 1.463 0 O-C-N 118.261 -1.494 . . . . 63.02 110.517 -178.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mp -110.78 -64.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 118.429 -0.795 . . . . 75.31 110.69 -173.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.6 p -100.09 176.42 5.41 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.686 -1.15 . . . . 74.23 109.976 -172.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -176.78 4.8 Favored 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.004 0.82 . . . . 75.21 112.707 -176.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -68.77 -174.24 0.55 Allowed 'General case' 0 C--N 1.353 0.748 0 CA-C-O 119.136 -0.459 . . . . 73.14 110.428 -169.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.547 -1.421 . . . . 63.32 109.547 176.981 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 N-CA-C 110.259 -1.136 . . . . 61.34 110.259 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.66 -157.34 9.07 Favored Glycine 0 C--N 1.353 1.488 0 CA-C-O 118.439 -1.201 . . . . 64.5 111.146 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.66 42.63 1.81 Allowed 'General case' 0 C--N 1.356 0.883 0 CA-C-N 118.115 0.957 . . . . 73.51 109.846 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.85 -147.89 3.91 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-O 118.609 -1.106 . . . . 61.3 112.572 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.3 m80 -113.97 -22.73 9.94 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.452 0.626 . . . . 72.41 110.887 -171.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -110.46 135.64 20.65 Favored Pre-proline 0 C--N 1.361 1.085 0 O-C-N 119.437 -2.039 . . . . 72.14 106.529 -171.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.49 150.5 57.81 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.593 2.319 . . . . 65.22 112.603 -174.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -81.25 -41.86 21.58 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.564 -0.732 . . . . 75.34 109.448 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -143.38 175.57 9.81 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.699 -1.143 . . . . 74.32 109.255 -176.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -130.9 144.4 51.43 Favored 'General case' 0 C--N 1.357 0.902 0 CA-C-O 118.274 -0.87 . . . . 74.22 110.757 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.458 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -104.65 164.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.054 0.846 . . . . 73.55 111.103 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.5 mtp85 -77.25 25.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 73.15 110.904 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.07 -115.66 4.09 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 62.11 112.444 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -116.1 -76.63 0.57 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 75.53 110.871 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -113.36 155.86 44.02 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.675 0.75 . . . . 72.11 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -78.68 -179.88 5.86 Favored 'Trans proline' 0 C--N 1.366 1.482 0 O-C-N 118.47 -1.384 . . . . 74.43 110.897 -176.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 78.9 mt -108.36 -63.67 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.895 0 CA-C-O 118.303 -0.856 . . . . 75.24 111.142 -171.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.4 p -98.3 175.29 6.11 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.918 -1.039 . . . . 72.31 110.058 -173.097 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -136.32 177.02 8.17 Favored 'General case' 0 C--N 1.359 0.995 0 CA-C-O 118.63 -0.7 . . . . 73.32 111.652 -176.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -67.3 171.73 5.57 Favored 'General case' 0 C--N 1.353 0.727 0 CA-C-N 118.728 0.695 . . . . 72.41 111.029 -168.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.799 0 C-N-CA 119.938 -1.125 . . . . 71.31 111.624 174.869 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.649 0 N-CA-C 110.328 -1.109 . . . . 74.43 110.328 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.37 -164.09 5.96 Favored Glycine 0 C--N 1.353 1.527 0 CA-C-N 118.214 1.007 . . . . 73.14 111.408 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.53 41.56 2.0 Favored 'General case' 0 C--N 1.355 0.826 0 CA-C-N 117.906 0.853 . . . . 74.23 109.367 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.33 -144.69 3.69 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.47 -1.183 . . . . 73.41 112.088 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 42.4 m80 -115.46 -23.4 8.84 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.701 0.75 . . . . 73.13 110.831 -169.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.2 t -110.02 136.8 20.41 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.364 -2.085 . . . . 64.32 106.655 -172.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -70.94 151.45 62.37 Favored 'Trans proline' 0 C--N 1.358 1.026 0 CA-C-N 123.666 2.345 . . . . 74.4 113.05 -174.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -82.9 -40.44 20.19 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.525 -0.75 . . . . 60.45 109.612 177.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.5 p90 -145.46 174.55 11.05 Favored 'General case' 0 C--N 1.354 0.769 0 CA-C-O 117.594 -1.193 . . . . 64.43 109.419 -178.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -130.01 144.54 51.39 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-O 118.05 -0.976 . . . . 73.44 110.889 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.457 ' C ' ' H ' ' A' ' 13' ' ' GLY . 21.9 t -105.95 164.91 4.11 Favored 'Isoleucine or valine' 0 C--N 1.359 0.98 0 O-C-N 124.136 0.898 . . . . 74.43 111.15 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.4 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 30.8 mtp180 -77.21 25.3 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 74.21 110.864 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.48 4.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.784 -0.722 . . . . 62.3 112.479 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -116.24 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 72.33 110.821 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -114.25 156.27 44.52 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.656 0.741 . . . . 72.51 110.861 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -78.95 177.73 8.36 Favored 'Trans proline' 0 C--N 1.365 1.413 0 O-C-N 118.532 -1.352 . . . . 62.22 110.421 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -108.83 -58.6 3.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-O 118.144 -0.932 . . . . 72.51 111.798 -172.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.5 p -97.41 177.2 5.61 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 117.808 -1.092 . . . . 71.11 110.206 -173.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -138.78 178.6 7.03 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-N 118.746 0.703 . . . . 64.12 111.73 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -69.71 178.98 2.33 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.694 0.679 . . . . 74.04 109.927 -170.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.751 0 CA-C-O 117.832 -1.538 . . . . 62.33 109.934 178.097 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.626 0 N-CA-C 110.302 -1.119 . . . . 73.1 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.6 -158.65 5.29 Favored Glycine 0 C--N 1.353 1.487 0 CA-C-O 118.864 -0.964 . . . . 63.54 111.308 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -117.57 42.29 2.63 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-N 118.007 0.903 . . . . 62.35 109.341 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.71 -143.46 2.93 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.31 -1.272 . . . . 64.15 111.906 179.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.8 m170 -115.47 -23.26 8.9 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.93 0.865 . . . . 73.12 110.911 -170.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -109.14 136.27 20.13 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.405 -2.059 . . . . 71.01 106.433 -172.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -71.52 150.97 58.42 Favored 'Trans proline' 0 C--N 1.358 1.034 0 CA-C-N 123.598 2.321 . . . . 72.25 112.471 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -82.74 -40.06 21.06 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.604 -0.712 . . . . 73.45 109.721 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.1 p90 -143.75 174.66 10.61 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-O 117.589 -1.196 . . . . 70.03 109.498 -178.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.69 144.44 51.29 Favored 'General case' 0 C--N 1.356 0.874 0 CA-C-O 118.058 -0.973 . . . . 73.22 110.711 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.461 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.3 t -105.56 164.8 4.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 O-C-N 124.104 0.878 . . . . 74.24 111.16 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.401 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 10.0 mtt85 -77.47 25.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 75.34 110.893 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.46 4.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.739 . . . . 52.1 112.491 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -116.13 -76.18 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 62.53 110.864 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -113.91 155.76 44.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 74.23 110.874 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -77.54 178.12 8.0 Favored 'Trans proline' 0 C--N 1.365 1.438 0 O-C-N 118.84 -1.189 . . . . 75.23 110.569 -177.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 73.8 mt -105.64 -61.27 2.55 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 CA-C-O 118.509 -0.757 . . . . 71.31 111.077 -171.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 p -99.92 178.02 4.93 Favored 'General case' 0 C--N 1.354 0.78 0 CA-C-O 117.942 -1.027 . . . . 62.04 110.257 -171.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -137.1 178.44 7.08 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-O 118.751 -0.642 . . . . 70.03 111.435 -176.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.49 169.93 11.57 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-N 118.776 0.717 . . . . 64.44 111.118 -168.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.802 0 CA-C-O 118.216 -1.324 . . . . 63.02 111.184 177.717 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.653 0 N-CA-C 110.748 -0.941 . . . . 71.22 110.748 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.1 -161.58 5.35 Favored Glycine 0 C--N 1.353 1.517 0 CA-C-O 118.82 -0.989 . . . . 63.35 111.512 -179.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.04 42.02 2.28 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.95 0.875 . . . . 74.11 109.236 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.97 -143.08 3.48 Favored Glycine 0 C--N 1.353 1.512 0 CA-C-O 118.334 -1.259 . . . . 72.14 112.062 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.2 m80 -116.58 -22.67 8.57 Favored 'General case' 0 C--N 1.359 0.999 0 CA-C-N 117.855 0.827 . . . . 61.52 110.851 -169.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -109.75 136.08 20.36 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.131 -2.231 . . . . 71.42 106.607 -173.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.12 151.19 66.88 Favored 'Trans proline' 0 C--N 1.358 1.078 0 CA-C-N 123.662 2.343 . . . . 60.33 112.167 -175.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -83.91 -39.14 20.19 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-O 118.483 -0.77 . . . . 74.15 109.947 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -145.62 174.08 11.49 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.888 -1.053 . . . . 74.21 109.533 -178.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -132.73 136.25 46.26 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-O 117.167 -1.397 . . . . 74.21 109.676 -178.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.471 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -102.43 164.91 3.06 Favored 'Isoleucine or valine' 0 C--N 1.357 0.921 0 CA-C-N 119.152 0.887 . . . . 74.41 111.168 175.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.9 mtp180 -76.64 29.64 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 75.23 110.852 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.471 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.25 4.05 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.742 -0.742 . . . . 71.13 112.492 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -116.1 -75.49 0.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.873 0.368 . . . . 72.34 110.887 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -118.89 156.08 52.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.695 0.76 . . . . 75.41 110.862 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -78.04 178.54 7.47 Favored 'Trans proline' 0 C--N 1.365 1.433 0 O-C-N 118.572 -1.331 . . . . 71.23 110.702 -177.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.5 mt -107.35 -60.57 2.84 Favored 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-O 118.268 -0.872 . . . . 71.34 111.242 -171.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 70.6 p -105.2 176.69 5.08 Favored 'General case' 0 C--N 1.353 0.743 0 CA-C-O 117.84 -1.076 . . . . 72.02 109.938 -171.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -136.63 179.65 6.24 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-N 118.65 0.659 . . . . 75.1 111.584 -173.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -67.9 173.12 4.71 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 118.642 0.655 . . . . 63.21 110.678 -169.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.778 0 CA-C-O 118.361 -1.244 . . . . 73.35 110.833 178.29 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.69 0 N-CA-C 110.79 -0.924 . . . . 71.5 110.79 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.98 -163.65 7.65 Favored Glycine 0 C--N 1.352 1.462 0 CA-C-N 118.179 0.989 . . . . 72.4 111.878 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.03 40.08 2.01 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-N 117.677 0.738 . . . . 73.24 109.756 178.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.49 -146.05 3.64 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-O 118.604 -1.109 . . . . 52.02 112.889 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -114.89 -22.95 9.36 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 117.53 0.665 . . . . 75.44 110.802 -170.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -110.86 135.77 20.78 Favored Pre-proline 0 C--N 1.362 1.129 0 O-C-N 119.161 -2.212 . . . . 74.4 106.872 -172.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.96 151.99 68.1 Favored 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.767 2.381 . . . . 71.22 112.877 -174.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -83.93 -41.68 17.11 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-O 118.618 -0.706 . . . . 73.11 109.701 178.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -145.95 172.33 13.52 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.657 -1.163 . . . . 73.44 109.248 -178.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -127.77 143.97 51.11 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 118.226 -0.892 . . . . 73.35 110.684 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.47 ' C ' ' H ' ' A' ' 13' ' ' GLY . 21.9 t -105.24 164.97 3.85 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 O-C-N 124.139 0.9 . . . . 74.21 111.138 177.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.401 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 13.9 mtp85 -76.83 25.85 0.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 73.23 110.898 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.06 -115.55 4.08 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 54.04 112.473 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.3 -76.2 0.57 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.816 0.341 . . . . 74.32 110.822 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -114.94 156.45 45.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.602 0.715 . . . . 71.41 110.895 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -78.42 179.22 6.7 Favored 'Trans proline' 0 C--N 1.366 1.462 0 O-C-N 118.798 -1.212 . . . . 74.52 110.577 -177.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.9 mt -106.43 -59.97 3.12 Favored 'Isoleucine or valine' 0 C--N 1.355 0.839 0 CA-C-O 118.415 -0.802 . . . . 71.52 111.28 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.3 p -108.0 177.2 4.88 Favored 'General case' 0 C--N 1.353 0.753 0 CA-C-O 117.755 -1.117 . . . . 75.04 109.934 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -138.33 179.55 6.39 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 118.943 0.792 . . . . 75.22 112.196 -172.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -69.47 179.1 2.18 Favored 'General case' 0 C--N 1.352 0.715 0 CA-C-N 118.449 0.568 . . . . 73.54 110.576 -168.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.773 0 CA-C-O 118.235 -1.314 . . . . 62.15 109.882 177.193 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.684 0 N-CA-C 110.965 -0.854 . . . . 72.14 110.965 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.83 -163.01 8.49 Favored Glycine 0 C--N 1.352 1.471 0 CA-C-N 118.083 0.941 . . . . 73.14 111.947 -178.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.09 40.68 1.88 Allowed 'General case' 0 C--N 1.356 0.881 0 CA-C-N 117.647 0.723 . . . . 62.24 109.678 178.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.48 -146.66 3.85 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.531 -1.149 . . . . 64.33 112.771 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -114.64 -22.77 9.58 Favored 'General case' 0 C--N 1.359 1.001 0 CA-C-N 117.524 0.662 . . . . 74.34 110.839 -171.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.4 t -111.45 136.3 21.0 Favored Pre-proline 0 C--N 1.362 1.112 0 O-C-N 119.282 -2.136 . . . . 74.1 106.701 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.49 153.26 65.68 Favored 'Trans proline' 0 C--N 1.358 1.062 0 CA-C-N 123.706 2.359 . . . . 73.11 113.185 -174.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -85.14 -42.57 14.64 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 118.665 -0.683 . . . . 73.4 109.653 178.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -145.8 172.14 13.76 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 117.583 -1.199 . . . . 74.04 109.145 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -127.57 143.77 51.14 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-O 118.04 -0.981 . . . . 71.33 110.824 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.469 ' C ' ' H ' ' A' ' 13' ' ' GLY . 21.9 t -105.44 165.17 3.84 Favored 'Isoleucine or valine' 0 C--N 1.357 0.931 0 O-C-N 124.138 0.899 . . . . 64.5 111.135 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.403 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 12.6 mtp180 -76.88 25.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 73.11 110.865 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.45 4.07 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 75.41 112.514 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -116.15 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.898 0.38 . . . . 73.14 110.903 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -115.34 156.2 46.03 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.647 0.737 . . . . 74.52 110.929 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.15 174.73 12.04 Favored 'Trans proline' 0 C--N 1.365 1.437 0 O-C-N 118.771 -1.226 . . . . 72.01 110.74 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -100.0 -61.75 2.23 Favored 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-O 118.677 -0.677 . . . . 74.42 110.093 -172.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.0 p -106.64 177.25 4.91 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 117.737 -1.125 . . . . 72.33 110.564 -169.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -137.93 -179.88 6.03 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.907 0.776 . . . . 65.4 112.391 -173.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.08 -179.83 2.07 Favored 'General case' 0 C--N 1.354 0.775 0 CA-C-N 118.505 0.593 . . . . 72.42 110.63 -168.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.755 0 CA-C-O 118.153 -1.359 . . . . 72.22 109.968 176.313 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 N-CA-C 110.787 -0.925 . . . . 64.41 110.787 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.53 -162.16 7.42 Favored Glycine 0 C--N 1.353 1.484 0 CA-C-O 118.834 -0.981 . . . . 72.11 111.851 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -111.94 39.83 2.3 Favored 'General case' 0 C--N 1.356 0.866 0 CA-C-N 117.804 0.802 . . . . 73.23 109.753 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.1 -145.52 3.17 Favored Glycine 0 C--N 1.354 1.545 0 CA-C-O 118.549 -1.14 . . . . 61.14 112.751 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.5 m80 -114.99 -23.05 9.26 Favored 'General case' 0 C--N 1.359 0.993 0 CA-C-N 117.572 0.686 . . . . 74.51 110.893 -169.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.2 t -110.76 136.47 20.7 Favored Pre-proline 0 C--N 1.361 1.096 0 O-C-N 119.306 -2.121 . . . . 73.34 106.694 -172.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 152.63 65.92 Favored 'Trans proline' 0 C--N 1.358 1.077 0 CA-C-N 123.776 2.384 . . . . 72.45 112.839 -174.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.95 -41.33 17.46 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.687 -0.673 . . . . 74.3 109.794 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -146.46 173.8 11.96 Favored 'General case' 0 C--N 1.353 0.738 0 CA-C-O 117.566 -1.207 . . . . 73.14 109.177 -178.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -128.67 144.1 51.09 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-O 118.147 -0.93 . . . . 74.44 110.917 179.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.459 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -105.2 164.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.917 0 O-C-N 124.117 0.886 . . . . 74.33 111.1 177.207 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.402 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 3.6 mtt-85 -77.2 25.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 73.24 110.88 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.36 4.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.719 -0.753 . . . . 60.13 112.495 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.25 -76.0 0.58 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.343 . . . . 73.22 110.854 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -115.14 156.77 45.0 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.659 0.742 . . . . 65.43 110.913 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -79.48 178.47 7.34 Favored 'Trans proline' 0 C--N 1.365 1.404 0 O-C-N 118.454 -1.393 . . . . 74.0 110.194 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.8 mm -109.25 -57.16 4.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 CA-C-O 118.138 -0.934 . . . . 72.1 112.036 -172.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 77.9 p -103.54 176.18 5.24 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 117.767 -1.111 . . . . 74.43 110.047 -172.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -138.68 178.62 7.01 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-N 118.916 0.78 . . . . 73.21 112.208 -173.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -69.9 178.28 2.74 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-N 118.555 0.616 . . . . 73.43 110.557 -168.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.259 1.718 0 CA-C-O 118.169 -1.351 . . . . 75.01 109.876 176.484 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 110.202 -1.159 . . . . 71.54 110.202 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.03 -161.75 13.82 Favored Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.513 -1.16 . . . . 63.4 110.961 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.39 43.22 1.2 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.01 0.905 . . . . 73.21 109.393 178.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -150.24 3.0 Favored Glycine 0 C--N 1.352 1.457 0 CA-C-O 118.896 -0.947 . . . . 74.14 112.674 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.6 m170 -113.56 -22.33 10.36 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.32 0.648 . . . . 73.34 110.854 -171.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.2 t -111.67 136.36 21.1 Favored Pre-proline 0 C--N 1.362 1.116 0 O-C-N 119.264 -2.147 . . . . 74.31 106.632 -172.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.01 152.72 63.1 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 123.796 2.391 . . . . 73.53 112.865 -174.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -82.5 -43.64 16.93 Favored 'General case' 0 C--N 1.353 0.756 0 CA-C-O 118.715 -0.66 . . . . 74.31 109.52 178.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -143.68 176.48 9.19 Favored 'General case' 0 C--N 1.353 0.733 0 CA-C-O 117.592 -1.194 . . . . 74.12 109.02 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -131.69 143.62 50.41 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.164 -0.922 . . . . 72.13 110.872 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.464 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -104.41 165.08 3.55 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 O-C-N 124.019 0.824 . . . . 72.33 111.137 177.017 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.403 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 61.2 mtp180 -76.9 25.71 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 75.13 110.903 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.464 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.14 -115.72 4.1 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.776 -0.726 . . . . 74.12 112.489 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -116.06 -76.15 0.58 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.875 0.369 . . . . 65.22 110.876 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -115.11 155.96 46.0 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.67 0.747 . . . . 72.33 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -78.85 179.69 6.26 Favored 'Trans proline' 0 C--N 1.366 1.478 0 O-C-N 118.53 -1.353 . . . . 73.31 111.108 -176.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 76.0 mt -107.8 -62.95 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 CA-C-O 118.07 -0.967 . . . . 74.42 111.257 -171.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 63.5 p -97.94 175.67 6.05 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.857 -1.068 . . . . 71.44 110.344 -172.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -136.9 176.15 8.97 Favored 'General case' 0 C--N 1.359 0.98 0 CA-C-O 118.718 -0.658 . . . . 74.34 111.711 -177.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -67.77 -177.09 0.73 Allowed 'General case' 0 C--N 1.353 0.746 0 CA-C-N 118.601 0.637 . . . . 72.12 110.305 -168.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.753 0 CA-C-O 117.763 -1.576 . . . . 71.15 109.751 179.069 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.7 0 N-CA-C 110.608 -0.997 . . . . 71.3 110.608 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -160.69 8.01 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-O 118.63 -1.095 . . . . 63.13 111.88 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -113.02 40.91 2.2 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 117.9 0.85 . . . . 54.51 109.907 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.13 -146.93 4.46 Favored Glycine 0 C--N 1.354 1.533 0 CA-C-O 118.55 -1.139 . . . . 74.12 112.928 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -113.82 -22.98 9.89 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-N 117.559 0.68 . . . . 74.23 110.848 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -110.15 135.69 20.54 Favored Pre-proline 0 C--N 1.361 1.108 0 O-C-N 119.145 -2.222 . . . . 72.1 106.865 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.54 151.58 70.31 Favored 'Trans proline' 0 C--N 1.358 1.064 0 CA-C-N 123.709 2.36 . . . . 73.33 112.75 -174.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -83.39 -42.15 17.35 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 118.673 -0.68 . . . . 71.03 109.667 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -143.6 173.4 11.68 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.876 -1.059 . . . . 74.35 109.416 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -132.32 137.64 47.5 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-O 117.062 -1.447 . . . . 73.21 109.778 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.466 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -103.22 164.9 3.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-N 119.231 0.923 . . . . 73.41 111.172 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 56.7 mtp85 -76.74 29.51 0.13 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 75.14 110.911 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.65 4.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.743 -0.741 . . . . 70.21 112.463 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -116.11 -76.1 0.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 74.23 110.849 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -116.95 156.42 48.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.632 0.729 . . . . 74.43 110.915 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.79 178.26 7.48 Favored 'Trans proline' 0 C--N 1.365 1.428 0 O-C-N 118.133 -1.562 . . . . 74.04 110.238 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.5 mm -110.78 -57.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.909 0 CA-C-O 118.126 -0.94 . . . . 75.35 112.158 -172.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.1 p -100.86 176.31 5.33 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-O 117.79 -1.1 . . . . 62.43 110.017 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -140.3 -178.62 5.57 Favored 'General case' 0 C--N 1.358 0.948 0 CA-C-N 118.992 0.815 . . . . 73.21 112.178 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -70.15 -177.31 1.35 Allowed 'General case' 0 C--N 1.354 0.768 0 CA-C-N 118.587 0.63 . . . . 71.32 110.793 -168.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 109.986 -1.245 . . . . 70.24 109.986 175.584 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.662 0 N-CA-C 110.383 -1.087 . . . . 73.31 110.383 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.83 -164.56 5.56 Favored Glycine 0 C--N 1.354 1.541 0 C-N-CA 120.243 -0.979 . . . . 74.01 111.619 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.2 41.67 1.93 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 117.784 0.792 . . . . 75.01 109.367 178.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.09 -144.91 4.26 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.333 -1.26 . . . . 50.31 112.218 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.3 m80 -115.45 -22.33 9.36 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-N 117.781 0.79 . . . . 75.34 110.905 -170.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.7 t -110.14 136.87 20.45 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.175 -2.203 . . . . 74.51 106.872 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -70.05 150.54 66.59 Favored 'Trans proline' 0 C--N 1.356 0.964 0 CA-C-N 123.802 2.393 . . . . 74.32 112.743 -175.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -82.52 -41.03 20.2 Favored 'General case' 0 C--N 1.356 0.857 0 CA-C-O 118.68 -0.676 . . . . 74.54 109.771 177.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -144.79 173.98 11.38 Favored 'General case' 0 C--N 1.353 0.728 0 CA-C-O 117.869 -1.062 . . . . 74.33 109.417 -177.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -132.51 137.04 47.04 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-O 117.16 -1.4 . . . . 74.1 109.702 -178.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.465 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -102.57 164.91 3.1 Favored 'Isoleucine or valine' 0 C--N 1.357 0.928 0 CA-C-N 119.191 0.905 . . . . 73.43 111.096 175.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.9 mtm180 -76.92 29.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 73.31 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.85 -115.51 4.08 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.709 -0.757 . . . . 74.04 112.473 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.96 -76.24 0.58 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.868 0.366 . . . . 74.1 110.873 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -116.97 156.02 48.67 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.638 0.732 . . . . 75.41 110.903 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -78.79 174.46 12.22 Favored 'Trans proline' 0 C--N 1.366 1.466 0 O-C-N 118.524 -1.356 . . . . 65.43 110.561 -178.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 mp -103.1 -64.41 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.911 0 CA-C-O 118.456 -0.783 . . . . 73.21 110.112 -172.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.0 p -98.15 178.36 5.1 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-O 117.75 -1.119 . . . . 73.02 110.606 -170.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -137.7 179.45 6.41 Favored 'General case' 0 C--N 1.36 1.037 0 CA-C-N 118.847 0.749 . . . . 74.32 112.053 -175.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.2 176.61 3.17 Favored 'General case' 0 C--N 1.354 0.767 0 CA-C-O 118.648 -0.692 . . . . 75.54 110.237 -169.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.82 0 CA-C-O 118.182 -1.344 . . . . 54.12 110.048 177.747 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.983 -1.247 . . . . 60.5 109.983 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.15 -161.03 12.52 Favored Glycine 0 C--N 1.354 1.557 0 CA-C-O 118.758 -1.023 . . . . 53.12 111.373 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.2 42.04 1.44 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 117.751 0.775 . . . . 75.32 109.938 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.56 -149.56 4.51 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-O 118.711 -1.049 . . . . 63.22 112.723 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -113.76 -22.41 10.21 Favored 'General case' 0 C--N 1.359 0.989 0 C-N-CA 123.235 0.614 . . . . 75.41 110.893 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.1 t -109.86 135.53 20.45 Favored Pre-proline 0 C--N 1.361 1.079 0 O-C-N 119.183 -2.198 . . . . 73.55 106.893 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.89 149.09 65.62 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.726 2.367 . . . . 71.42 112.49 -175.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -80.24 -44.8 19.08 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.715 -0.66 . . . . 63.3 109.542 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.4 p90 -140.98 173.93 11.0 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.973 -1.013 . . . . 72.11 109.41 -175.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -133.4 135.74 44.84 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.165 -1.398 . . . . 75.45 109.574 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.465 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.1 t -101.89 164.85 2.95 Favored 'Isoleucine or valine' 0 C--N 1.357 0.912 0 CA-C-N 119.2 0.909 . . . . 75.4 111.119 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 61.2 mtp85 -76.83 29.91 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 72.52 110.887 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -104.04 -115.4 4.07 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.78 -0.724 . . . . 73.23 112.504 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -116.26 -75.34 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.856 0.36 . . . . 71.52 110.868 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -118.16 155.87 51.07 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.642 0.734 . . . . 73.32 110.855 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -79.49 174.29 12.05 Favored 'Trans proline' 0 C--N 1.366 1.489 0 O-C-N 118.403 -1.419 . . . . 70.31 110.883 -177.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mp -102.86 -64.54 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.904 0 CA-C-O 118.389 -0.815 . . . . 73.4 110.072 -172.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.1 p -98.26 176.22 5.79 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 117.792 -1.099 . . . . 75.34 110.866 -170.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -137.82 178.51 7.06 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.79 0.723 . . . . 74.01 112.125 -176.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -69.39 -178.36 1.36 Allowed 'General case' 0 C--N 1.353 0.723 0 CA-C-N 118.502 0.592 . . . . 74.14 110.571 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 110.029 -1.228 . . . . 62.22 110.029 176.048 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.61 0 N-CA-C 109.968 -1.253 . . . . 50.42 109.968 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.27 -162.18 8.47 Favored Glycine 0 C--N 1.353 1.509 0 C-N-CA 120.344 -0.932 . . . . 64.55 111.268 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.61 43.49 1.24 Allowed 'General case' 0 C--N 1.357 0.891 0 CA-C-N 117.823 0.811 . . . . 73.22 109.135 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.13 -148.73 3.77 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.611 -1.105 . . . . 60.31 112.177 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -114.07 -23.06 9.72 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 117.437 0.619 . . . . 73.24 110.84 -172.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.7 t -108.79 136.12 20.03 Favored Pre-proline 0 C--N 1.361 1.091 0 O-C-N 119.145 -2.222 . . . . 73.22 106.607 -172.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.56 148.45 59.95 Favored 'Trans proline' 0 C--N 1.357 1.023 0 CA-C-N 123.663 2.344 . . . . 75.1 112.265 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -80.08 -42.05 24.42 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.539 -0.743 . . . . 73.53 109.514 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -142.58 174.54 10.54 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 118.017 -0.992 . . . . 73.54 109.662 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -133.25 136.9 45.84 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 117.14 -1.409 . . . . 73.24 109.62 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.463 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -102.56 164.86 3.11 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 CA-C-N 119.174 0.897 . . . . 74.15 111.145 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -77.06 29.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 73.05 110.85 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.463 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.92 -115.32 4.06 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.766 -0.73 . . . . 64.45 112.483 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -116.1 -75.74 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.85 0.357 . . . . 74.32 110.884 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -117.55 155.74 50.05 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.676 0.751 . . . . 74.34 110.891 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.16 173.51 13.29 Favored 'Trans proline' 0 C--N 1.366 1.484 0 O-C-N 118.508 -1.364 . . . . 72.33 111.009 -176.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.39 -64.88 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-O 118.39 -0.814 . . . . 73.21 110.004 -172.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.6 p -95.25 175.65 6.52 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.0 -1.0 . . . . 70.23 110.842 -170.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -136.6 177.8 7.57 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-O 118.661 -0.685 . . . . 74.1 111.542 -177.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -66.95 177.86 1.57 Allowed 'General case' 0 C--N 1.353 0.759 0 CA-C-N 118.824 0.738 . . . . 70.3 110.702 -169.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.775 0 CA-C-O 118.214 -1.326 . . . . 61.54 109.874 179.28 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.691 0 N-CA-C 110.429 -1.068 . . . . 42.4 110.429 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -156.11 5.02 Favored Glycine 0 C--N 1.353 1.511 0 CA-C-O 118.581 -1.122 . . . . 74.21 111.293 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -120.1 42.17 3.01 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 118.225 1.013 . . . . 72.23 109.541 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.09 -143.74 3.23 Favored Glycine 0 C--N 1.353 1.522 0 CA-C-O 118.233 -1.315 . . . . 73.5 111.916 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 -114.63 -22.42 9.76 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-N 117.934 0.867 . . . . 73.12 110.817 -170.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -109.76 136.82 20.31 Favored Pre-proline 0 C--N 1.361 1.089 0 O-C-N 119.465 -2.022 . . . . 74.15 106.474 -172.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -72.07 150.91 55.06 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.677 2.349 . . . . 74.52 112.498 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -81.8 -39.76 23.57 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.603 -0.713 . . . . 72.35 109.637 178.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 p90 -145.78 175.71 10.2 Favored 'General case' 0 C--N 1.353 0.726 0 CA-C-O 117.491 -1.243 . . . . 73.23 109.385 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -130.14 145.29 51.69 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-O 118.106 -0.95 . . . . 74.54 110.929 177.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.464 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -105.47 164.99 3.92 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.159 0.912 . . . . 71.31 111.109 177.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.4 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 26.1 mtt85 -77.23 25.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.456 . . . . 63.01 110.893 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.464 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.08 -115.81 4.11 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.742 -0.742 . . . . 71.43 112.474 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -116.06 -76.43 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.35 . . . . 75.5 110.863 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.6 m-85 -113.44 155.91 44.05 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.634 0.73 . . . . 73.24 110.876 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -78.74 173.56 13.45 Favored 'Trans proline' 0 C--N 1.364 1.384 0 O-C-N 118.609 -1.311 . . . . 72.34 110.542 -177.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.9 mp -102.07 -64.69 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-O 118.62 -0.705 . . . . 72.53 109.75 -173.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.0 p -90.75 177.6 6.28 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 118.058 -0.972 . . . . 73.34 111.076 -170.279 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -137.51 177.14 8.1 Favored 'General case' 0 C--N 1.358 0.955 0 CA-C-O 118.64 -0.695 . . . . 74.41 111.495 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -71.57 169.35 15.69 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.87 0.759 . . . . 75.23 111.098 -168.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.811 0 C-N-CA 119.858 -1.163 . . . . 61.41 111.404 174.281 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 110.577 -1.009 . . . . 71.34 110.577 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.5 -158.36 6.02 Favored Glycine 0 C--N 1.353 1.497 0 CA-C-O 118.662 -1.077 . . . . 55.43 111.557 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.87 41.8 2.64 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.032 0.916 . . . . 72.51 109.644 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.99 -144.4 3.38 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 118.323 -1.265 . . . . 72.31 112.111 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -114.92 -23.02 9.31 Favored 'General case' 0 C--N 1.358 0.973 0 CA-C-N 117.83 0.815 . . . . 71.12 110.872 -170.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.5 t -109.64 136.8 20.27 Favored Pre-proline 0 C--N 1.362 1.117 0 O-C-N 119.325 -2.109 . . . . 70.1 106.612 -172.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.1 151.31 61.29 Favored 'Trans proline' 0 C--N 1.357 1.019 0 CA-C-N 123.6 2.321 . . . . 72.42 112.643 -175.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.89 -41.68 17.17 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-O 118.765 -0.636 . . . . 74.15 109.728 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -145.27 174.71 10.86 Favored 'General case' 0 C--N 1.353 0.736 0 CA-C-O 117.502 -1.237 . . . . 71.22 109.196 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -130.24 145.09 51.71 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 118.139 -0.934 . . . . 63.33 110.927 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.465 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -104.98 165.03 3.74 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 O-C-N 124.212 0.945 . . . . 74.11 111.125 177.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.402 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 41.1 mtp85 -76.97 26.23 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 72.1 110.89 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.37 -116.02 4.14 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 60.13 112.519 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -116.27 -76.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.8 0.334 . . . . 75.15 110.908 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -113.93 156.1 44.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.634 0.731 . . . . 75.22 110.911 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -79.7 174.48 11.67 Favored 'Trans proline' 0 C--N 1.365 1.441 0 O-C-N 117.96 -1.653 . . . . 74.52 110.602 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mp -100.64 -63.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.913 0 CA-C-O 118.632 -0.699 . . . . 72.24 110.058 -172.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 28.0 p -98.46 177.22 5.41 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 117.941 -1.028 . . . . 72.43 110.802 -169.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -136.16 -179.64 5.79 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.649 -0.691 . . . . 75.24 111.73 -175.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -70.24 171.08 10.4 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 118.828 0.74 . . . . 71.01 111.357 -168.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.741 0 CA-C-O 117.989 -1.451 . . . . 61.24 111.386 176.245 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.644 0 N-CA-C 110.101 -1.2 . . . . 63.2 110.101 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.7 -164.73 15.87 Favored Glycine 0 C--N 1.353 1.52 0 C-N-CA 120.342 -0.932 . . . . 71.4 111.652 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -105.2 45.44 0.96 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 117.559 0.68 . . . . 61.34 109.712 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -84.78 -150.0 11.49 Favored Glycine 0 C--N 1.354 1.54 0 CA-C-O 118.469 -1.184 . . . . 75.55 113.077 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 45.3 m170 -113.3 -23.27 10.0 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.46 0.63 . . . . 73.12 110.862 -173.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 91.9 t -111.15 132.24 21.81 Favored Pre-proline 0 C--N 1.362 1.139 0 O-C-N 119.08 -2.263 . . . . 75.33 106.988 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -68.96 153.17 72.97 Favored 'Trans proline' 0 C--N 1.356 0.965 0 CA-C-N 123.631 2.333 . . . . 65.34 112.9 -172.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -83.46 -46.87 11.99 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 118.82 -0.61 . . . . 74.5 109.429 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 p90 -141.66 168.29 20.11 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 117.669 -1.158 . . . . 75.42 109.09 -177.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -123.92 144.87 49.52 Favored 'General case' 0 C--N 1.356 0.885 0 CA-C-O 118.257 -0.878 . . . . 74.34 110.49 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.461 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -105.31 164.98 3.87 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 O-C-N 124.237 0.961 . . . . 73.34 111.138 177.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.402 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 22.5 mtp180 -77.16 25.68 0.16 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 72.01 110.918 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.28 -115.83 4.12 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 52.22 112.525 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -116.18 -76.22 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 65.42 110.88 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -113.7 156.27 43.86 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.681 0.753 . . . . 74.51 110.845 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -77.85 -177.72 4.07 Favored 'Trans proline' 0 C--N 1.366 1.463 0 O-C-N 118.261 -1.494 . . . . 63.02 110.517 -178.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mp -110.78 -64.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 118.429 -0.795 . . . . 75.31 110.69 -173.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.6 p -100.09 176.42 5.41 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.686 -1.15 . . . . 74.23 109.976 -172.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -176.78 4.8 Favored 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.004 0.82 . . . . 75.21 112.707 -176.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -68.77 -174.24 0.55 Allowed 'General case' 0 C--N 1.353 0.748 0 CA-C-O 119.136 -0.459 . . . . 73.14 110.428 -169.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.547 -1.421 . . . . 63.32 109.547 176.981 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 N-CA-C 110.259 -1.136 . . . . 61.34 110.259 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.66 -157.34 9.07 Favored Glycine 0 C--N 1.353 1.488 0 CA-C-O 118.439 -1.201 . . . . 64.5 111.146 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.66 42.63 1.81 Allowed 'General case' 0 C--N 1.356 0.883 0 CA-C-N 118.115 0.957 . . . . 73.51 109.846 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.85 -147.89 3.91 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-O 118.609 -1.106 . . . . 61.3 112.572 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.3 m80 -113.97 -22.73 9.94 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.452 0.626 . . . . 72.41 110.887 -171.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -110.46 135.64 20.65 Favored Pre-proline 0 C--N 1.361 1.085 0 O-C-N 119.437 -2.039 . . . . 72.14 106.529 -171.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.49 150.5 57.81 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.593 2.319 . . . . 65.22 112.603 -174.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -81.25 -41.86 21.58 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.564 -0.732 . . . . 75.34 109.448 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -143.38 175.57 9.81 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.699 -1.143 . . . . 74.32 109.255 -176.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -130.9 144.4 51.43 Favored 'General case' 0 C--N 1.357 0.902 0 CA-C-O 118.274 -0.87 . . . . 74.22 110.757 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.458 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -104.65 164.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.054 0.846 . . . . 73.55 111.103 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 25.5 mtp85 -77.25 25.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 73.15 110.904 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.07 -115.66 4.09 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 62.11 112.444 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -116.1 -76.63 0.57 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 75.53 110.871 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -113.36 155.86 44.02 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.675 0.75 . . . . 72.11 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -78.68 -179.88 5.86 Favored 'Trans proline' 0 C--N 1.366 1.482 0 O-C-N 118.47 -1.384 . . . . 74.43 110.897 -176.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 78.9 mt -108.36 -63.67 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.895 0 CA-C-O 118.303 -0.856 . . . . 75.24 111.142 -171.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.4 p -98.3 175.29 6.11 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.918 -1.039 . . . . 72.31 110.058 -173.097 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -136.32 177.02 8.17 Favored 'General case' 0 C--N 1.359 0.995 0 CA-C-O 118.63 -0.7 . . . . 73.32 111.652 -176.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -67.3 171.73 5.57 Favored 'General case' 0 C--N 1.353 0.727 0 CA-C-N 118.728 0.695 . . . . 72.41 111.029 -168.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.799 0 C-N-CA 119.938 -1.125 . . . . 71.31 111.624 174.869 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.649 0 N-CA-C 110.328 -1.109 . . . . 74.43 110.328 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.37 -164.09 5.96 Favored Glycine 0 C--N 1.353 1.527 0 CA-C-N 118.214 1.007 . . . . 73.14 111.408 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.53 41.56 2.0 Favored 'General case' 0 C--N 1.355 0.826 0 CA-C-N 117.906 0.853 . . . . 74.23 109.367 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.33 -144.69 3.69 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.47 -1.183 . . . . 73.41 112.088 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 42.4 m80 -115.46 -23.4 8.84 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.701 0.75 . . . . 73.13 110.831 -169.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.2 t -110.02 136.8 20.41 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.364 -2.085 . . . . 64.32 106.655 -172.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -70.94 151.45 62.37 Favored 'Trans proline' 0 C--N 1.358 1.026 0 CA-C-N 123.666 2.345 . . . . 74.4 113.05 -174.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -82.9 -40.44 20.19 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.525 -0.75 . . . . 60.45 109.612 177.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.5 p90 -145.46 174.55 11.05 Favored 'General case' 0 C--N 1.354 0.769 0 CA-C-O 117.594 -1.193 . . . . 64.43 109.419 -178.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -130.01 144.54 51.39 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-O 118.05 -0.976 . . . . 73.44 110.889 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.457 ' C ' ' H ' ' A' ' 13' ' ' GLY . 21.9 t -105.95 164.91 4.11 Favored 'Isoleucine or valine' 0 C--N 1.359 0.98 0 O-C-N 124.136 0.898 . . . . 74.43 111.15 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.4 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 30.8 mtp180 -77.21 25.3 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 74.21 110.864 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.48 4.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.784 -0.722 . . . . 62.3 112.479 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -116.24 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 72.33 110.821 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -114.25 156.27 44.52 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.656 0.741 . . . . 72.51 110.861 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -78.95 177.73 8.36 Favored 'Trans proline' 0 C--N 1.365 1.413 0 O-C-N 118.532 -1.352 . . . . 62.22 110.421 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -108.83 -58.6 3.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-O 118.144 -0.932 . . . . 72.51 111.798 -172.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.5 p -97.41 177.2 5.61 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 117.808 -1.092 . . . . 71.11 110.206 -173.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -138.78 178.6 7.03 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-N 118.746 0.703 . . . . 64.12 111.73 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -69.71 178.98 2.33 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.694 0.679 . . . . 74.04 109.927 -170.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.751 0 CA-C-O 117.832 -1.538 . . . . 62.33 109.934 178.097 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.626 0 N-CA-C 110.302 -1.119 . . . . 73.1 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.6 -158.65 5.29 Favored Glycine 0 C--N 1.353 1.487 0 CA-C-O 118.864 -0.964 . . . . 63.54 111.308 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -117.57 42.29 2.63 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-N 118.007 0.903 . . . . 62.35 109.341 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.71 -143.46 2.93 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.31 -1.272 . . . . 64.15 111.906 179.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.8 m170 -115.47 -23.26 8.9 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.93 0.865 . . . . 73.12 110.911 -170.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -109.14 136.27 20.13 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.405 -2.059 . . . . 71.01 106.433 -172.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -71.52 150.97 58.42 Favored 'Trans proline' 0 C--N 1.358 1.034 0 CA-C-N 123.598 2.321 . . . . 72.25 112.471 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -82.74 -40.06 21.06 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.604 -0.712 . . . . 73.45 109.721 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.1 p90 -143.75 174.66 10.61 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-O 117.589 -1.196 . . . . 70.03 109.498 -178.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.69 144.44 51.29 Favored 'General case' 0 C--N 1.356 0.874 0 CA-C-O 118.058 -0.973 . . . . 73.22 110.711 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.461 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.3 t -105.56 164.8 4.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 O-C-N 124.104 0.878 . . . . 74.24 111.16 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.401 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 10.0 mtt85 -77.47 25.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 75.34 110.893 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.461 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.46 4.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.739 . . . . 52.1 112.491 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -116.13 -76.18 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 62.53 110.864 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -113.91 155.76 44.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 74.23 110.874 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -77.54 178.12 8.0 Favored 'Trans proline' 0 C--N 1.365 1.438 0 O-C-N 118.84 -1.189 . . . . 75.23 110.569 -177.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 73.8 mt -105.64 -61.27 2.55 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 CA-C-O 118.509 -0.757 . . . . 71.31 111.077 -171.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 p -99.92 178.02 4.93 Favored 'General case' 0 C--N 1.354 0.78 0 CA-C-O 117.942 -1.027 . . . . 62.04 110.257 -171.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -137.1 178.44 7.08 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-O 118.751 -0.642 . . . . 70.03 111.435 -176.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.49 169.93 11.57 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-N 118.776 0.717 . . . . 64.44 111.118 -168.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.802 0 CA-C-O 118.216 -1.324 . . . . 63.02 111.184 177.717 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.653 0 N-CA-C 110.748 -0.941 . . . . 71.22 110.748 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.1 -161.58 5.35 Favored Glycine 0 C--N 1.353 1.517 0 CA-C-O 118.82 -0.989 . . . . 63.35 111.512 -179.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.04 42.02 2.28 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.95 0.875 . . . . 74.11 109.236 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.97 -143.08 3.48 Favored Glycine 0 C--N 1.353 1.512 0 CA-C-O 118.334 -1.259 . . . . 72.14 112.062 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.2 m80 -116.58 -22.67 8.57 Favored 'General case' 0 C--N 1.359 0.999 0 CA-C-N 117.855 0.827 . . . . 61.52 110.851 -169.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -109.75 136.08 20.36 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.131 -2.231 . . . . 71.42 106.607 -173.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.12 151.19 66.88 Favored 'Trans proline' 0 C--N 1.358 1.078 0 CA-C-N 123.662 2.343 . . . . 60.33 112.167 -175.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -83.91 -39.14 20.19 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-O 118.483 -0.77 . . . . 74.15 109.947 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -145.62 174.08 11.49 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.888 -1.053 . . . . 74.21 109.533 -178.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -132.73 136.25 46.26 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-O 117.167 -1.397 . . . . 74.21 109.676 -178.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.471 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -102.43 164.91 3.06 Favored 'Isoleucine or valine' 0 C--N 1.357 0.921 0 CA-C-N 119.152 0.887 . . . . 74.41 111.168 175.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.9 mtp180 -76.64 29.64 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 75.23 110.852 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.471 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.25 4.05 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.742 -0.742 . . . . 71.13 112.492 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -116.1 -75.49 0.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.873 0.368 . . . . 72.34 110.887 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -118.89 156.08 52.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.695 0.76 . . . . 75.41 110.862 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -78.04 178.54 7.47 Favored 'Trans proline' 0 C--N 1.365 1.433 0 O-C-N 118.572 -1.331 . . . . 71.23 110.702 -177.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.5 mt -107.35 -60.57 2.84 Favored 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-O 118.268 -0.872 . . . . 71.34 111.242 -171.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 70.6 p -105.2 176.69 5.08 Favored 'General case' 0 C--N 1.353 0.743 0 CA-C-O 117.84 -1.076 . . . . 72.02 109.938 -171.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -136.63 179.65 6.24 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-N 118.65 0.659 . . . . 75.1 111.584 -173.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -67.9 173.12 4.71 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 118.642 0.655 . . . . 63.21 110.678 -169.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.778 0 CA-C-O 118.361 -1.244 . . . . 73.35 110.833 178.29 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.69 0 N-CA-C 110.79 -0.924 . . . . 71.5 110.79 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.98 -163.65 7.65 Favored Glycine 0 C--N 1.352 1.462 0 CA-C-N 118.179 0.989 . . . . 72.4 111.878 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.03 40.08 2.01 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-N 117.677 0.738 . . . . 73.24 109.756 178.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.49 -146.05 3.64 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-O 118.604 -1.109 . . . . 52.02 112.889 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -114.89 -22.95 9.36 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 117.53 0.665 . . . . 75.44 110.802 -170.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -110.86 135.77 20.78 Favored Pre-proline 0 C--N 1.362 1.129 0 O-C-N 119.161 -2.212 . . . . 74.4 106.872 -172.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.96 151.99 68.1 Favored 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.767 2.381 . . . . 71.22 112.877 -174.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -83.93 -41.68 17.11 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-O 118.618 -0.706 . . . . 73.11 109.701 178.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -145.95 172.33 13.52 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.657 -1.163 . . . . 73.44 109.248 -178.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -127.77 143.97 51.11 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 118.226 -0.892 . . . . 73.35 110.684 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.47 ' C ' ' H ' ' A' ' 13' ' ' GLY . 21.9 t -105.24 164.97 3.85 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 O-C-N 124.139 0.9 . . . . 74.21 111.138 177.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.401 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 13.9 mtp85 -76.83 25.85 0.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 73.23 110.898 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.06 -115.55 4.08 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 54.04 112.473 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.3 -76.2 0.57 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.816 0.341 . . . . 74.32 110.822 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -114.94 156.45 45.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.602 0.715 . . . . 71.41 110.895 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -78.42 179.22 6.7 Favored 'Trans proline' 0 C--N 1.366 1.462 0 O-C-N 118.798 -1.212 . . . . 74.52 110.577 -177.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.9 mt -106.43 -59.97 3.12 Favored 'Isoleucine or valine' 0 C--N 1.355 0.839 0 CA-C-O 118.415 -0.802 . . . . 71.52 111.28 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.3 p -108.0 177.2 4.88 Favored 'General case' 0 C--N 1.353 0.753 0 CA-C-O 117.755 -1.117 . . . . 75.04 109.934 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -138.33 179.55 6.39 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 118.943 0.792 . . . . 75.22 112.196 -172.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -69.47 179.1 2.18 Favored 'General case' 0 C--N 1.352 0.715 0 CA-C-N 118.449 0.568 . . . . 73.54 110.576 -168.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.773 0 CA-C-O 118.235 -1.314 . . . . 62.15 109.882 177.193 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.684 0 N-CA-C 110.965 -0.854 . . . . 72.14 110.965 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.83 -163.01 8.49 Favored Glycine 0 C--N 1.352 1.471 0 CA-C-N 118.083 0.941 . . . . 73.14 111.947 -178.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.09 40.68 1.88 Allowed 'General case' 0 C--N 1.356 0.881 0 CA-C-N 117.647 0.723 . . . . 62.24 109.678 178.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.48 -146.66 3.85 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.531 -1.149 . . . . 64.33 112.771 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -114.64 -22.77 9.58 Favored 'General case' 0 C--N 1.359 1.001 0 CA-C-N 117.524 0.662 . . . . 74.34 110.839 -171.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.4 t -111.45 136.3 21.0 Favored Pre-proline 0 C--N 1.362 1.112 0 O-C-N 119.282 -2.136 . . . . 74.1 106.701 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.49 153.26 65.68 Favored 'Trans proline' 0 C--N 1.358 1.062 0 CA-C-N 123.706 2.359 . . . . 73.11 113.185 -174.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -85.14 -42.57 14.64 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 118.665 -0.683 . . . . 73.4 109.653 178.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -145.8 172.14 13.76 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 117.583 -1.199 . . . . 74.04 109.145 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -127.57 143.77 51.14 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-O 118.04 -0.981 . . . . 71.33 110.824 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.469 ' C ' ' H ' ' A' ' 13' ' ' GLY . 21.9 t -105.44 165.17 3.84 Favored 'Isoleucine or valine' 0 C--N 1.357 0.931 0 O-C-N 124.138 0.899 . . . . 64.5 111.135 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.403 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 12.6 mtp180 -76.88 25.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 73.11 110.865 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.45 4.07 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 75.41 112.514 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -116.15 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.898 0.38 . . . . 73.14 110.903 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -115.34 156.2 46.03 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.647 0.737 . . . . 74.52 110.929 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.15 174.73 12.04 Favored 'Trans proline' 0 C--N 1.365 1.437 0 O-C-N 118.771 -1.226 . . . . 72.01 110.74 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -100.0 -61.75 2.23 Favored 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-O 118.677 -0.677 . . . . 74.42 110.093 -172.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.0 p -106.64 177.25 4.91 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 117.737 -1.125 . . . . 72.33 110.564 -169.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -137.93 -179.88 6.03 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.907 0.776 . . . . 65.4 112.391 -173.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.08 -179.83 2.07 Favored 'General case' 0 C--N 1.354 0.775 0 CA-C-N 118.505 0.593 . . . . 72.42 110.63 -168.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.755 0 CA-C-O 118.153 -1.359 . . . . 72.22 109.968 176.313 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 N-CA-C 110.787 -0.925 . . . . 64.41 110.787 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.53 -162.16 7.42 Favored Glycine 0 C--N 1.353 1.484 0 CA-C-O 118.834 -0.981 . . . . 72.11 111.851 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -111.94 39.83 2.3 Favored 'General case' 0 C--N 1.356 0.866 0 CA-C-N 117.804 0.802 . . . . 73.23 109.753 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.1 -145.52 3.17 Favored Glycine 0 C--N 1.354 1.545 0 CA-C-O 118.549 -1.14 . . . . 61.14 112.751 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.5 m80 -114.99 -23.05 9.26 Favored 'General case' 0 C--N 1.359 0.993 0 CA-C-N 117.572 0.686 . . . . 74.51 110.893 -169.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.2 t -110.76 136.47 20.7 Favored Pre-proline 0 C--N 1.361 1.096 0 O-C-N 119.306 -2.121 . . . . 73.34 106.694 -172.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 152.63 65.92 Favored 'Trans proline' 0 C--N 1.358 1.077 0 CA-C-N 123.776 2.384 . . . . 72.45 112.839 -174.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.95 -41.33 17.46 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.687 -0.673 . . . . 74.3 109.794 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -146.46 173.8 11.96 Favored 'General case' 0 C--N 1.353 0.738 0 CA-C-O 117.566 -1.207 . . . . 73.14 109.177 -178.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -128.67 144.1 51.09 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-O 118.147 -0.93 . . . . 74.44 110.917 179.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -105.2 164.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.917 0 O-C-N 124.117 0.886 . . . . 74.33 111.1 177.207 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.402 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 3.6 mtt-85 -77.2 25.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 73.24 110.88 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.36 4.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.719 -0.753 . . . . 60.13 112.495 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.25 -76.0 0.58 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.343 . . . . 73.22 110.854 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -115.14 156.77 45.0 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.659 0.742 . . . . 65.43 110.913 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -79.48 178.47 7.34 Favored 'Trans proline' 0 C--N 1.365 1.404 0 O-C-N 118.454 -1.393 . . . . 74.0 110.194 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.8 mm -109.25 -57.16 4.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 CA-C-O 118.138 -0.934 . . . . 72.1 112.036 -172.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 77.9 p -103.54 176.18 5.24 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 117.767 -1.111 . . . . 74.43 110.047 -172.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -138.68 178.62 7.01 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-N 118.916 0.78 . . . . 73.21 112.208 -173.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -69.9 178.28 2.74 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-N 118.555 0.616 . . . . 73.43 110.557 -168.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.259 1.718 0 CA-C-O 118.169 -1.351 . . . . 75.01 109.876 176.484 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 110.202 -1.159 . . . . 71.54 110.202 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.03 -161.75 13.82 Favored Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.513 -1.16 . . . . 63.4 110.961 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.39 43.22 1.2 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.01 0.905 . . . . 73.21 109.393 178.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -150.24 3.0 Favored Glycine 0 C--N 1.352 1.457 0 CA-C-O 118.896 -0.947 . . . . 74.14 112.674 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.6 m170 -113.56 -22.33 10.36 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.32 0.648 . . . . 73.34 110.854 -171.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.2 t -111.67 136.36 21.1 Favored Pre-proline 0 C--N 1.362 1.116 0 O-C-N 119.264 -2.147 . . . . 74.31 106.632 -172.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.01 152.72 63.1 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 123.796 2.391 . . . . 73.53 112.865 -174.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -82.5 -43.64 16.93 Favored 'General case' 0 C--N 1.353 0.756 0 CA-C-O 118.715 -0.66 . . . . 74.31 109.52 178.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -143.68 176.48 9.19 Favored 'General case' 0 C--N 1.353 0.733 0 CA-C-O 117.592 -1.194 . . . . 74.12 109.02 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -131.69 143.62 50.41 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.164 -0.922 . . . . 72.13 110.872 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.464 ' C ' ' H ' ' A' ' 13' ' ' GLY . 22.0 t -104.41 165.08 3.55 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 O-C-N 124.019 0.824 . . . . 72.33 111.137 177.017 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.403 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 61.2 mtp180 -76.9 25.71 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 75.13 110.903 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.464 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.14 -115.72 4.1 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.776 -0.726 . . . . 74.12 112.489 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -116.06 -76.15 0.58 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.875 0.369 . . . . 65.22 110.876 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -115.11 155.96 46.0 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.67 0.747 . . . . 72.33 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -78.85 179.69 6.26 Favored 'Trans proline' 0 C--N 1.366 1.478 0 O-C-N 118.53 -1.353 . . . . 73.31 111.108 -176.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 76.0 mt -107.8 -62.95 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 CA-C-O 118.07 -0.967 . . . . 74.42 111.257 -171.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 63.5 p -97.94 175.67 6.05 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.857 -1.068 . . . . 71.44 110.344 -172.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -136.9 176.15 8.97 Favored 'General case' 0 C--N 1.359 0.98 0 CA-C-O 118.718 -0.658 . . . . 74.34 111.711 -177.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -67.77 -177.09 0.73 Allowed 'General case' 0 C--N 1.353 0.746 0 CA-C-N 118.601 0.637 . . . . 72.12 110.305 -168.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.753 0 CA-C-O 117.763 -1.576 . . . . 71.15 109.751 179.069 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.7 0 N-CA-C 110.608 -0.997 . . . . 71.299999999999997 110.608 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -160.69 8.01 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-O 118.63 -1.095 . . . . 62.310000000000002 111.88 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -113.02 40.91 2.2 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 117.9 0.85 . . . . 53.0 109.907 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.13 -146.93 4.46 Favored Glycine 0 C--N 1.354 1.533 0 CA-C-O 118.55 -1.139 . . . . 65.430000000000007 112.928 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -113.82 -22.98 9.89 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-N 117.559 0.68 . . . . 74.200000000000003 110.848 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -110.15 135.69 20.54 Favored Pre-proline 0 C--N 1.361 1.108 0 O-C-N 119.145 -2.222 . . . . 72.099999999999994 106.865 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.54 151.58 70.31 Favored 'Trans proline' 0 C--N 1.358 1.064 0 CA-C-N 123.709 2.36 . . . . 73.329999999999998 112.75 -174.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -83.39 -42.15 17.35 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 118.673 -0.68 . . . . 71.030000000000001 109.667 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -143.6 173.4 11.68 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.876 -1.059 . . . . 74.349999999999994 109.416 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -132.32 137.64 47.5 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-O 117.062 -1.447 . . . . 52.020000000000003 109.778 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -103.22 164.9 3.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-N 119.231 0.923 . . . . 73.409999999999997 111.172 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 56.7 mtp85 -76.74 29.51 0.13 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 75.140000000000001 110.911 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.65 4.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.743 -0.741 . . . . 70.209999999999994 112.463 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -116.11 -76.1 0.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 64.129999999999995 110.849 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -116.95 156.42 48.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.632 0.729 . . . . 74.430000000000007 110.915 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.79 178.26 7.48 Favored 'Trans proline' 0 C--N 1.365 1.428 0 O-C-N 118.133 -1.562 . . . . 74.040000000000006 110.238 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.5 mm -110.78 -57.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.909 0 CA-C-O 118.126 -0.94 . . . . 61.450000000000003 112.158 -172.404 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.1 p -100.86 176.31 5.33 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-O 117.79 -1.1 . . . . 62.43 110.017 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -140.3 -178.62 5.57 Favored 'General case' 0 C--N 1.358 0.948 0 CA-C-N 118.992 0.815 . . . . 73.209999999999994 112.178 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -70.15 -177.31 1.35 Allowed 'General case' 0 C--N 1.354 0.768 0 CA-C-N 118.587 0.63 . . . . 71.319999999999993 110.793 -168.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 109.986 -1.245 . . . . 70.239999999999995 109.986 175.584 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.662 0 N-CA-C 110.383 -1.087 . . . . 73.310000000000002 110.383 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.83 -164.56 5.56 Favored Glycine 0 C--N 1.354 1.541 0 C-N-CA 120.243 -0.979 . . . . 52.340000000000003 111.619 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.2 41.67 1.93 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 117.784 0.792 . . . . 71.109999999999999 109.367 178.313 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.09 -144.91 4.26 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.333 -1.26 . . . . 50.310000000000002 112.218 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.3 m80 -115.45 -22.33 9.36 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-N 117.781 0.79 . . . . 75.340000000000003 110.905 -170.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.7 t -110.14 136.87 20.45 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.175 -2.203 . . . . 63.329999999999998 106.872 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -70.05 150.54 66.59 Favored 'Trans proline' 0 C--N 1.356 0.964 0 CA-C-N 123.802 2.393 . . . . 74.319999999999993 112.743 -175.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -82.52 -41.03 20.2 Favored 'General case' 0 C--N 1.356 0.857 0 CA-C-O 118.68 -0.676 . . . . 74.540000000000006 109.771 177.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -144.79 173.98 11.38 Favored 'General case' 0 C--N 1.353 0.728 0 CA-C-O 117.869 -1.062 . . . . 74.329999999999998 109.417 -177.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -132.51 137.04 47.04 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-O 117.16 -1.4 . . . . 74.099999999999994 109.702 -178.016 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.57 164.91 3.1 Favored 'Isoleucine or valine' 0 C--N 1.357 0.928 0 CA-C-N 119.191 0.905 . . . . 73.430000000000007 111.096 175.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 74.9 mtm180 -76.92 29.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 61.240000000000002 110.866 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.438 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.85 -115.51 4.08 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.709 -0.757 . . . . 74.040000000000006 112.473 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.96 -76.24 0.58 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.868 0.366 . . . . 74.099999999999994 110.873 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -116.97 156.02 48.67 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.638 0.732 . . . . 75.409999999999997 110.903 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -78.79 174.46 12.22 Favored 'Trans proline' 0 C--N 1.366 1.466 0 O-C-N 118.524 -1.356 . . . . 65.430000000000007 110.561 -178.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.423 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -103.1 -64.41 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.911 0 CA-C-O 118.456 -0.783 . . . . 71.420000000000002 110.112 -172.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.0 p -98.15 178.36 5.1 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-O 117.75 -1.119 . . . . 73.019999999999996 110.606 -170.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -137.7 179.45 6.41 Favored 'General case' 0 C--N 1.36 1.037 0 CA-C-N 118.847 0.749 . . . . 74.319999999999993 112.053 -175.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.2 176.61 3.17 Favored 'General case' 0 C--N 1.354 0.767 0 CA-C-O 118.648 -0.692 . . . . 75.540000000000006 110.237 -169.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.82 0 CA-C-O 118.182 -1.344 . . . . 54.119999999999997 110.048 177.747 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.983 -1.247 . . . . 53.329999999999998 109.983 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.15 -161.03 12.52 Favored Glycine 0 C--N 1.354 1.557 0 CA-C-O 118.758 -1.023 . . . . 53.119999999999997 111.373 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.2 42.04 1.44 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 117.751 0.775 . . . . 75.319999999999993 109.938 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.56 -149.56 4.51 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-O 118.711 -1.049 . . . . 53.43 112.723 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -113.76 -22.41 10.21 Favored 'General case' 0 C--N 1.359 0.989 0 C-N-CA 123.235 0.614 . . . . 75.409999999999997 110.893 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.1 t -109.86 135.53 20.45 Favored Pre-proline 0 C--N 1.361 1.079 0 O-C-N 119.183 -2.198 . . . . 55.5 106.893 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.89 149.09 65.62 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.726 2.367 . . . . 43.439999999999998 112.49 -175.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -80.24 -44.8 19.08 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.715 -0.66 . . . . 63.299999999999997 109.542 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.4 p90 -140.98 173.93 11.0 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.973 -1.013 . . . . 71.109999999999999 109.41 -175.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -133.4 135.74 44.84 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.165 -1.398 . . . . 75.450000000000003 109.574 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.1 t -101.89 164.85 2.95 Favored 'Isoleucine or valine' 0 C--N 1.357 0.912 0 CA-C-N 119.2 0.909 . . . . 75.400000000000006 111.119 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp85 -76.83 29.91 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 72.519999999999996 110.887 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -104.04 -115.4 4.07 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.78 -0.724 . . . . 73.230000000000004 112.504 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -116.26 -75.34 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.856 0.36 . . . . 71.519999999999996 110.868 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -118.16 155.87 51.07 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.642 0.734 . . . . 73.319999999999993 110.855 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -79.49 174.29 12.05 Favored 'Trans proline' 0 C--N 1.366 1.489 0 O-C-N 118.403 -1.419 . . . . 70.310000000000002 110.883 -177.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.41 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -102.86 -64.54 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.904 0 CA-C-O 118.389 -0.815 . . . . 64.340000000000003 110.072 -172.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.1 p -98.26 176.22 5.79 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 117.792 -1.099 . . . . 63.219999999999999 110.866 -170.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -137.82 178.51 7.06 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.79 0.723 . . . . 74.010000000000005 112.125 -176.63 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -69.39 -178.36 1.36 Allowed 'General case' 0 C--N 1.353 0.723 0 CA-C-N 118.502 0.592 . . . . 74.140000000000001 110.571 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 110.029 -1.228 . . . . 33.520000000000003 110.029 176.048 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.61 0 N-CA-C 109.968 -1.253 . . . . 43.210000000000001 109.968 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.27 -162.18 8.47 Favored Glycine 0 C--N 1.353 1.509 0 C-N-CA 120.344 -0.932 . . . . 64.549999999999997 111.268 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.61 43.49 1.24 Allowed 'General case' 0 C--N 1.357 0.891 0 CA-C-N 117.823 0.811 . . . . 73.219999999999999 109.135 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.13 -148.73 3.77 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.611 -1.105 . . . . 51.450000000000003 112.177 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -114.07 -23.06 9.72 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 117.437 0.619 . . . . 73.140000000000001 110.84 -172.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.7 t -108.79 136.12 20.03 Favored Pre-proline 0 C--N 1.361 1.091 0 O-C-N 119.145 -2.222 . . . . 71.25 106.607 -172.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.56 148.45 59.95 Favored 'Trans proline' 0 C--N 1.357 1.023 0 CA-C-N 123.663 2.344 . . . . 75.099999999999994 112.265 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -80.08 -42.05 24.42 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.539 -0.743 . . . . 73.530000000000001 109.514 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -142.58 174.54 10.54 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 118.017 -0.992 . . . . 62.119999999999997 109.662 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -133.25 136.9 45.84 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 117.14 -1.409 . . . . 71.239999999999995 109.62 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.56 164.86 3.11 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 CA-C-N 119.174 0.897 . . . . 62.049999999999997 111.145 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 59.3 mtp180 -77.06 29.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 73.049999999999997 110.85 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.92 -115.32 4.06 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.766 -0.73 . . . . 64.450000000000003 112.483 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -116.1 -75.74 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.85 0.357 . . . . 74.319999999999993 110.884 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -117.55 155.74 50.05 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.676 0.751 . . . . 72.439999999999998 110.891 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.16 173.51 13.29 Favored 'Trans proline' 0 C--N 1.366 1.484 0 O-C-N 118.508 -1.364 . . . . 72.329999999999998 111.009 -176.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.39 -64.88 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-O 118.39 -0.814 . . . . 61.409999999999997 110.004 -172.508 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.6 p -95.25 175.65 6.52 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.0 -1.0 . . . . 70.230000000000004 110.842 -170.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -136.6 177.8 7.57 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-O 118.661 -0.685 . . . . 65.519999999999996 111.542 -177.163 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -66.95 177.86 1.57 Allowed 'General case' 0 C--N 1.353 0.759 0 CA-C-N 118.824 0.738 . . . . 64.439999999999998 110.702 -169.595 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.775 0 CA-C-O 118.214 -1.326 . . . . 50.530000000000001 109.874 179.28 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.691 0 N-CA-C 110.429 -1.068 . . . . 42.399999999999999 110.429 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -156.11 5.02 Favored Glycine 0 C--N 1.353 1.511 0 CA-C-O 118.581 -1.122 . . . . 74.209999999999994 111.293 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -120.1 42.17 3.01 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 118.225 1.013 . . . . 72.230000000000004 109.541 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.09 -143.74 3.23 Favored Glycine 0 C--N 1.353 1.522 0 CA-C-O 118.233 -1.315 . . . . 72.140000000000001 111.916 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 -114.63 -22.42 9.76 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-N 117.934 0.867 . . . . 70.129999999999995 110.817 -170.499 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -109.76 136.82 20.31 Favored Pre-proline 0 C--N 1.361 1.089 0 O-C-N 119.465 -2.022 . . . . 70.109999999999999 106.474 -172.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -72.07 150.91 55.06 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.677 2.349 . . . . 74.519999999999996 112.498 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -81.8 -39.76 23.57 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.603 -0.713 . . . . 64.120000000000005 109.637 178.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 p90 -145.78 175.71 10.2 Favored 'General case' 0 C--N 1.353 0.726 0 CA-C-O 117.491 -1.243 . . . . 73.230000000000004 109.385 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -130.14 145.29 51.69 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-O 118.106 -0.95 . . . . 73.329999999999998 110.929 177.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.47 164.99 3.92 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.159 0.912 . . . . 71.310000000000002 111.109 177.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 26.1 mtt85 -77.23 25.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.456 . . . . 62.329999999999998 110.893 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.08 -115.81 4.11 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.742 -0.742 . . . . 71.430000000000007 112.474 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -116.06 -76.43 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.35 . . . . 75.5 110.863 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.6 m-85 -113.44 155.91 44.05 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.634 0.73 . . . . 73.239999999999995 110.876 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -78.74 173.56 13.45 Favored 'Trans proline' 0 C--N 1.364 1.384 0 O-C-N 118.609 -1.311 . . . . 65.129999999999995 110.542 -177.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.422 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -102.07 -64.69 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-O 118.62 -0.705 . . . . 65.540000000000006 109.75 -173.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.0 p -90.75 177.6 6.28 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 118.058 -0.972 . . . . 62.43 111.076 -170.279 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -137.51 177.14 8.1 Favored 'General case' 0 C--N 1.358 0.955 0 CA-C-O 118.64 -0.695 . . . . 71.140000000000001 111.495 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -71.57 169.35 15.69 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.87 0.759 . . . . 75.230000000000004 111.098 -168.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.811 0 C-N-CA 119.858 -1.163 . . . . 53.200000000000003 111.404 174.281 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 110.577 -1.009 . . . . 71.340000000000003 110.577 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.5 -158.36 6.02 Favored Glycine 0 C--N 1.353 1.497 0 CA-C-O 118.662 -1.077 . . . . 55.43 111.557 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.87 41.8 2.64 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.032 0.916 . . . . 72.510000000000005 109.644 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.99 -144.4 3.38 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 118.323 -1.265 . . . . 72.310000000000002 112.111 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -114.92 -23.02 9.31 Favored 'General case' 0 C--N 1.358 0.973 0 CA-C-N 117.83 0.815 . . . . 65.230000000000004 110.872 -170.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.5 t -109.64 136.8 20.27 Favored Pre-proline 0 C--N 1.362 1.117 0 O-C-N 119.325 -2.109 . . . . 61.25 106.612 -172.077 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.1 151.31 61.29 Favored 'Trans proline' 0 C--N 1.357 1.019 0 CA-C-N 123.6 2.321 . . . . 51.399999999999999 112.643 -175.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.89 -41.68 17.17 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-O 118.765 -0.636 . . . . 72.209999999999994 109.728 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -145.27 174.71 10.86 Favored 'General case' 0 C--N 1.353 0.736 0 CA-C-O 117.502 -1.237 . . . . 63.32 109.196 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -130.24 145.09 51.71 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 118.139 -0.934 . . . . 63.329999999999998 110.927 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.98 165.03 3.74 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 O-C-N 124.212 0.945 . . . . 72.129999999999995 111.125 177.201 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.581 ' N ' HG12 ' A' ' 11' ' ' VAL . 41.1 mtp85 -76.97 26.23 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 71.530000000000001 110.89 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.436 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.37 -116.02 4.14 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 60.130000000000003 112.519 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -116.27 -76.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.8 0.334 . . . . 73.519999999999996 110.908 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -113.93 156.1 44.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.634 0.731 . . . . 75.219999999999999 110.911 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -79.7 174.48 11.67 Favored 'Trans proline' 0 C--N 1.365 1.441 0 O-C-N 117.96 -1.653 . . . . 53.399999999999999 110.602 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -100.64 -63.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.913 0 CA-C-O 118.632 -0.699 . . . . 60.409999999999997 110.058 -172.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 28.0 p -98.46 177.22 5.41 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 117.941 -1.028 . . . . 63.350000000000001 110.802 -169.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -136.16 -179.64 5.79 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.649 -0.691 . . . . 74.109999999999999 111.73 -175.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -70.24 171.08 10.4 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 118.828 0.74 . . . . 71.010000000000005 111.357 -168.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.741 0 CA-C-O 117.989 -1.451 . . . . 12.35 111.386 176.245 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.644 0 N-CA-C 110.101 -1.2 . . . . 61.299999999999997 110.101 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.7 -164.73 15.87 Favored Glycine 0 C--N 1.353 1.52 0 C-N-CA 120.342 -0.932 . . . . 71.400000000000006 111.652 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -105.2 45.44 0.96 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 117.559 0.68 . . . . 61.340000000000003 109.712 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -84.78 -150.0 11.49 Favored Glycine 0 C--N 1.354 1.54 0 CA-C-O 118.469 -1.184 . . . . 74.530000000000001 113.077 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 45.3 m170 -113.3 -23.27 10.0 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.46 0.63 . . . . 73.120000000000005 110.862 -173.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 91.9 t -111.15 132.24 21.81 Favored Pre-proline 0 C--N 1.362 1.139 0 O-C-N 119.08 -2.263 . . . . 72.340000000000003 106.988 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -68.96 153.17 72.97 Favored 'Trans proline' 0 C--N 1.356 0.965 0 CA-C-N 123.631 2.333 . . . . 62.409999999999997 112.9 -172.19 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -83.46 -46.87 11.99 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 118.82 -0.61 . . . . 73.140000000000001 109.429 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 p90 -141.66 168.29 20.11 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 117.669 -1.158 . . . . 75.420000000000002 109.09 -177.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -123.92 144.87 49.52 Favored 'General case' 0 C--N 1.356 0.885 0 CA-C-O 118.257 -0.878 . . . . 74.329999999999998 110.49 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.31 164.98 3.87 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 O-C-N 124.237 0.961 . . . . 73.340000000000003 111.138 177.426 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 22.5 mtp180 -77.16 25.68 0.16 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 72.010000000000005 110.918 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.28 -115.83 4.12 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 52.119999999999997 112.525 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -116.18 -76.22 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 65.420000000000002 110.88 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -113.7 156.27 43.86 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.681 0.753 . . . . 62.210000000000001 110.845 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -77.85 -177.72 4.07 Favored 'Trans proline' 0 C--N 1.366 1.463 0 O-C-N 118.261 -1.494 . . . . 61.43 110.517 -178.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mp -110.78 -64.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 118.429 -0.795 . . . . 75.310000000000002 110.69 -173.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.6 p -100.09 176.42 5.41 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.686 -1.15 . . . . 74.230000000000004 109.976 -172.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -176.78 4.8 Favored 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.004 0.82 . . . . 75.209999999999994 112.707 -176.835 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -68.77 -174.24 0.55 Allowed 'General case' 0 C--N 1.353 0.748 0 CA-C-O 119.136 -0.459 . . . . 73.140000000000001 110.428 -169.177 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.547 -1.421 . . . . 53.130000000000003 109.547 176.981 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 N-CA-C 110.259 -1.136 . . . . 51.200000000000003 110.259 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.66 -157.34 9.07 Favored Glycine 0 C--N 1.353 1.488 0 CA-C-O 118.439 -1.201 . . . . 53.399999999999999 111.146 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.66 42.63 1.81 Allowed 'General case' 0 C--N 1.356 0.883 0 CA-C-N 118.115 0.957 . . . . 73.200000000000003 109.846 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.85 -147.89 3.91 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-O 118.609 -1.106 . . . . 61.299999999999997 112.572 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.3 m80 -113.97 -22.73 9.94 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.452 0.626 . . . . 71.319999999999993 110.887 -171.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -110.46 135.64 20.65 Favored Pre-proline 0 C--N 1.361 1.085 0 O-C-N 119.437 -2.039 . . . . 55.240000000000002 106.529 -171.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.49 150.5 57.81 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.593 2.319 . . . . 65.219999999999999 112.603 -174.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -81.25 -41.86 21.58 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.564 -0.732 . . . . 75.340000000000003 109.448 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -143.38 175.57 9.81 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.699 -1.143 . . . . 74.319999999999993 109.255 -176.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -130.9 144.4 51.43 Favored 'General case' 0 C--N 1.357 0.902 0 CA-C-O 118.274 -0.87 . . . . 74.219999999999999 110.757 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.65 164.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.054 0.846 . . . . 63.310000000000002 111.103 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.579 ' N ' HG12 ' A' ' 11' ' ' VAL . 25.5 mtp85 -77.25 25.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 64.340000000000003 110.904 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.07 -115.66 4.09 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 62.109999999999999 112.444 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -116.1 -76.63 0.57 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 75.530000000000001 110.871 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -113.36 155.86 44.02 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.675 0.75 . . . . 72.109999999999999 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -78.68 -179.88 5.86 Favored 'Trans proline' 0 C--N 1.366 1.482 0 O-C-N 118.47 -1.384 . . . . 52.009999999999998 110.897 -176.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 78.9 mt -108.36 -63.67 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.895 0 CA-C-O 118.303 -0.856 . . . . 72.409999999999997 111.142 -171.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.4 p -98.3 175.29 6.11 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.918 -1.039 . . . . 72.209999999999994 110.058 -173.097 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -136.32 177.02 8.17 Favored 'General case' 0 C--N 1.359 0.995 0 CA-C-O 118.63 -0.7 . . . . 52.420000000000002 111.652 -176.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -67.3 171.73 5.57 Favored 'General case' 0 C--N 1.353 0.727 0 CA-C-N 118.728 0.695 . . . . 72.409999999999997 111.029 -168.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.799 0 C-N-CA 119.938 -1.125 . . . . 41.350000000000001 111.624 174.869 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.649 0 N-CA-C 110.328 -1.109 . . . . 50.219999999999999 110.328 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.37 -164.09 5.96 Favored Glycine 0 C--N 1.353 1.527 0 CA-C-N 118.214 1.007 . . . . 63.530000000000001 111.408 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.53 41.56 2.0 Favored 'General case' 0 C--N 1.355 0.826 0 CA-C-N 117.906 0.853 . . . . 54.350000000000001 109.367 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.33 -144.69 3.69 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.47 -1.183 . . . . 73.409999999999997 112.088 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 42.4 m80 -115.46 -23.4 8.84 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.701 0.75 . . . . 72.219999999999999 110.831 -169.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.2 t -110.02 136.8 20.41 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.364 -2.085 . . . . 64.239999999999995 106.655 -172.078 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -70.94 151.45 62.37 Favored 'Trans proline' 0 C--N 1.358 1.026 0 CA-C-N 123.666 2.345 . . . . 74.019999999999996 113.05 -174.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -82.9 -40.44 20.19 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.525 -0.75 . . . . 60.450000000000003 109.612 177.531 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.5 p90 -145.46 174.55 11.05 Favored 'General case' 0 C--N 1.354 0.769 0 CA-C-O 117.594 -1.193 . . . . 51.229999999999997 109.419 -178.274 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -130.01 144.54 51.39 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-O 118.05 -0.976 . . . . 73.439999999999998 110.889 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.95 164.91 4.11 Favored 'Isoleucine or valine' 0 C--N 1.359 0.98 0 O-C-N 124.136 0.898 . . . . 74.430000000000007 111.15 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 30.8 mtp180 -77.21 25.3 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 74.209999999999994 110.864 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.48 4.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.784 -0.722 . . . . 62.299999999999997 112.479 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -116.24 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 72.329999999999998 110.821 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -114.25 156.27 44.52 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.656 0.741 . . . . 65.25 110.861 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -78.95 177.73 8.36 Favored 'Trans proline' 0 C--N 1.365 1.413 0 O-C-N 118.532 -1.352 . . . . 62.219999999999999 110.421 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -108.83 -58.6 3.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-O 118.144 -0.932 . . . . 32.420000000000002 111.798 -172.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.5 p -97.41 177.2 5.61 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 117.808 -1.092 . . . . 71.109999999999999 110.206 -173.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -138.78 178.6 7.03 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-N 118.746 0.703 . . . . 64.120000000000005 111.73 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -69.71 178.98 2.33 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.694 0.679 . . . . 74.040000000000006 109.927 -170.235 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.751 0 CA-C-O 117.832 -1.538 . . . . 62.329999999999998 109.934 178.097 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.626 0 N-CA-C 110.302 -1.119 . . . . 62.219999999999999 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.6 -158.65 5.29 Favored Glycine 0 C--N 1.353 1.487 0 CA-C-O 118.864 -0.964 . . . . 24.120000000000001 111.308 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -117.57 42.29 2.63 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-N 118.007 0.903 . . . . 62.350000000000001 109.341 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.71 -143.46 2.93 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.31 -1.272 . . . . 40.140000000000001 111.906 179.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.8 m170 -115.47 -23.26 8.9 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.93 0.865 . . . . 73.120000000000005 110.911 -170.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -109.14 136.27 20.13 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.405 -2.059 . . . . 71.010000000000005 106.433 -172.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -71.52 150.97 58.42 Favored 'Trans proline' 0 C--N 1.358 1.034 0 CA-C-N 123.598 2.321 . . . . 72.25 112.471 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -82.74 -40.06 21.06 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.604 -0.712 . . . . 73.450000000000003 109.721 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.1 p90 -143.75 174.66 10.61 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-O 117.589 -1.196 . . . . 65.200000000000003 109.498 -178.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.69 144.44 51.29 Favored 'General case' 0 C--N 1.356 0.874 0 CA-C-O 118.058 -0.973 . . . . 71.120000000000005 110.711 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.578 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.3 t -105.56 164.8 4.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 O-C-N 124.104 0.878 . . . . 71.349999999999994 111.16 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.578 ' N ' HG12 ' A' ' 11' ' ' VAL . 10.0 mtt85 -77.47 25.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 60.350000000000001 110.893 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.43 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.46 4.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.739 . . . . 31.300000000000001 112.491 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -116.13 -76.18 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 62.530000000000001 110.864 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -113.91 155.76 44.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 74.230000000000004 110.874 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -77.54 178.12 8.0 Favored 'Trans proline' 0 C--N 1.365 1.438 0 O-C-N 118.84 -1.189 . . . . 75.230000000000004 110.569 -177.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 73.8 mt -105.64 -61.27 2.55 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 CA-C-O 118.509 -0.757 . . . . 55.020000000000003 111.077 -171.683 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 p -99.92 178.02 4.93 Favored 'General case' 0 C--N 1.354 0.78 0 CA-C-O 117.942 -1.027 . . . . 62.039999999999999 110.257 -171.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -137.1 178.44 7.08 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-O 118.751 -0.642 . . . . 63.340000000000003 111.435 -176.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.49 169.93 11.57 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-N 118.776 0.717 . . . . 64.439999999999998 111.118 -168.066 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.802 0 CA-C-O 118.216 -1.324 . . . . 63.020000000000003 111.184 177.717 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.653 0 N-CA-C 110.748 -0.941 . . . . 71.219999999999999 110.748 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.1 -161.58 5.35 Favored Glycine 0 C--N 1.353 1.517 0 CA-C-O 118.82 -0.989 . . . . 63.100000000000001 111.512 -179.518 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.04 42.02 2.28 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.95 0.875 . . . . 74.109999999999999 109.236 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.97 -143.08 3.48 Favored Glycine 0 C--N 1.353 1.512 0 CA-C-O 118.334 -1.259 . . . . 72.140000000000001 112.062 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.2 m80 -116.58 -22.67 8.57 Favored 'General case' 0 C--N 1.359 0.999 0 CA-C-N 117.855 0.827 . . . . 61.520000000000003 110.851 -169.037 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -109.75 136.08 20.36 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.131 -2.231 . . . . 71.420000000000002 106.607 -173.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.12 151.19 66.88 Favored 'Trans proline' 0 C--N 1.358 1.078 0 CA-C-N 123.662 2.343 . . . . 60.329999999999998 112.167 -175.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -83.91 -39.14 20.19 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-O 118.483 -0.77 . . . . 74.150000000000006 109.947 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -145.62 174.08 11.49 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.888 -1.053 . . . . 72.420000000000002 109.533 -178.372 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -132.73 136.25 46.26 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-O 117.167 -1.397 . . . . 74.209999999999994 109.676 -178.731 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.43 164.91 3.06 Favored 'Isoleucine or valine' 0 C--N 1.357 0.921 0 CA-C-N 119.152 0.887 . . . . 74.329999999999998 111.168 175.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.9 mtp180 -76.64 29.64 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.219999999999999 110.852 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.25 4.05 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.742 -0.742 . . . . 65.340000000000003 112.492 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -116.1 -75.49 0.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.873 0.368 . . . . 72.340000000000003 110.887 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -118.89 156.08 52.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.695 0.76 . . . . 75.409999999999997 110.862 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -78.04 178.54 7.47 Favored 'Trans proline' 0 C--N 1.365 1.433 0 O-C-N 118.572 -1.331 . . . . 71.230000000000004 110.702 -177.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.5 mt -107.35 -60.57 2.84 Favored 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-O 118.268 -0.872 . . . . 71.340000000000003 111.242 -171.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 70.6 p -105.2 176.69 5.08 Favored 'General case' 0 C--N 1.353 0.743 0 CA-C-O 117.84 -1.076 . . . . 54.43 109.938 -171.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -136.63 179.65 6.24 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-N 118.65 0.659 . . . . 71.010000000000005 111.584 -173.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -67.9 173.12 4.71 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 118.642 0.655 . . . . 63.210000000000001 110.678 -169.187 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.778 0 CA-C-O 118.361 -1.244 . . . . 31.23 110.833 178.29 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.69 0 N-CA-C 110.79 -0.924 . . . . 63.399999999999999 110.79 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.98 -163.65 7.65 Favored Glycine 0 C--N 1.352 1.462 0 CA-C-N 118.179 0.989 . . . . 72.400000000000006 111.878 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.03 40.08 2.01 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-N 117.677 0.738 . . . . 73.239999999999995 109.756 178.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.49 -146.05 3.64 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-O 118.604 -1.109 . . . . 52.020000000000003 112.889 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -114.89 -22.95 9.36 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 117.53 0.665 . . . . 75.439999999999998 110.802 -170.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -110.86 135.77 20.78 Favored Pre-proline 0 C--N 1.362 1.129 0 O-C-N 119.161 -2.212 . . . . 74.400000000000006 106.872 -172.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.96 151.99 68.1 Favored 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.767 2.381 . . . . 53.399999999999999 112.877 -174.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -83.93 -41.68 17.11 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-O 118.618 -0.706 . . . . 73.109999999999999 109.701 178.853 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -145.95 172.33 13.52 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.657 -1.163 . . . . 61.32 109.248 -178.485 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -127.77 143.97 51.11 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 118.226 -0.892 . . . . 73.349999999999994 110.684 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.24 164.97 3.85 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 O-C-N 124.139 0.9 . . . . 74.209999999999994 111.138 177.177 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 13.9 mtp85 -76.83 25.85 0.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 73.230000000000004 110.898 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.06 -115.55 4.08 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 54.039999999999999 112.473 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.3 -76.2 0.57 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.816 0.341 . . . . 74.129999999999995 110.822 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -114.94 156.45 45.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.602 0.715 . . . . 71.409999999999997 110.895 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -78.42 179.22 6.7 Favored 'Trans proline' 0 C--N 1.366 1.462 0 O-C-N 118.798 -1.212 . . . . 73.340000000000003 110.577 -177.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.9 mt -106.43 -59.97 3.12 Favored 'Isoleucine or valine' 0 C--N 1.355 0.839 0 CA-C-O 118.415 -0.802 . . . . 71.519999999999996 111.28 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.3 p -108.0 177.2 4.88 Favored 'General case' 0 C--N 1.353 0.753 0 CA-C-O 117.755 -1.117 . . . . 74.340000000000003 109.934 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -138.33 179.55 6.39 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 118.943 0.792 . . . . 72.030000000000001 112.196 -172.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -69.47 179.1 2.18 Favored 'General case' 0 C--N 1.352 0.715 0 CA-C-N 118.449 0.568 . . . . 55.32 110.576 -168.495 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.773 0 CA-C-O 118.235 -1.314 . . . . 62.149999999999999 109.882 177.193 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.684 0 N-CA-C 110.965 -0.854 . . . . 72.140000000000001 110.965 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.83 -163.01 8.49 Favored Glycine 0 C--N 1.352 1.471 0 CA-C-N 118.083 0.941 . . . . 73.140000000000001 111.947 -178.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.09 40.68 1.88 Allowed 'General case' 0 C--N 1.356 0.881 0 CA-C-N 117.647 0.723 . . . . 50.439999999999998 109.678 178.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.48 -146.66 3.85 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.531 -1.149 . . . . 62.549999999999997 112.771 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -114.64 -22.77 9.58 Favored 'General case' 0 C--N 1.359 1.001 0 CA-C-N 117.524 0.662 . . . . 74.340000000000003 110.839 -171.015 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.4 t -111.45 136.3 21.0 Favored Pre-proline 0 C--N 1.362 1.112 0 O-C-N 119.282 -2.136 . . . . 41.119999999999997 106.701 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.49 153.26 65.68 Favored 'Trans proline' 0 C--N 1.358 1.062 0 CA-C-N 123.706 2.359 . . . . 54.450000000000003 113.185 -174.253 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -85.14 -42.57 14.64 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 118.665 -0.683 . . . . 73.400000000000006 109.653 178.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -145.8 172.14 13.76 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 117.583 -1.199 . . . . 73.349999999999994 109.145 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -127.57 143.77 51.14 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-O 118.04 -0.981 . . . . 71.329999999999998 110.824 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.44 165.17 3.84 Favored 'Isoleucine or valine' 0 C--N 1.357 0.931 0 O-C-N 124.138 0.899 . . . . 64.5 111.135 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.585 ' N ' HG12 ' A' ' 11' ' ' VAL . 12.6 mtp180 -76.88 25.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 72.510000000000005 110.865 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.45 4.07 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 34.520000000000003 112.514 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -116.15 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.898 0.38 . . . . 65.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -115.34 156.2 46.03 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.647 0.737 . . . . 53.130000000000003 110.929 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.15 174.73 12.04 Favored 'Trans proline' 0 C--N 1.365 1.437 0 O-C-N 118.771 -1.226 . . . . 71.340000000000003 110.74 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.413 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.6 mp -100.0 -61.75 2.23 Favored 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-O 118.677 -0.677 . . . . 72.209999999999994 110.093 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.0 p -106.64 177.25 4.91 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 117.737 -1.125 . . . . 71.430000000000007 110.564 -169.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -137.93 -179.88 6.03 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.907 0.776 . . . . 64.030000000000001 112.391 -173.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.08 -179.83 2.07 Favored 'General case' 0 C--N 1.354 0.775 0 CA-C-N 118.505 0.593 . . . . 64.209999999999994 110.63 -168.444 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.755 0 CA-C-O 118.153 -1.359 . . . . 72.209999999999994 109.968 176.313 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 N-CA-C 110.787 -0.925 . . . . 64.409999999999997 110.787 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.53 -162.16 7.42 Favored Glycine 0 C--N 1.353 1.484 0 CA-C-O 118.834 -0.981 . . . . 55.100000000000001 111.851 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -111.94 39.83 2.3 Favored 'General case' 0 C--N 1.356 0.866 0 CA-C-N 117.804 0.802 . . . . 71.439999999999998 109.753 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.1 -145.52 3.17 Favored Glycine 0 C--N 1.354 1.545 0 CA-C-O 118.549 -1.14 . . . . 61.140000000000001 112.751 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.5 m80 -114.99 -23.05 9.26 Favored 'General case' 0 C--N 1.359 0.993 0 CA-C-N 117.572 0.686 . . . . 74.109999999999999 110.893 -169.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.2 t -110.76 136.47 20.7 Favored Pre-proline 0 C--N 1.361 1.096 0 O-C-N 119.306 -2.121 . . . . 73.340000000000003 106.694 -172.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 152.63 65.92 Favored 'Trans proline' 0 C--N 1.358 1.077 0 CA-C-N 123.776 2.384 . . . . 72.450000000000003 112.839 -174.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.95 -41.33 17.46 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.687 -0.673 . . . . 74.299999999999997 109.794 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -146.46 173.8 11.96 Favored 'General case' 0 C--N 1.353 0.738 0 CA-C-O 117.566 -1.207 . . . . 72.109999999999999 109.177 -178.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -128.67 144.1 51.09 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-O 118.147 -0.93 . . . . 74.439999999999998 110.917 179.23 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.2 164.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.917 0 O-C-N 124.117 0.886 . . . . 60.229999999999997 111.1 177.207 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 3.6 mtt-85 -77.2 25.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 70.140000000000001 110.88 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.36 4.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.719 -0.753 . . . . 41.109999999999999 112.495 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.25 -76.0 0.58 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.343 . . . . 65.120000000000005 110.854 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -115.14 156.77 45.0 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.659 0.742 . . . . 53.340000000000003 110.913 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -79.48 178.47 7.34 Favored 'Trans proline' 0 C--N 1.365 1.404 0 O-C-N 118.454 -1.393 . . . . 51.210000000000001 110.194 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.8 mm -109.25 -57.16 4.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 CA-C-O 118.138 -0.934 . . . . 65.099999999999994 112.036 -172.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 77.9 p -103.54 176.18 5.24 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 117.767 -1.111 . . . . 74.430000000000007 110.047 -172.409 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -138.68 178.62 7.01 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-N 118.916 0.78 . . . . 63.119999999999997 112.208 -173.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -69.9 178.28 2.74 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-N 118.555 0.616 . . . . 71.430000000000007 110.557 -168.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.259 1.718 0 CA-C-O 118.169 -1.351 . . . . 30.109999999999999 109.876 176.484 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 110.202 -1.159 . . . . 55.240000000000002 110.202 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.03 -161.75 13.82 Favored Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.513 -1.16 . . . . 63.399999999999999 110.961 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.39 43.22 1.2 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.01 0.905 . . . . 53.109999999999999 109.393 178.506 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -150.24 3.0 Favored Glycine 0 C--N 1.352 1.457 0 CA-C-O 118.896 -0.947 . . . . 74.140000000000001 112.674 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.6 m170 -113.56 -22.33 10.36 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.32 0.648 . . . . 73.340000000000003 110.854 -171.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.2 t -111.67 136.36 21.1 Favored Pre-proline 0 C--N 1.362 1.116 0 O-C-N 119.264 -2.147 . . . . 64.349999999999994 106.632 -172.324 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.01 152.72 63.1 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 123.796 2.391 . . . . 73.439999999999998 112.865 -174.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -82.5 -43.64 16.93 Favored 'General case' 0 C--N 1.353 0.756 0 CA-C-O 118.715 -0.66 . . . . 74.310000000000002 109.52 178.143 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -143.68 176.48 9.19 Favored 'General case' 0 C--N 1.353 0.733 0 CA-C-O 117.592 -1.194 . . . . 71.510000000000005 109.02 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -131.69 143.62 50.41 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.164 -0.922 . . . . 72.129999999999995 110.872 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.41 165.08 3.55 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 O-C-N 124.019 0.824 . . . . 65.310000000000002 111.137 177.017 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.587 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp180 -76.9 25.71 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 73.530000000000001 110.903 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.437 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.14 -115.72 4.1 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.776 -0.726 . . . . 63.130000000000003 112.489 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -116.06 -76.15 0.58 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.875 0.369 . . . . 65.219999999999999 110.876 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -115.11 155.96 46.0 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.67 0.747 . . . . 72.329999999999998 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -78.85 179.69 6.26 Favored 'Trans proline' 0 C--N 1.366 1.478 0 O-C-N 118.53 -1.353 . . . . 70.040000000000006 111.108 -176.791 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 76.0 mt -107.8 -62.95 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 CA-C-O 118.07 -0.967 . . . . 53.409999999999997 111.257 -171.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 63.5 p -97.94 175.67 6.05 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.857 -1.068 . . . . 50.240000000000002 110.344 -172.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -136.9 176.15 8.97 Favored 'General case' 0 C--N 1.359 0.98 0 CA-C-O 118.718 -0.658 . . . . 74.340000000000003 111.711 -177.06 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -67.77 -177.09 0.73 Allowed 'General case' 0 C--N 1.353 0.746 0 CA-C-N 118.601 0.637 . . . . 71.319999999999993 110.305 -168.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.753 0 CA-C-O 117.763 -1.576 . . . . 64.450000000000003 109.751 179.069 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.7 0 N-CA-C 110.608 -0.997 . . . . 71.299999999999997 110.608 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -160.69 8.01 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-O 118.63 -1.095 . . . . 62.310000000000002 111.88 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -113.02 40.91 2.2 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 117.9 0.85 . . . . 53.0 109.907 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.13 -146.93 4.46 Favored Glycine 0 C--N 1.354 1.533 0 CA-C-O 118.55 -1.139 . . . . 65.430000000000007 112.928 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -113.82 -22.98 9.89 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-N 117.559 0.68 . . . . 74.200000000000003 110.848 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -110.15 135.69 20.54 Favored Pre-proline 0 C--N 1.361 1.108 0 O-C-N 119.145 -2.222 . . . . 72.099999999999994 106.865 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.54 151.58 70.31 Favored 'Trans proline' 0 C--N 1.358 1.064 0 CA-C-N 123.709 2.36 . . . . 73.329999999999998 112.75 -174.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -83.39 -42.15 17.35 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 118.673 -0.68 . . . . 71.030000000000001 109.667 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -143.6 173.4 11.68 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.876 -1.059 . . . . 74.349999999999994 109.416 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -132.32 137.64 47.5 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-O 117.062 -1.447 . . . . 52.020000000000003 109.778 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -103.22 164.9 3.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-N 119.231 0.923 . . . . 73.409999999999997 111.172 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 56.7 mtp85 -76.74 29.51 0.13 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 75.140000000000001 110.911 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.65 4.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.743 -0.741 . . . . 70.209999999999994 112.463 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -116.11 -76.1 0.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 64.129999999999995 110.849 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -116.95 156.42 48.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.632 0.729 . . . . 74.430000000000007 110.915 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.79 178.26 7.48 Favored 'Trans proline' 0 C--N 1.365 1.428 0 O-C-N 118.133 -1.562 . . . . 74.040000000000006 110.238 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.5 mm -110.78 -57.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.909 0 CA-C-O 118.126 -0.94 . . . . 61.450000000000003 112.158 -172.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.1 p -100.86 176.31 5.33 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-O 117.79 -1.1 . . . . 62.43 110.017 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -140.3 -178.62 5.57 Favored 'General case' 0 C--N 1.358 0.948 0 CA-C-N 118.992 0.815 . . . . 73.209999999999994 112.178 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -70.15 -177.31 1.35 Allowed 'General case' 0 C--N 1.354 0.768 0 CA-C-N 118.587 0.63 . . . . 71.319999999999993 110.793 -168.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 109.986 -1.245 . . . . 70.239999999999995 109.986 175.584 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.662 0 N-CA-C 110.383 -1.087 . . . . 73.310000000000002 110.383 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.83 -164.56 5.56 Favored Glycine 0 C--N 1.354 1.541 0 C-N-CA 120.243 -0.979 . . . . 52.340000000000003 111.619 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.2 41.67 1.93 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 117.784 0.792 . . . . 71.109999999999999 109.367 178.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.09 -144.91 4.26 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.333 -1.26 . . . . 50.310000000000002 112.218 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.3 m80 -115.45 -22.33 9.36 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-N 117.781 0.79 . . . . 75.340000000000003 110.905 -170.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.7 t -110.14 136.87 20.45 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.175 -2.203 . . . . 63.329999999999998 106.872 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -70.05 150.54 66.59 Favored 'Trans proline' 0 C--N 1.356 0.964 0 CA-C-N 123.802 2.393 . . . . 74.319999999999993 112.743 -175.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -82.52 -41.03 20.2 Favored 'General case' 0 C--N 1.356 0.857 0 CA-C-O 118.68 -0.676 . . . . 74.540000000000006 109.771 177.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -144.79 173.98 11.38 Favored 'General case' 0 C--N 1.353 0.728 0 CA-C-O 117.869 -1.062 . . . . 74.329999999999998 109.417 -177.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -132.51 137.04 47.04 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-O 117.16 -1.4 . . . . 74.099999999999994 109.702 -178.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.57 164.91 3.1 Favored 'Isoleucine or valine' 0 C--N 1.357 0.928 0 CA-C-N 119.191 0.905 . . . . 73.430000000000007 111.096 175.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 74.9 mtm180 -76.92 29.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 61.240000000000002 110.866 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.438 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.85 -115.51 4.08 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.709 -0.757 . . . . 74.040000000000006 112.473 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.96 -76.24 0.58 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.868 0.366 . . . . 74.099999999999994 110.873 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -116.97 156.02 48.67 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.638 0.732 . . . . 75.409999999999997 110.903 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -78.79 174.46 12.22 Favored 'Trans proline' 0 C--N 1.366 1.466 0 O-C-N 118.524 -1.356 . . . . 65.430000000000007 110.561 -178.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.423 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -103.1 -64.41 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.911 0 CA-C-O 118.456 -0.783 . . . . 71.420000000000002 110.112 -172.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.0 p -98.15 178.36 5.1 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-O 117.75 -1.119 . . . . 73.019999999999996 110.606 -170.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -137.7 179.45 6.41 Favored 'General case' 0 C--N 1.36 1.037 0 CA-C-N 118.847 0.749 . . . . 74.319999999999993 112.053 -175.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.2 176.61 3.17 Favored 'General case' 0 C--N 1.354 0.767 0 CA-C-O 118.648 -0.692 . . . . 75.540000000000006 110.237 -169.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.82 0 CA-C-O 118.182 -1.344 . . . . 54.119999999999997 110.048 177.747 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.983 -1.247 . . . . 53.329999999999998 109.983 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.15 -161.03 12.52 Favored Glycine 0 C--N 1.354 1.557 0 CA-C-O 118.758 -1.023 . . . . 53.119999999999997 111.373 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.2 42.04 1.44 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 117.751 0.775 . . . . 75.319999999999993 109.938 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.56 -149.56 4.51 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-O 118.711 -1.049 . . . . 53.43 112.723 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -113.76 -22.41 10.21 Favored 'General case' 0 C--N 1.359 0.989 0 C-N-CA 123.235 0.614 . . . . 75.409999999999997 110.893 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.1 t -109.86 135.53 20.45 Favored Pre-proline 0 C--N 1.361 1.079 0 O-C-N 119.183 -2.198 . . . . 55.5 106.893 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.89 149.09 65.62 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.726 2.367 . . . . 43.439999999999998 112.49 -175.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -80.24 -44.8 19.08 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.715 -0.66 . . . . 63.299999999999997 109.542 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.4 p90 -140.98 173.93 11.0 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.973 -1.013 . . . . 71.109999999999999 109.41 -175.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -133.4 135.74 44.84 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.165 -1.398 . . . . 75.450000000000003 109.574 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.1 t -101.89 164.85 2.95 Favored 'Isoleucine or valine' 0 C--N 1.357 0.912 0 CA-C-N 119.2 0.909 . . . . 75.400000000000006 111.119 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp85 -76.83 29.91 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 72.519999999999996 110.887 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -104.04 -115.4 4.07 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.78 -0.724 . . . . 73.230000000000004 112.504 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -116.26 -75.34 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.856 0.36 . . . . 71.519999999999996 110.868 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -118.16 155.87 51.07 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.642 0.734 . . . . 73.319999999999993 110.855 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -79.49 174.29 12.05 Favored 'Trans proline' 0 C--N 1.366 1.489 0 O-C-N 118.403 -1.419 . . . . 70.310000000000002 110.883 -177.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.41 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -102.86 -64.54 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.904 0 CA-C-O 118.389 -0.815 . . . . 64.340000000000003 110.072 -172.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.1 p -98.26 176.22 5.79 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 117.792 -1.099 . . . . 63.219999999999999 110.866 -170.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -137.82 178.51 7.06 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.79 0.723 . . . . 74.010000000000005 112.125 -176.63 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -69.39 -178.36 1.36 Allowed 'General case' 0 C--N 1.353 0.723 0 CA-C-N 118.502 0.592 . . . . 74.140000000000001 110.571 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 110.029 -1.228 . . . . 33.520000000000003 110.029 176.048 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.61 0 N-CA-C 109.968 -1.253 . . . . 43.210000000000001 109.968 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.27 -162.18 8.47 Favored Glycine 0 C--N 1.353 1.509 0 C-N-CA 120.344 -0.932 . . . . 64.549999999999997 111.268 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.61 43.49 1.24 Allowed 'General case' 0 C--N 1.357 0.891 0 CA-C-N 117.823 0.811 . . . . 73.219999999999999 109.135 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.13 -148.73 3.77 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.611 -1.105 . . . . 51.450000000000003 112.177 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -114.07 -23.06 9.72 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 117.437 0.619 . . . . 73.140000000000001 110.84 -172.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.7 t -108.79 136.12 20.03 Favored Pre-proline 0 C--N 1.361 1.091 0 O-C-N 119.145 -2.222 . . . . 71.25 106.607 -172.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.56 148.45 59.95 Favored 'Trans proline' 0 C--N 1.357 1.023 0 CA-C-N 123.663 2.344 . . . . 75.099999999999994 112.265 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -80.08 -42.05 24.42 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.539 -0.743 . . . . 73.530000000000001 109.514 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -142.58 174.54 10.54 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 118.017 -0.992 . . . . 62.119999999999997 109.662 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -133.25 136.9 45.84 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 117.14 -1.409 . . . . 71.239999999999995 109.62 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.56 164.86 3.11 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 CA-C-N 119.174 0.897 . . . . 62.049999999999997 111.145 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 59.3 mtp180 -77.06 29.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 73.049999999999997 110.85 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.92 -115.32 4.06 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.766 -0.73 . . . . 64.450000000000003 112.483 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -116.1 -75.74 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.85 0.357 . . . . 74.319999999999993 110.884 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -117.55 155.74 50.05 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.676 0.751 . . . . 72.439999999999998 110.891 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.16 173.51 13.29 Favored 'Trans proline' 0 C--N 1.366 1.484 0 O-C-N 118.508 -1.364 . . . . 72.329999999999998 111.009 -176.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.39 -64.88 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-O 118.39 -0.814 . . . . 61.409999999999997 110.004 -172.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.6 p -95.25 175.65 6.52 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.0 -1.0 . . . . 70.230000000000004 110.842 -170.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -136.6 177.8 7.57 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-O 118.661 -0.685 . . . . 65.519999999999996 111.542 -177.163 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -66.95 177.86 1.57 Allowed 'General case' 0 C--N 1.353 0.759 0 CA-C-N 118.824 0.738 . . . . 64.439999999999998 110.702 -169.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.775 0 CA-C-O 118.214 -1.326 . . . . 50.530000000000001 109.874 179.28 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.691 0 N-CA-C 110.429 -1.068 . . . . 42.399999999999999 110.429 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -156.11 5.02 Favored Glycine 0 C--N 1.353 1.511 0 CA-C-O 118.581 -1.122 . . . . 74.209999999999994 111.293 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -120.1 42.17 3.01 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 118.225 1.013 . . . . 72.230000000000004 109.541 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.09 -143.74 3.23 Favored Glycine 0 C--N 1.353 1.522 0 CA-C-O 118.233 -1.315 . . . . 72.140000000000001 111.916 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 -114.63 -22.42 9.76 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-N 117.934 0.867 . . . . 70.129999999999995 110.817 -170.499 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -109.76 136.82 20.31 Favored Pre-proline 0 C--N 1.361 1.089 0 O-C-N 119.465 -2.022 . . . . 70.109999999999999 106.474 -172.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -72.07 150.91 55.06 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.677 2.349 . . . . 74.519999999999996 112.498 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -81.8 -39.76 23.57 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.603 -0.713 . . . . 64.120000000000005 109.637 178.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 p90 -145.78 175.71 10.2 Favored 'General case' 0 C--N 1.353 0.726 0 CA-C-O 117.491 -1.243 . . . . 73.230000000000004 109.385 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -130.14 145.29 51.69 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-O 118.106 -0.95 . . . . 73.329999999999998 110.929 177.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.47 164.99 3.92 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.159 0.912 . . . . 71.310000000000002 111.109 177.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 26.1 mtt85 -77.23 25.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.456 . . . . 62.329999999999998 110.893 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.08 -115.81 4.11 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.742 -0.742 . . . . 71.430000000000007 112.474 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -116.06 -76.43 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.35 . . . . 75.5 110.863 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.6 m-85 -113.44 155.91 44.05 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.634 0.73 . . . . 73.239999999999995 110.876 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -78.74 173.56 13.45 Favored 'Trans proline' 0 C--N 1.364 1.384 0 O-C-N 118.609 -1.311 . . . . 65.129999999999995 110.542 -177.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.422 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -102.07 -64.69 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-O 118.62 -0.705 . . . . 65.540000000000006 109.75 -173.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.0 p -90.75 177.6 6.28 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 118.058 -0.972 . . . . 62.43 111.076 -170.279 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -137.51 177.14 8.1 Favored 'General case' 0 C--N 1.358 0.955 0 CA-C-O 118.64 -0.695 . . . . 71.140000000000001 111.495 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -71.57 169.35 15.69 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.87 0.759 . . . . 75.230000000000004 111.098 -168.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.811 0 C-N-CA 119.858 -1.163 . . . . 53.200000000000003 111.404 174.281 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 110.577 -1.009 . . . . 71.340000000000003 110.577 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.5 -158.36 6.02 Favored Glycine 0 C--N 1.353 1.497 0 CA-C-O 118.662 -1.077 . . . . 55.43 111.557 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.87 41.8 2.64 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.032 0.916 . . . . 72.510000000000005 109.644 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.99 -144.4 3.38 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 118.323 -1.265 . . . . 72.310000000000002 112.111 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -114.92 -23.02 9.31 Favored 'General case' 0 C--N 1.358 0.973 0 CA-C-N 117.83 0.815 . . . . 65.230000000000004 110.872 -170.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.5 t -109.64 136.8 20.27 Favored Pre-proline 0 C--N 1.362 1.117 0 O-C-N 119.325 -2.109 . . . . 61.25 106.612 -172.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.1 151.31 61.29 Favored 'Trans proline' 0 C--N 1.357 1.019 0 CA-C-N 123.6 2.321 . . . . 51.399999999999999 112.643 -175.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.89 -41.68 17.17 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-O 118.765 -0.636 . . . . 72.209999999999994 109.728 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -145.27 174.71 10.86 Favored 'General case' 0 C--N 1.353 0.736 0 CA-C-O 117.502 -1.237 . . . . 63.32 109.196 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -130.24 145.09 51.71 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 118.139 -0.934 . . . . 63.329999999999998 110.927 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.98 165.03 3.74 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 O-C-N 124.212 0.945 . . . . 72.129999999999995 111.125 177.201 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.581 ' N ' HG12 ' A' ' 11' ' ' VAL . 41.1 mtp85 -76.97 26.23 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 71.530000000000001 110.89 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.436 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.37 -116.02 4.14 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 60.130000000000003 112.519 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -116.27 -76.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.8 0.334 . . . . 73.519999999999996 110.908 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -113.93 156.1 44.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.634 0.731 . . . . 75.219999999999999 110.911 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -79.7 174.48 11.67 Favored 'Trans proline' 0 C--N 1.365 1.441 0 O-C-N 117.96 -1.653 . . . . 53.399999999999999 110.602 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -100.64 -63.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.913 0 CA-C-O 118.632 -0.699 . . . . 60.409999999999997 110.058 -172.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 28.0 p -98.46 177.22 5.41 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 117.941 -1.028 . . . . 63.350000000000001 110.802 -169.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -136.16 -179.64 5.79 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.649 -0.691 . . . . 74.109999999999999 111.73 -175.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -70.24 171.08 10.4 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 118.828 0.74 . . . . 71.010000000000005 111.357 -168.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.741 0 CA-C-O 117.989 -1.451 . . . . 12.35 111.386 176.245 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.644 0 N-CA-C 110.101 -1.2 . . . . 61.299999999999997 110.101 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.7 -164.73 15.87 Favored Glycine 0 C--N 1.353 1.52 0 C-N-CA 120.342 -0.932 . . . . 71.400000000000006 111.652 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -105.2 45.44 0.96 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 117.559 0.68 . . . . 61.340000000000003 109.712 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -84.78 -150.0 11.49 Favored Glycine 0 C--N 1.354 1.54 0 CA-C-O 118.469 -1.184 . . . . 74.530000000000001 113.077 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 45.3 m170 -113.3 -23.27 10.0 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.46 0.63 . . . . 73.120000000000005 110.862 -173.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 91.9 t -111.15 132.24 21.81 Favored Pre-proline 0 C--N 1.362 1.139 0 O-C-N 119.08 -2.263 . . . . 72.340000000000003 106.988 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -68.96 153.17 72.97 Favored 'Trans proline' 0 C--N 1.356 0.965 0 CA-C-N 123.631 2.333 . . . . 62.409999999999997 112.9 -172.19 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -83.46 -46.87 11.99 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 118.82 -0.61 . . . . 73.140000000000001 109.429 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 p90 -141.66 168.29 20.11 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 117.669 -1.158 . . . . 75.420000000000002 109.09 -177.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -123.92 144.87 49.52 Favored 'General case' 0 C--N 1.356 0.885 0 CA-C-O 118.257 -0.878 . . . . 74.329999999999998 110.49 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.31 164.98 3.87 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 O-C-N 124.237 0.961 . . . . 73.340000000000003 111.138 177.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 22.5 mtp180 -77.16 25.68 0.16 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 72.010000000000005 110.918 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.28 -115.83 4.12 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 52.119999999999997 112.525 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -116.18 -76.22 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 65.420000000000002 110.88 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -113.7 156.27 43.86 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.681 0.753 . . . . 62.210000000000001 110.845 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -77.85 -177.72 4.07 Favored 'Trans proline' 0 C--N 1.366 1.463 0 O-C-N 118.261 -1.494 . . . . 61.43 110.517 -178.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mp -110.78 -64.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 118.429 -0.795 . . . . 75.310000000000002 110.69 -173.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.6 p -100.09 176.42 5.41 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.686 -1.15 . . . . 74.230000000000004 109.976 -172.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -176.78 4.8 Favored 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.004 0.82 . . . . 75.209999999999994 112.707 -176.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -68.77 -174.24 0.55 Allowed 'General case' 0 C--N 1.353 0.748 0 CA-C-O 119.136 -0.459 . . . . 73.140000000000001 110.428 -169.177 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.547 -1.421 . . . . 53.130000000000003 109.547 176.981 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 N-CA-C 110.259 -1.136 . . . . 51.200000000000003 110.259 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.66 -157.34 9.07 Favored Glycine 0 C--N 1.353 1.488 0 CA-C-O 118.439 -1.201 . . . . 53.399999999999999 111.146 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.66 42.63 1.81 Allowed 'General case' 0 C--N 1.356 0.883 0 CA-C-N 118.115 0.957 . . . . 73.200000000000003 109.846 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.85 -147.89 3.91 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-O 118.609 -1.106 . . . . 61.299999999999997 112.572 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.3 m80 -113.97 -22.73 9.94 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.452 0.626 . . . . 71.319999999999993 110.887 -171.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -110.46 135.64 20.65 Favored Pre-proline 0 C--N 1.361 1.085 0 O-C-N 119.437 -2.039 . . . . 55.240000000000002 106.529 -171.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.49 150.5 57.81 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.593 2.319 . . . . 65.219999999999999 112.603 -174.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -81.25 -41.86 21.58 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.564 -0.732 . . . . 75.340000000000003 109.448 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -143.38 175.57 9.81 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.699 -1.143 . . . . 74.319999999999993 109.255 -176.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -130.9 144.4 51.43 Favored 'General case' 0 C--N 1.357 0.902 0 CA-C-O 118.274 -0.87 . . . . 74.219999999999999 110.757 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.65 164.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.054 0.846 . . . . 63.310000000000002 111.103 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.579 ' N ' HG12 ' A' ' 11' ' ' VAL . 25.5 mtp85 -77.25 25.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 64.340000000000003 110.904 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.07 -115.66 4.09 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 62.109999999999999 112.444 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -116.1 -76.63 0.57 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 75.530000000000001 110.871 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -113.36 155.86 44.02 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.675 0.75 . . . . 72.109999999999999 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -78.68 -179.88 5.86 Favored 'Trans proline' 0 C--N 1.366 1.482 0 O-C-N 118.47 -1.384 . . . . 52.009999999999998 110.897 -176.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 78.9 mt -108.36 -63.67 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.895 0 CA-C-O 118.303 -0.856 . . . . 72.409999999999997 111.142 -171.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.4 p -98.3 175.29 6.11 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.918 -1.039 . . . . 72.209999999999994 110.058 -173.097 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -136.32 177.02 8.17 Favored 'General case' 0 C--N 1.359 0.995 0 CA-C-O 118.63 -0.7 . . . . 52.420000000000002 111.652 -176.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -67.3 171.73 5.57 Favored 'General case' 0 C--N 1.353 0.727 0 CA-C-N 118.728 0.695 . . . . 72.409999999999997 111.029 -168.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.799 0 C-N-CA 119.938 -1.125 . . . . 41.350000000000001 111.624 174.869 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.649 0 N-CA-C 110.328 -1.109 . . . . 50.219999999999999 110.328 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.37 -164.09 5.96 Favored Glycine 0 C--N 1.353 1.527 0 CA-C-N 118.214 1.007 . . . . 63.530000000000001 111.408 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.53 41.56 2.0 Favored 'General case' 0 C--N 1.355 0.826 0 CA-C-N 117.906 0.853 . . . . 54.350000000000001 109.367 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.33 -144.69 3.69 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.47 -1.183 . . . . 73.409999999999997 112.088 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 42.4 m80 -115.46 -23.4 8.84 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.701 0.75 . . . . 72.219999999999999 110.831 -169.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.2 t -110.02 136.8 20.41 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.364 -2.085 . . . . 64.239999999999995 106.655 -172.078 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -70.94 151.45 62.37 Favored 'Trans proline' 0 C--N 1.358 1.026 0 CA-C-N 123.666 2.345 . . . . 74.019999999999996 113.05 -174.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -82.9 -40.44 20.19 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.525 -0.75 . . . . 60.450000000000003 109.612 177.531 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.5 p90 -145.46 174.55 11.05 Favored 'General case' 0 C--N 1.354 0.769 0 CA-C-O 117.594 -1.193 . . . . 51.229999999999997 109.419 -178.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -130.01 144.54 51.39 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-O 118.05 -0.976 . . . . 73.439999999999998 110.889 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.95 164.91 4.11 Favored 'Isoleucine or valine' 0 C--N 1.359 0.98 0 O-C-N 124.136 0.898 . . . . 74.430000000000007 111.15 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 30.8 mtp180 -77.21 25.3 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 74.209999999999994 110.864 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.48 4.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.784 -0.722 . . . . 62.299999999999997 112.479 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -116.24 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 72.329999999999998 110.821 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -114.25 156.27 44.52 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.656 0.741 . . . . 65.25 110.861 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -78.95 177.73 8.36 Favored 'Trans proline' 0 C--N 1.365 1.413 0 O-C-N 118.532 -1.352 . . . . 62.219999999999999 110.421 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -108.83 -58.6 3.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-O 118.144 -0.932 . . . . 32.420000000000002 111.798 -172.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.5 p -97.41 177.2 5.61 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 117.808 -1.092 . . . . 71.109999999999999 110.206 -173.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -138.78 178.6 7.03 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-N 118.746 0.703 . . . . 64.120000000000005 111.73 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -69.71 178.98 2.33 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.694 0.679 . . . . 74.040000000000006 109.927 -170.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.751 0 CA-C-O 117.832 -1.538 . . . . 62.329999999999998 109.934 178.097 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.626 0 N-CA-C 110.302 -1.119 . . . . 62.219999999999999 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.6 -158.65 5.29 Favored Glycine 0 C--N 1.353 1.487 0 CA-C-O 118.864 -0.964 . . . . 24.120000000000001 111.308 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -117.57 42.29 2.63 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-N 118.007 0.903 . . . . 62.350000000000001 109.341 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.71 -143.46 2.93 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.31 -1.272 . . . . 40.140000000000001 111.906 179.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.8 m170 -115.47 -23.26 8.9 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.93 0.865 . . . . 73.120000000000005 110.911 -170.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -109.14 136.27 20.13 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.405 -2.059 . . . . 71.010000000000005 106.433 -172.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -71.52 150.97 58.42 Favored 'Trans proline' 0 C--N 1.358 1.034 0 CA-C-N 123.598 2.321 . . . . 72.25 112.471 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -82.74 -40.06 21.06 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.604 -0.712 . . . . 73.450000000000003 109.721 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.1 p90 -143.75 174.66 10.61 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-O 117.589 -1.196 . . . . 65.200000000000003 109.498 -178.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.69 144.44 51.29 Favored 'General case' 0 C--N 1.356 0.874 0 CA-C-O 118.058 -0.973 . . . . 71.120000000000005 110.711 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.3 t -105.56 164.8 4.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 O-C-N 124.104 0.878 . . . . 71.349999999999994 111.16 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.578 ' N ' HG12 ' A' ' 11' ' ' VAL . 10.0 mtt85 -77.47 25.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 60.350000000000001 110.893 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.43 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.46 4.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.739 . . . . 31.300000000000001 112.491 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -116.13 -76.18 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 62.530000000000001 110.864 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -113.91 155.76 44.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 74.230000000000004 110.874 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -77.54 178.12 8.0 Favored 'Trans proline' 0 C--N 1.365 1.438 0 O-C-N 118.84 -1.189 . . . . 75.230000000000004 110.569 -177.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 73.8 mt -105.64 -61.27 2.55 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 CA-C-O 118.509 -0.757 . . . . 55.020000000000003 111.077 -171.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 p -99.92 178.02 4.93 Favored 'General case' 0 C--N 1.354 0.78 0 CA-C-O 117.942 -1.027 . . . . 62.039999999999999 110.257 -171.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -137.1 178.44 7.08 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-O 118.751 -0.642 . . . . 63.340000000000003 111.435 -176.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.49 169.93 11.57 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-N 118.776 0.717 . . . . 64.439999999999998 111.118 -168.066 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.802 0 CA-C-O 118.216 -1.324 . . . . 63.020000000000003 111.184 177.717 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.653 0 N-CA-C 110.748 -0.941 . . . . 71.219999999999999 110.748 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.1 -161.58 5.35 Favored Glycine 0 C--N 1.353 1.517 0 CA-C-O 118.82 -0.989 . . . . 63.100000000000001 111.512 -179.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.04 42.02 2.28 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.95 0.875 . . . . 74.109999999999999 109.236 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.97 -143.08 3.48 Favored Glycine 0 C--N 1.353 1.512 0 CA-C-O 118.334 -1.259 . . . . 72.140000000000001 112.062 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.2 m80 -116.58 -22.67 8.57 Favored 'General case' 0 C--N 1.359 0.999 0 CA-C-N 117.855 0.827 . . . . 61.520000000000003 110.851 -169.037 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -109.75 136.08 20.36 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.131 -2.231 . . . . 71.420000000000002 106.607 -173.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.12 151.19 66.88 Favored 'Trans proline' 0 C--N 1.358 1.078 0 CA-C-N 123.662 2.343 . . . . 60.329999999999998 112.167 -175.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -83.91 -39.14 20.19 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-O 118.483 -0.77 . . . . 74.150000000000006 109.947 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -145.62 174.08 11.49 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.888 -1.053 . . . . 72.420000000000002 109.533 -178.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -132.73 136.25 46.26 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-O 117.167 -1.397 . . . . 74.209999999999994 109.676 -178.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.43 164.91 3.06 Favored 'Isoleucine or valine' 0 C--N 1.357 0.921 0 CA-C-N 119.152 0.887 . . . . 74.329999999999998 111.168 175.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.9 mtp180 -76.64 29.64 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.219999999999999 110.852 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.25 4.05 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.742 -0.742 . . . . 65.340000000000003 112.492 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -116.1 -75.49 0.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.873 0.368 . . . . 72.340000000000003 110.887 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -118.89 156.08 52.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.695 0.76 . . . . 75.409999999999997 110.862 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -78.04 178.54 7.47 Favored 'Trans proline' 0 C--N 1.365 1.433 0 O-C-N 118.572 -1.331 . . . . 71.230000000000004 110.702 -177.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.5 mt -107.35 -60.57 2.84 Favored 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-O 118.268 -0.872 . . . . 71.340000000000003 111.242 -171.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 70.6 p -105.2 176.69 5.08 Favored 'General case' 0 C--N 1.353 0.743 0 CA-C-O 117.84 -1.076 . . . . 54.43 109.938 -171.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -136.63 179.65 6.24 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-N 118.65 0.659 . . . . 71.010000000000005 111.584 -173.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -67.9 173.12 4.71 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 118.642 0.655 . . . . 63.210000000000001 110.678 -169.187 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.778 0 CA-C-O 118.361 -1.244 . . . . 31.23 110.833 178.29 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.69 0 N-CA-C 110.79 -0.924 . . . . 63.399999999999999 110.79 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.98 -163.65 7.65 Favored Glycine 0 C--N 1.352 1.462 0 CA-C-N 118.179 0.989 . . . . 72.400000000000006 111.878 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.03 40.08 2.01 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-N 117.677 0.738 . . . . 73.239999999999995 109.756 178.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.49 -146.05 3.64 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-O 118.604 -1.109 . . . . 52.020000000000003 112.889 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -114.89 -22.95 9.36 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 117.53 0.665 . . . . 75.439999999999998 110.802 -170.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -110.86 135.77 20.78 Favored Pre-proline 0 C--N 1.362 1.129 0 O-C-N 119.161 -2.212 . . . . 74.400000000000006 106.872 -172.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.96 151.99 68.1 Favored 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.767 2.381 . . . . 53.399999999999999 112.877 -174.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -83.93 -41.68 17.11 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-O 118.618 -0.706 . . . . 73.109999999999999 109.701 178.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -145.95 172.33 13.52 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.657 -1.163 . . . . 61.32 109.248 -178.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -127.77 143.97 51.11 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 118.226 -0.892 . . . . 73.349999999999994 110.684 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.24 164.97 3.85 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 O-C-N 124.139 0.9 . . . . 74.209999999999994 111.138 177.177 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 13.9 mtp85 -76.83 25.85 0.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 73.230000000000004 110.898 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.06 -115.55 4.08 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 54.039999999999999 112.473 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.3 -76.2 0.57 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.816 0.341 . . . . 74.129999999999995 110.822 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -114.94 156.45 45.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.602 0.715 . . . . 71.409999999999997 110.895 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -78.42 179.22 6.7 Favored 'Trans proline' 0 C--N 1.366 1.462 0 O-C-N 118.798 -1.212 . . . . 73.340000000000003 110.577 -177.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.9 mt -106.43 -59.97 3.12 Favored 'Isoleucine or valine' 0 C--N 1.355 0.839 0 CA-C-O 118.415 -0.802 . . . . 71.519999999999996 111.28 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.3 p -108.0 177.2 4.88 Favored 'General case' 0 C--N 1.353 0.753 0 CA-C-O 117.755 -1.117 . . . . 74.340000000000003 109.934 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -138.33 179.55 6.39 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 118.943 0.792 . . . . 72.030000000000001 112.196 -172.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -69.47 179.1 2.18 Favored 'General case' 0 C--N 1.352 0.715 0 CA-C-N 118.449 0.568 . . . . 55.32 110.576 -168.495 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.773 0 CA-C-O 118.235 -1.314 . . . . 62.149999999999999 109.882 177.193 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.684 0 N-CA-C 110.965 -0.854 . . . . 72.140000000000001 110.965 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.83 -163.01 8.49 Favored Glycine 0 C--N 1.352 1.471 0 CA-C-N 118.083 0.941 . . . . 73.140000000000001 111.947 -178.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.09 40.68 1.88 Allowed 'General case' 0 C--N 1.356 0.881 0 CA-C-N 117.647 0.723 . . . . 50.439999999999998 109.678 178.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.48 -146.66 3.85 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.531 -1.149 . . . . 62.549999999999997 112.771 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -114.64 -22.77 9.58 Favored 'General case' 0 C--N 1.359 1.001 0 CA-C-N 117.524 0.662 . . . . 74.340000000000003 110.839 -171.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.4 t -111.45 136.3 21.0 Favored Pre-proline 0 C--N 1.362 1.112 0 O-C-N 119.282 -2.136 . . . . 41.119999999999997 106.701 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.49 153.26 65.68 Favored 'Trans proline' 0 C--N 1.358 1.062 0 CA-C-N 123.706 2.359 . . . . 54.450000000000003 113.185 -174.253 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -85.14 -42.57 14.64 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 118.665 -0.683 . . . . 73.400000000000006 109.653 178.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -145.8 172.14 13.76 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 117.583 -1.199 . . . . 73.349999999999994 109.145 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -127.57 143.77 51.14 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-O 118.04 -0.981 . . . . 71.329999999999998 110.824 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.44 165.17 3.84 Favored 'Isoleucine or valine' 0 C--N 1.357 0.931 0 O-C-N 124.138 0.899 . . . . 64.5 111.135 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.585 ' N ' HG12 ' A' ' 11' ' ' VAL . 12.6 mtp180 -76.88 25.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 72.510000000000005 110.865 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.45 4.07 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 34.520000000000003 112.514 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -116.15 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.898 0.38 . . . . 65.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -115.34 156.2 46.03 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.647 0.737 . . . . 53.130000000000003 110.929 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.15 174.73 12.04 Favored 'Trans proline' 0 C--N 1.365 1.437 0 O-C-N 118.771 -1.226 . . . . 71.340000000000003 110.74 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.413 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.6 mp -100.0 -61.75 2.23 Favored 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-O 118.677 -0.677 . . . . 72.209999999999994 110.093 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.0 p -106.64 177.25 4.91 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 117.737 -1.125 . . . . 71.430000000000007 110.564 -169.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -137.93 -179.88 6.03 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.907 0.776 . . . . 64.030000000000001 112.391 -173.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.08 -179.83 2.07 Favored 'General case' 0 C--N 1.354 0.775 0 CA-C-N 118.505 0.593 . . . . 64.209999999999994 110.63 -168.444 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.755 0 CA-C-O 118.153 -1.359 . . . . 72.209999999999994 109.968 176.313 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 N-CA-C 110.787 -0.925 . . . . 64.409999999999997 110.787 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.53 -162.16 7.42 Favored Glycine 0 C--N 1.353 1.484 0 CA-C-O 118.834 -0.981 . . . . 55.100000000000001 111.851 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -111.94 39.83 2.3 Favored 'General case' 0 C--N 1.356 0.866 0 CA-C-N 117.804 0.802 . . . . 71.439999999999998 109.753 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.1 -145.52 3.17 Favored Glycine 0 C--N 1.354 1.545 0 CA-C-O 118.549 -1.14 . . . . 61.140000000000001 112.751 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.5 m80 -114.99 -23.05 9.26 Favored 'General case' 0 C--N 1.359 0.993 0 CA-C-N 117.572 0.686 . . . . 74.109999999999999 110.893 -169.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.2 t -110.76 136.47 20.7 Favored Pre-proline 0 C--N 1.361 1.096 0 O-C-N 119.306 -2.121 . . . . 73.340000000000003 106.694 -172.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 152.63 65.92 Favored 'Trans proline' 0 C--N 1.358 1.077 0 CA-C-N 123.776 2.384 . . . . 72.450000000000003 112.839 -174.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.95 -41.33 17.46 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.687 -0.673 . . . . 74.299999999999997 109.794 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -146.46 173.8 11.96 Favored 'General case' 0 C--N 1.353 0.738 0 CA-C-O 117.566 -1.207 . . . . 72.109999999999999 109.177 -178.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -128.67 144.1 51.09 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-O 118.147 -0.93 . . . . 74.439999999999998 110.917 179.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.2 164.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.917 0 O-C-N 124.117 0.886 . . . . 60.229999999999997 111.1 177.207 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 3.6 mtt-85 -77.2 25.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 70.140000000000001 110.88 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.36 4.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.719 -0.753 . . . . 41.109999999999999 112.495 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.25 -76.0 0.58 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.343 . . . . 65.120000000000005 110.854 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -115.14 156.77 45.0 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.659 0.742 . . . . 53.340000000000003 110.913 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -79.48 178.47 7.34 Favored 'Trans proline' 0 C--N 1.365 1.404 0 O-C-N 118.454 -1.393 . . . . 51.210000000000001 110.194 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.8 mm -109.25 -57.16 4.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 CA-C-O 118.138 -0.934 . . . . 65.099999999999994 112.036 -172.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 77.9 p -103.54 176.18 5.24 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 117.767 -1.111 . . . . 74.430000000000007 110.047 -172.409 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -138.68 178.62 7.01 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-N 118.916 0.78 . . . . 63.119999999999997 112.208 -173.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -69.9 178.28 2.74 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-N 118.555 0.616 . . . . 71.430000000000007 110.557 -168.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.259 1.718 0 CA-C-O 118.169 -1.351 . . . . 30.109999999999999 109.876 176.484 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 110.202 -1.159 . . . . 55.240000000000002 110.202 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.03 -161.75 13.82 Favored Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.513 -1.16 . . . . 63.399999999999999 110.961 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.39 43.22 1.2 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.01 0.905 . . . . 53.109999999999999 109.393 178.506 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -150.24 3.0 Favored Glycine 0 C--N 1.352 1.457 0 CA-C-O 118.896 -0.947 . . . . 74.140000000000001 112.674 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.6 m170 -113.56 -22.33 10.36 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.32 0.648 . . . . 73.340000000000003 110.854 -171.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.2 t -111.67 136.36 21.1 Favored Pre-proline 0 C--N 1.362 1.116 0 O-C-N 119.264 -2.147 . . . . 64.349999999999994 106.632 -172.324 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.01 152.72 63.1 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 123.796 2.391 . . . . 73.439999999999998 112.865 -174.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -82.5 -43.64 16.93 Favored 'General case' 0 C--N 1.353 0.756 0 CA-C-O 118.715 -0.66 . . . . 74.310000000000002 109.52 178.143 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -143.68 176.48 9.19 Favored 'General case' 0 C--N 1.353 0.733 0 CA-C-O 117.592 -1.194 . . . . 71.510000000000005 109.02 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -131.69 143.62 50.41 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.164 -0.922 . . . . 72.129999999999995 110.872 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.41 165.08 3.55 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 O-C-N 124.019 0.824 . . . . 65.310000000000002 111.137 177.017 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.587 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp180 -76.9 25.71 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 73.530000000000001 110.903 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.437 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.14 -115.72 4.1 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.776 -0.726 . . . . 63.130000000000003 112.489 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -116.06 -76.15 0.58 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.875 0.369 . . . . 65.219999999999999 110.876 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -115.11 155.96 46.0 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.67 0.747 . . . . 72.329999999999998 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -78.85 179.69 6.26 Favored 'Trans proline' 0 C--N 1.366 1.478 0 O-C-N 118.53 -1.353 . . . . 70.040000000000006 111.108 -176.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 76.0 mt -107.8 -62.95 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 CA-C-O 118.07 -0.967 . . . . 53.409999999999997 111.257 -171.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 63.5 p -97.94 175.67 6.05 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.857 -1.068 . . . . 50.240000000000002 110.344 -172.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -136.9 176.15 8.97 Favored 'General case' 0 C--N 1.359 0.98 0 CA-C-O 118.718 -0.658 . . . . 74.340000000000003 111.711 -177.06 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -67.77 -177.09 0.73 Allowed 'General case' 0 C--N 1.353 0.746 0 CA-C-N 118.601 0.637 . . . . 71.319999999999993 110.305 -168.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.753 0 CA-C-O 117.763 -1.576 . . . . 64.450000000000003 109.751 179.069 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.7 0 N-CA-C 110.608 -0.997 . . . . 71.299999999999997 110.608 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -160.69 8.01 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-O 118.63 -1.095 . . . . 62.310000000000002 111.88 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -113.02 40.91 2.2 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 117.9 0.85 . . . . 53.0 109.907 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.13 -146.93 4.46 Favored Glycine 0 C--N 1.354 1.533 0 CA-C-O 118.55 -1.139 . . . . 65.430000000000007 112.928 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -113.82 -22.98 9.89 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-N 117.559 0.68 . . . . 74.200000000000003 110.848 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -110.15 135.69 20.54 Favored Pre-proline 0 C--N 1.361 1.108 0 O-C-N 119.145 -2.222 . . . . 72.099999999999994 106.865 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.54 151.58 70.31 Favored 'Trans proline' 0 C--N 1.358 1.064 0 CA-C-N 123.709 2.36 . . . . 73.329999999999998 112.75 -174.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -83.39 -42.15 17.35 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 118.673 -0.68 . . . . 71.030000000000001 109.667 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -143.6 173.4 11.68 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.876 -1.059 . . . . 74.349999999999994 109.416 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -132.32 137.64 47.5 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-O 117.062 -1.447 . . . . 52.020000000000003 109.778 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -103.22 164.9 3.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-N 119.231 0.923 . . . . 73.409999999999997 111.172 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 56.7 mtp85 -76.74 29.51 0.13 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 75.140000000000001 110.911 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.65 4.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.743 -0.741 . . . . 70.209999999999994 112.463 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -116.11 -76.1 0.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 64.129999999999995 110.849 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -116.95 156.42 48.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.632 0.729 . . . . 74.430000000000007 110.915 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.79 178.26 7.48 Favored 'Trans proline' 0 C--N 1.365 1.428 0 O-C-N 118.133 -1.562 . . . . 74.040000000000006 110.238 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.5 mm -110.78 -57.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.909 0 CA-C-O 118.126 -0.94 . . . . 61.450000000000003 112.158 -172.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.1 p -100.86 176.31 5.33 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-O 117.79 -1.1 . . . . 62.43 110.017 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -140.3 -178.62 5.57 Favored 'General case' 0 C--N 1.358 0.948 0 CA-C-N 118.992 0.815 . . . . 73.209999999999994 112.178 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -70.15 -177.31 1.35 Allowed 'General case' 0 C--N 1.354 0.768 0 CA-C-N 118.587 0.63 . . . . 71.319999999999993 110.793 -168.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 109.986 -1.245 . . . . 70.239999999999995 109.986 175.584 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.662 0 N-CA-C 110.383 -1.087 . . . . 73.310000000000002 110.383 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.83 -164.56 5.56 Favored Glycine 0 C--N 1.354 1.541 0 C-N-CA 120.243 -0.979 . . . . 52.340000000000003 111.619 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.2 41.67 1.93 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 117.784 0.792 . . . . 71.109999999999999 109.367 178.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.09 -144.91 4.26 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.333 -1.26 . . . . 50.310000000000002 112.218 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.3 m80 -115.45 -22.33 9.36 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-N 117.781 0.79 . . . . 75.340000000000003 110.905 -170.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.7 t -110.14 136.87 20.45 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.175 -2.203 . . . . 63.329999999999998 106.872 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -70.05 150.54 66.59 Favored 'Trans proline' 0 C--N 1.356 0.964 0 CA-C-N 123.802 2.393 . . . . 74.319999999999993 112.743 -175.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -82.52 -41.03 20.2 Favored 'General case' 0 C--N 1.356 0.857 0 CA-C-O 118.68 -0.676 . . . . 74.540000000000006 109.771 177.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -144.79 173.98 11.38 Favored 'General case' 0 C--N 1.353 0.728 0 CA-C-O 117.869 -1.062 . . . . 74.329999999999998 109.417 -177.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -132.51 137.04 47.04 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-O 117.16 -1.4 . . . . 74.099999999999994 109.702 -178.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.57 164.91 3.1 Favored 'Isoleucine or valine' 0 C--N 1.357 0.928 0 CA-C-N 119.191 0.905 . . . . 73.430000000000007 111.096 175.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 74.9 mtm180 -76.92 29.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 61.240000000000002 110.866 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.438 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.85 -115.51 4.08 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.709 -0.757 . . . . 74.040000000000006 112.473 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.96 -76.24 0.58 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.868 0.366 . . . . 74.099999999999994 110.873 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -116.97 156.02 48.67 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.638 0.732 . . . . 75.409999999999997 110.903 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -78.79 174.46 12.22 Favored 'Trans proline' 0 C--N 1.366 1.466 0 O-C-N 118.524 -1.356 . . . . 65.430000000000007 110.561 -178.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.423 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -103.1 -64.41 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.911 0 CA-C-O 118.456 -0.783 . . . . 71.420000000000002 110.112 -172.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.0 p -98.15 178.36 5.1 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-O 117.75 -1.119 . . . . 73.019999999999996 110.606 -170.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -137.7 179.45 6.41 Favored 'General case' 0 C--N 1.36 1.037 0 CA-C-N 118.847 0.749 . . . . 74.319999999999993 112.053 -175.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.2 176.61 3.17 Favored 'General case' 0 C--N 1.354 0.767 0 CA-C-O 118.648 -0.692 . . . . 75.540000000000006 110.237 -169.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.82 0 CA-C-O 118.182 -1.344 . . . . 54.119999999999997 110.048 177.747 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.983 -1.247 . . . . 53.329999999999998 109.983 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.15 -161.03 12.52 Favored Glycine 0 C--N 1.354 1.557 0 CA-C-O 118.758 -1.023 . . . . 53.119999999999997 111.373 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.2 42.04 1.44 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 117.751 0.775 . . . . 75.319999999999993 109.938 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.56 -149.56 4.51 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-O 118.711 -1.049 . . . . 53.43 112.723 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -113.76 -22.41 10.21 Favored 'General case' 0 C--N 1.359 0.989 0 C-N-CA 123.235 0.614 . . . . 75.409999999999997 110.893 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.1 t -109.86 135.53 20.45 Favored Pre-proline 0 C--N 1.361 1.079 0 O-C-N 119.183 -2.198 . . . . 55.5 106.893 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.89 149.09 65.62 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.726 2.367 . . . . 43.439999999999998 112.49 -175.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -80.24 -44.8 19.08 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.715 -0.66 . . . . 63.299999999999997 109.542 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.4 p90 -140.98 173.93 11.0 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.973 -1.013 . . . . 71.109999999999999 109.41 -175.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -133.4 135.74 44.84 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.165 -1.398 . . . . 75.450000000000003 109.574 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.1 t -101.89 164.85 2.95 Favored 'Isoleucine or valine' 0 C--N 1.357 0.912 0 CA-C-N 119.2 0.909 . . . . 75.400000000000006 111.119 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp85 -76.83 29.91 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 72.519999999999996 110.887 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -104.04 -115.4 4.07 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.78 -0.724 . . . . 73.230000000000004 112.504 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -116.26 -75.34 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.856 0.36 . . . . 71.519999999999996 110.868 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -118.16 155.87 51.07 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.642 0.734 . . . . 73.319999999999993 110.855 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -79.49 174.29 12.05 Favored 'Trans proline' 0 C--N 1.366 1.489 0 O-C-N 118.403 -1.419 . . . . 70.310000000000002 110.883 -177.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.41 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -102.86 -64.54 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.904 0 CA-C-O 118.389 -0.815 . . . . 64.340000000000003 110.072 -172.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.1 p -98.26 176.22 5.79 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 117.792 -1.099 . . . . 63.219999999999999 110.866 -170.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -137.82 178.51 7.06 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.79 0.723 . . . . 74.010000000000005 112.125 -176.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -69.39 -178.36 1.36 Allowed 'General case' 0 C--N 1.353 0.723 0 CA-C-N 118.502 0.592 . . . . 74.140000000000001 110.571 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 110.029 -1.228 . . . . 33.520000000000003 110.029 176.048 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.61 0 N-CA-C 109.968 -1.253 . . . . 43.210000000000001 109.968 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.27 -162.18 8.47 Favored Glycine 0 C--N 1.353 1.509 0 C-N-CA 120.344 -0.932 . . . . 64.549999999999997 111.268 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.61 43.49 1.24 Allowed 'General case' 0 C--N 1.357 0.891 0 CA-C-N 117.823 0.811 . . . . 73.219999999999999 109.135 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.13 -148.73 3.77 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.611 -1.105 . . . . 51.450000000000003 112.177 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -114.07 -23.06 9.72 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 117.437 0.619 . . . . 73.140000000000001 110.84 -172.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.7 t -108.79 136.12 20.03 Favored Pre-proline 0 C--N 1.361 1.091 0 O-C-N 119.145 -2.222 . . . . 71.25 106.607 -172.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.56 148.45 59.95 Favored 'Trans proline' 0 C--N 1.357 1.023 0 CA-C-N 123.663 2.344 . . . . 75.099999999999994 112.265 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -80.08 -42.05 24.42 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.539 -0.743 . . . . 73.530000000000001 109.514 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -142.58 174.54 10.54 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 118.017 -0.992 . . . . 62.119999999999997 109.662 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -133.25 136.9 45.84 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 117.14 -1.409 . . . . 71.239999999999995 109.62 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.56 164.86 3.11 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 CA-C-N 119.174 0.897 . . . . 62.049999999999997 111.145 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 59.3 mtp180 -77.06 29.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 73.049999999999997 110.85 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.92 -115.32 4.06 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.766 -0.73 . . . . 64.450000000000003 112.483 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -116.1 -75.74 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.85 0.357 . . . . 74.319999999999993 110.884 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -117.55 155.74 50.05 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.676 0.751 . . . . 72.439999999999998 110.891 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.16 173.51 13.29 Favored 'Trans proline' 0 C--N 1.366 1.484 0 O-C-N 118.508 -1.364 . . . . 72.329999999999998 111.009 -176.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.39 -64.88 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-O 118.39 -0.814 . . . . 61.409999999999997 110.004 -172.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.6 p -95.25 175.65 6.52 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.0 -1.0 . . . . 70.230000000000004 110.842 -170.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -136.6 177.8 7.57 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-O 118.661 -0.685 . . . . 65.519999999999996 111.542 -177.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -66.95 177.86 1.57 Allowed 'General case' 0 C--N 1.353 0.759 0 CA-C-N 118.824 0.738 . . . . 64.439999999999998 110.702 -169.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.775 0 CA-C-O 118.214 -1.326 . . . . 50.530000000000001 109.874 179.28 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.691 0 N-CA-C 110.429 -1.068 . . . . 42.399999999999999 110.429 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -156.11 5.02 Favored Glycine 0 C--N 1.353 1.511 0 CA-C-O 118.581 -1.122 . . . . 74.209999999999994 111.293 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -120.1 42.17 3.01 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 118.225 1.013 . . . . 72.230000000000004 109.541 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.09 -143.74 3.23 Favored Glycine 0 C--N 1.353 1.522 0 CA-C-O 118.233 -1.315 . . . . 72.140000000000001 111.916 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 -114.63 -22.42 9.76 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-N 117.934 0.867 . . . . 70.129999999999995 110.817 -170.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -109.76 136.82 20.31 Favored Pre-proline 0 C--N 1.361 1.089 0 O-C-N 119.465 -2.022 . . . . 70.109999999999999 106.474 -172.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -72.07 150.91 55.06 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.677 2.349 . . . . 74.519999999999996 112.498 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -81.8 -39.76 23.57 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.603 -0.713 . . . . 64.120000000000005 109.637 178.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 p90 -145.78 175.71 10.2 Favored 'General case' 0 C--N 1.353 0.726 0 CA-C-O 117.491 -1.243 . . . . 73.230000000000004 109.385 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -130.14 145.29 51.69 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-O 118.106 -0.95 . . . . 73.329999999999998 110.929 177.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.47 164.99 3.92 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.159 0.912 . . . . 71.310000000000002 111.109 177.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 26.1 mtt85 -77.23 25.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.456 . . . . 62.329999999999998 110.893 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.08 -115.81 4.11 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.742 -0.742 . . . . 71.430000000000007 112.474 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -116.06 -76.43 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.35 . . . . 75.5 110.863 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.6 m-85 -113.44 155.91 44.05 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.634 0.73 . . . . 73.239999999999995 110.876 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -78.74 173.56 13.45 Favored 'Trans proline' 0 C--N 1.364 1.384 0 O-C-N 118.609 -1.311 . . . . 65.129999999999995 110.542 -177.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.422 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -102.07 -64.69 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-O 118.62 -0.705 . . . . 65.540000000000006 109.75 -173.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.0 p -90.75 177.6 6.28 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 118.058 -0.972 . . . . 62.43 111.076 -170.279 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -137.51 177.14 8.1 Favored 'General case' 0 C--N 1.358 0.955 0 CA-C-O 118.64 -0.695 . . . . 71.140000000000001 111.495 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -71.57 169.35 15.69 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.87 0.759 . . . . 75.230000000000004 111.098 -168.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.811 0 C-N-CA 119.858 -1.163 . . . . 53.200000000000003 111.404 174.281 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 110.577 -1.009 . . . . 71.340000000000003 110.577 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.5 -158.36 6.02 Favored Glycine 0 C--N 1.353 1.497 0 CA-C-O 118.662 -1.077 . . . . 55.43 111.557 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.87 41.8 2.64 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.032 0.916 . . . . 72.510000000000005 109.644 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.99 -144.4 3.38 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 118.323 -1.265 . . . . 72.310000000000002 112.111 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -114.92 -23.02 9.31 Favored 'General case' 0 C--N 1.358 0.973 0 CA-C-N 117.83 0.815 . . . . 65.230000000000004 110.872 -170.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.5 t -109.64 136.8 20.27 Favored Pre-proline 0 C--N 1.362 1.117 0 O-C-N 119.325 -2.109 . . . . 61.25 106.612 -172.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.1 151.31 61.29 Favored 'Trans proline' 0 C--N 1.357 1.019 0 CA-C-N 123.6 2.321 . . . . 51.399999999999999 112.643 -175.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.89 -41.68 17.17 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-O 118.765 -0.636 . . . . 72.209999999999994 109.728 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -145.27 174.71 10.86 Favored 'General case' 0 C--N 1.353 0.736 0 CA-C-O 117.502 -1.237 . . . . 63.32 109.196 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -130.24 145.09 51.71 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 118.139 -0.934 . . . . 63.329999999999998 110.927 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.98 165.03 3.74 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 O-C-N 124.212 0.945 . . . . 72.129999999999995 111.125 177.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.581 ' N ' HG12 ' A' ' 11' ' ' VAL . 41.1 mtp85 -76.97 26.23 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 71.530000000000001 110.89 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.436 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.37 -116.02 4.14 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 60.130000000000003 112.519 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -116.27 -76.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.8 0.334 . . . . 73.519999999999996 110.908 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -113.93 156.1 44.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.634 0.731 . . . . 75.219999999999999 110.911 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -79.7 174.48 11.67 Favored 'Trans proline' 0 C--N 1.365 1.441 0 O-C-N 117.96 -1.653 . . . . 53.399999999999999 110.602 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -100.64 -63.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.913 0 CA-C-O 118.632 -0.699 . . . . 60.409999999999997 110.058 -172.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 28.0 p -98.46 177.22 5.41 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 117.941 -1.028 . . . . 63.350000000000001 110.802 -169.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -136.16 -179.64 5.79 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.649 -0.691 . . . . 74.109999999999999 111.73 -175.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -70.24 171.08 10.4 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 118.828 0.74 . . . . 71.010000000000005 111.357 -168.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.741 0 CA-C-O 117.989 -1.451 . . . . 12.35 111.386 176.245 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.644 0 N-CA-C 110.101 -1.2 . . . . 61.299999999999997 110.101 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.7 -164.73 15.87 Favored Glycine 0 C--N 1.353 1.52 0 C-N-CA 120.342 -0.932 . . . . 71.400000000000006 111.652 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -105.2 45.44 0.96 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 117.559 0.68 . . . . 61.340000000000003 109.712 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -84.78 -150.0 11.49 Favored Glycine 0 C--N 1.354 1.54 0 CA-C-O 118.469 -1.184 . . . . 74.530000000000001 113.077 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 45.3 m170 -113.3 -23.27 10.0 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.46 0.63 . . . . 73.120000000000005 110.862 -173.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 91.9 t -111.15 132.24 21.81 Favored Pre-proline 0 C--N 1.362 1.139 0 O-C-N 119.08 -2.263 . . . . 72.340000000000003 106.988 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -68.96 153.17 72.97 Favored 'Trans proline' 0 C--N 1.356 0.965 0 CA-C-N 123.631 2.333 . . . . 62.409999999999997 112.9 -172.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -83.46 -46.87 11.99 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 118.82 -0.61 . . . . 73.140000000000001 109.429 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 p90 -141.66 168.29 20.11 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 117.669 -1.158 . . . . 75.420000000000002 109.09 -177.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -123.92 144.87 49.52 Favored 'General case' 0 C--N 1.356 0.885 0 CA-C-O 118.257 -0.878 . . . . 74.329999999999998 110.49 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.31 164.98 3.87 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 O-C-N 124.237 0.961 . . . . 73.340000000000003 111.138 177.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 22.5 mtp180 -77.16 25.68 0.16 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 72.010000000000005 110.918 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.28 -115.83 4.12 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 52.119999999999997 112.525 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -116.18 -76.22 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 65.420000000000002 110.88 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -113.7 156.27 43.86 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.681 0.753 . . . . 62.210000000000001 110.845 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -77.85 -177.72 4.07 Favored 'Trans proline' 0 C--N 1.366 1.463 0 O-C-N 118.261 -1.494 . . . . 61.43 110.517 -178.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mp -110.78 -64.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 118.429 -0.795 . . . . 75.310000000000002 110.69 -173.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.6 p -100.09 176.42 5.41 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.686 -1.15 . . . . 74.230000000000004 109.976 -172.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -176.78 4.8 Favored 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.004 0.82 . . . . 75.209999999999994 112.707 -176.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -68.77 -174.24 0.55 Allowed 'General case' 0 C--N 1.353 0.748 0 CA-C-O 119.136 -0.459 . . . . 73.140000000000001 110.428 -169.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.547 -1.421 . . . . 53.130000000000003 109.547 176.981 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 N-CA-C 110.259 -1.136 . . . . 51.200000000000003 110.259 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.66 -157.34 9.07 Favored Glycine 0 C--N 1.353 1.488 0 CA-C-O 118.439 -1.201 . . . . 53.399999999999999 111.146 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.66 42.63 1.81 Allowed 'General case' 0 C--N 1.356 0.883 0 CA-C-N 118.115 0.957 . . . . 73.200000000000003 109.846 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.85 -147.89 3.91 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-O 118.609 -1.106 . . . . 61.299999999999997 112.572 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.3 m80 -113.97 -22.73 9.94 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.452 0.626 . . . . 71.319999999999993 110.887 -171.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -110.46 135.64 20.65 Favored Pre-proline 0 C--N 1.361 1.085 0 O-C-N 119.437 -2.039 . . . . 55.240000000000002 106.529 -171.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.49 150.5 57.81 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.593 2.319 . . . . 65.219999999999999 112.603 -174.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -81.25 -41.86 21.58 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.564 -0.732 . . . . 75.340000000000003 109.448 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -143.38 175.57 9.81 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.699 -1.143 . . . . 74.319999999999993 109.255 -176.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -130.9 144.4 51.43 Favored 'General case' 0 C--N 1.357 0.902 0 CA-C-O 118.274 -0.87 . . . . 74.219999999999999 110.757 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.65 164.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.054 0.846 . . . . 63.310000000000002 111.103 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.579 ' N ' HG12 ' A' ' 11' ' ' VAL . 25.5 mtp85 -77.25 25.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 64.340000000000003 110.904 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.07 -115.66 4.09 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 62.109999999999999 112.444 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -116.1 -76.63 0.57 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 75.530000000000001 110.871 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -113.36 155.86 44.02 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.675 0.75 . . . . 72.109999999999999 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -78.68 -179.88 5.86 Favored 'Trans proline' 0 C--N 1.366 1.482 0 O-C-N 118.47 -1.384 . . . . 52.009999999999998 110.897 -176.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 78.9 mt -108.36 -63.67 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.895 0 CA-C-O 118.303 -0.856 . . . . 72.409999999999997 111.142 -171.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.4 p -98.3 175.29 6.11 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.918 -1.039 . . . . 72.209999999999994 110.058 -173.097 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -136.32 177.02 8.17 Favored 'General case' 0 C--N 1.359 0.995 0 CA-C-O 118.63 -0.7 . . . . 52.420000000000002 111.652 -176.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -67.3 171.73 5.57 Favored 'General case' 0 C--N 1.353 0.727 0 CA-C-N 118.728 0.695 . . . . 72.409999999999997 111.029 -168.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.799 0 C-N-CA 119.938 -1.125 . . . . 41.350000000000001 111.624 174.869 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.649 0 N-CA-C 110.328 -1.109 . . . . 50.219999999999999 110.328 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.37 -164.09 5.96 Favored Glycine 0 C--N 1.353 1.527 0 CA-C-N 118.214 1.007 . . . . 63.530000000000001 111.408 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.53 41.56 2.0 Favored 'General case' 0 C--N 1.355 0.826 0 CA-C-N 117.906 0.853 . . . . 54.350000000000001 109.367 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.33 -144.69 3.69 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.47 -1.183 . . . . 73.409999999999997 112.088 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 42.4 m80 -115.46 -23.4 8.84 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.701 0.75 . . . . 72.219999999999999 110.831 -169.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.2 t -110.02 136.8 20.41 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.364 -2.085 . . . . 64.239999999999995 106.655 -172.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -70.94 151.45 62.37 Favored 'Trans proline' 0 C--N 1.358 1.026 0 CA-C-N 123.666 2.345 . . . . 74.019999999999996 113.05 -174.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -82.9 -40.44 20.19 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.525 -0.75 . . . . 60.450000000000003 109.612 177.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.5 p90 -145.46 174.55 11.05 Favored 'General case' 0 C--N 1.354 0.769 0 CA-C-O 117.594 -1.193 . . . . 51.229999999999997 109.419 -178.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -130.01 144.54 51.39 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-O 118.05 -0.976 . . . . 73.439999999999998 110.889 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.95 164.91 4.11 Favored 'Isoleucine or valine' 0 C--N 1.359 0.98 0 O-C-N 124.136 0.898 . . . . 74.430000000000007 111.15 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 30.8 mtp180 -77.21 25.3 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 74.209999999999994 110.864 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.48 4.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.784 -0.722 . . . . 62.299999999999997 112.479 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -116.24 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 72.329999999999998 110.821 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -114.25 156.27 44.52 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.656 0.741 . . . . 65.25 110.861 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -78.95 177.73 8.36 Favored 'Trans proline' 0 C--N 1.365 1.413 0 O-C-N 118.532 -1.352 . . . . 62.219999999999999 110.421 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -108.83 -58.6 3.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-O 118.144 -0.932 . . . . 32.420000000000002 111.798 -172.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.5 p -97.41 177.2 5.61 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 117.808 -1.092 . . . . 71.109999999999999 110.206 -173.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -138.78 178.6 7.03 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-N 118.746 0.703 . . . . 64.120000000000005 111.73 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -69.71 178.98 2.33 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.694 0.679 . . . . 74.040000000000006 109.927 -170.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.751 0 CA-C-O 117.832 -1.538 . . . . 62.329999999999998 109.934 178.097 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.626 0 N-CA-C 110.302 -1.119 . . . . 62.219999999999999 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.6 -158.65 5.29 Favored Glycine 0 C--N 1.353 1.487 0 CA-C-O 118.864 -0.964 . . . . 24.120000000000001 111.308 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -117.57 42.29 2.63 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-N 118.007 0.903 . . . . 62.350000000000001 109.341 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.71 -143.46 2.93 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.31 -1.272 . . . . 40.140000000000001 111.906 179.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.8 m170 -115.47 -23.26 8.9 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.93 0.865 . . . . 73.120000000000005 110.911 -170.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -109.14 136.27 20.13 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.405 -2.059 . . . . 71.010000000000005 106.433 -172.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -71.52 150.97 58.42 Favored 'Trans proline' 0 C--N 1.358 1.034 0 CA-C-N 123.598 2.321 . . . . 72.25 112.471 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -82.74 -40.06 21.06 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.604 -0.712 . . . . 73.450000000000003 109.721 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.1 p90 -143.75 174.66 10.61 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-O 117.589 -1.196 . . . . 65.200000000000003 109.498 -178.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.69 144.44 51.29 Favored 'General case' 0 C--N 1.356 0.874 0 CA-C-O 118.058 -0.973 . . . . 71.120000000000005 110.711 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.578 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.3 t -105.56 164.8 4.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 O-C-N 124.104 0.878 . . . . 71.349999999999994 111.16 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.578 ' N ' HG12 ' A' ' 11' ' ' VAL . 10.0 mtt85 -77.47 25.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 60.350000000000001 110.893 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.43 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.46 4.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.739 . . . . 31.300000000000001 112.491 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -116.13 -76.18 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 62.530000000000001 110.864 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -113.91 155.76 44.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 74.230000000000004 110.874 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -77.54 178.12 8.0 Favored 'Trans proline' 0 C--N 1.365 1.438 0 O-C-N 118.84 -1.189 . . . . 75.230000000000004 110.569 -177.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 73.8 mt -105.64 -61.27 2.55 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 CA-C-O 118.509 -0.757 . . . . 55.020000000000003 111.077 -171.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 p -99.92 178.02 4.93 Favored 'General case' 0 C--N 1.354 0.78 0 CA-C-O 117.942 -1.027 . . . . 62.039999999999999 110.257 -171.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -137.1 178.44 7.08 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-O 118.751 -0.642 . . . . 63.340000000000003 111.435 -176.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.49 169.93 11.57 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-N 118.776 0.717 . . . . 64.439999999999998 111.118 -168.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.802 0 CA-C-O 118.216 -1.324 . . . . 63.020000000000003 111.184 177.717 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.653 0 N-CA-C 110.748 -0.941 . . . . 71.219999999999999 110.748 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.1 -161.58 5.35 Favored Glycine 0 C--N 1.353 1.517 0 CA-C-O 118.82 -0.989 . . . . 63.100000000000001 111.512 -179.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.04 42.02 2.28 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.95 0.875 . . . . 74.109999999999999 109.236 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.97 -143.08 3.48 Favored Glycine 0 C--N 1.353 1.512 0 CA-C-O 118.334 -1.259 . . . . 72.140000000000001 112.062 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.2 m80 -116.58 -22.67 8.57 Favored 'General case' 0 C--N 1.359 0.999 0 CA-C-N 117.855 0.827 . . . . 61.520000000000003 110.851 -169.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -109.75 136.08 20.36 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.131 -2.231 . . . . 71.420000000000002 106.607 -173.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.12 151.19 66.88 Favored 'Trans proline' 0 C--N 1.358 1.078 0 CA-C-N 123.662 2.343 . . . . 60.329999999999998 112.167 -175.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -83.91 -39.14 20.19 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-O 118.483 -0.77 . . . . 74.150000000000006 109.947 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -145.62 174.08 11.49 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.888 -1.053 . . . . 72.420000000000002 109.533 -178.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -132.73 136.25 46.26 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-O 117.167 -1.397 . . . . 74.209999999999994 109.676 -178.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.43 164.91 3.06 Favored 'Isoleucine or valine' 0 C--N 1.357 0.921 0 CA-C-N 119.152 0.887 . . . . 74.329999999999998 111.168 175.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.9 mtp180 -76.64 29.64 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.219999999999999 110.852 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.25 4.05 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.742 -0.742 . . . . 65.340000000000003 112.492 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -116.1 -75.49 0.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.873 0.368 . . . . 72.340000000000003 110.887 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -118.89 156.08 52.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.695 0.76 . . . . 75.409999999999997 110.862 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -78.04 178.54 7.47 Favored 'Trans proline' 0 C--N 1.365 1.433 0 O-C-N 118.572 -1.331 . . . . 71.230000000000004 110.702 -177.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.5 mt -107.35 -60.57 2.84 Favored 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-O 118.268 -0.872 . . . . 71.340000000000003 111.242 -171.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 70.6 p -105.2 176.69 5.08 Favored 'General case' 0 C--N 1.353 0.743 0 CA-C-O 117.84 -1.076 . . . . 54.43 109.938 -171.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -136.63 179.65 6.24 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-N 118.65 0.659 . . . . 71.010000000000005 111.584 -173.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -67.9 173.12 4.71 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 118.642 0.655 . . . . 63.210000000000001 110.678 -169.187 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.778 0 CA-C-O 118.361 -1.244 . . . . 31.23 110.833 178.29 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.69 0 N-CA-C 110.79 -0.924 . . . . 63.399999999999999 110.79 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.98 -163.65 7.65 Favored Glycine 0 C--N 1.352 1.462 0 CA-C-N 118.179 0.989 . . . . 72.400000000000006 111.878 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.03 40.08 2.01 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-N 117.677 0.738 . . . . 73.239999999999995 109.756 178.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.49 -146.05 3.64 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-O 118.604 -1.109 . . . . 52.020000000000003 112.889 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -114.89 -22.95 9.36 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 117.53 0.665 . . . . 75.439999999999998 110.802 -170.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -110.86 135.77 20.78 Favored Pre-proline 0 C--N 1.362 1.129 0 O-C-N 119.161 -2.212 . . . . 74.400000000000006 106.872 -172.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.96 151.99 68.1 Favored 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.767 2.381 . . . . 53.399999999999999 112.877 -174.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -83.93 -41.68 17.11 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-O 118.618 -0.706 . . . . 73.109999999999999 109.701 178.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -145.95 172.33 13.52 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.657 -1.163 . . . . 61.32 109.248 -178.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -127.77 143.97 51.11 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 118.226 -0.892 . . . . 73.349999999999994 110.684 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.24 164.97 3.85 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 O-C-N 124.139 0.9 . . . . 74.209999999999994 111.138 177.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 13.9 mtp85 -76.83 25.85 0.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 73.230000000000004 110.898 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.06 -115.55 4.08 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 54.039999999999999 112.473 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.3 -76.2 0.57 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.816 0.341 . . . . 74.129999999999995 110.822 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -114.94 156.45 45.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.602 0.715 . . . . 71.409999999999997 110.895 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -78.42 179.22 6.7 Favored 'Trans proline' 0 C--N 1.366 1.462 0 O-C-N 118.798 -1.212 . . . . 73.340000000000003 110.577 -177.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.9 mt -106.43 -59.97 3.12 Favored 'Isoleucine or valine' 0 C--N 1.355 0.839 0 CA-C-O 118.415 -0.802 . . . . 71.519999999999996 111.28 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.3 p -108.0 177.2 4.88 Favored 'General case' 0 C--N 1.353 0.753 0 CA-C-O 117.755 -1.117 . . . . 74.340000000000003 109.934 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -138.33 179.55 6.39 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 118.943 0.792 . . . . 72.030000000000001 112.196 -172.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -69.47 179.1 2.18 Favored 'General case' 0 C--N 1.352 0.715 0 CA-C-N 118.449 0.568 . . . . 55.32 110.576 -168.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.773 0 CA-C-O 118.235 -1.314 . . . . 62.149999999999999 109.882 177.193 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.684 0 N-CA-C 110.965 -0.854 . . . . 72.140000000000001 110.965 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.83 -163.01 8.49 Favored Glycine 0 C--N 1.352 1.471 0 CA-C-N 118.083 0.941 . . . . 73.140000000000001 111.947 -178.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.09 40.68 1.88 Allowed 'General case' 0 C--N 1.356 0.881 0 CA-C-N 117.647 0.723 . . . . 50.439999999999998 109.678 178.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.48 -146.66 3.85 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.531 -1.149 . . . . 62.549999999999997 112.771 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -114.64 -22.77 9.58 Favored 'General case' 0 C--N 1.359 1.001 0 CA-C-N 117.524 0.662 . . . . 74.340000000000003 110.839 -171.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.4 t -111.45 136.3 21.0 Favored Pre-proline 0 C--N 1.362 1.112 0 O-C-N 119.282 -2.136 . . . . 41.119999999999997 106.701 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.49 153.26 65.68 Favored 'Trans proline' 0 C--N 1.358 1.062 0 CA-C-N 123.706 2.359 . . . . 54.450000000000003 113.185 -174.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -85.14 -42.57 14.64 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 118.665 -0.683 . . . . 73.400000000000006 109.653 178.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -145.8 172.14 13.76 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 117.583 -1.199 . . . . 73.349999999999994 109.145 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -127.57 143.77 51.14 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-O 118.04 -0.981 . . . . 71.329999999999998 110.824 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.44 165.17 3.84 Favored 'Isoleucine or valine' 0 C--N 1.357 0.931 0 O-C-N 124.138 0.899 . . . . 64.5 111.135 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.585 ' N ' HG12 ' A' ' 11' ' ' VAL . 12.6 mtp180 -76.88 25.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 72.510000000000005 110.865 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.45 4.07 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 34.520000000000003 112.514 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -116.15 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.898 0.38 . . . . 65.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -115.34 156.2 46.03 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.647 0.737 . . . . 53.130000000000003 110.929 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.15 174.73 12.04 Favored 'Trans proline' 0 C--N 1.365 1.437 0 O-C-N 118.771 -1.226 . . . . 71.340000000000003 110.74 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.413 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.6 mp -100.0 -61.75 2.23 Favored 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-O 118.677 -0.677 . . . . 72.209999999999994 110.093 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.0 p -106.64 177.25 4.91 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 117.737 -1.125 . . . . 71.430000000000007 110.564 -169.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -137.93 -179.88 6.03 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.907 0.776 . . . . 64.030000000000001 112.391 -173.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.08 -179.83 2.07 Favored 'General case' 0 C--N 1.354 0.775 0 CA-C-N 118.505 0.593 . . . . 64.209999999999994 110.63 -168.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.755 0 CA-C-O 118.153 -1.359 . . . . 72.209999999999994 109.968 176.313 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 N-CA-C 110.787 -0.925 . . . . 64.409999999999997 110.787 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.53 -162.16 7.42 Favored Glycine 0 C--N 1.353 1.484 0 CA-C-O 118.834 -0.981 . . . . 55.100000000000001 111.851 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -111.94 39.83 2.3 Favored 'General case' 0 C--N 1.356 0.866 0 CA-C-N 117.804 0.802 . . . . 71.439999999999998 109.753 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.1 -145.52 3.17 Favored Glycine 0 C--N 1.354 1.545 0 CA-C-O 118.549 -1.14 . . . . 61.140000000000001 112.751 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.5 m80 -114.99 -23.05 9.26 Favored 'General case' 0 C--N 1.359 0.993 0 CA-C-N 117.572 0.686 . . . . 74.109999999999999 110.893 -169.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.2 t -110.76 136.47 20.7 Favored Pre-proline 0 C--N 1.361 1.096 0 O-C-N 119.306 -2.121 . . . . 73.340000000000003 106.694 -172.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 152.63 65.92 Favored 'Trans proline' 0 C--N 1.358 1.077 0 CA-C-N 123.776 2.384 . . . . 72.450000000000003 112.839 -174.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.95 -41.33 17.46 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.687 -0.673 . . . . 74.299999999999997 109.794 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -146.46 173.8 11.96 Favored 'General case' 0 C--N 1.353 0.738 0 CA-C-O 117.566 -1.207 . . . . 72.109999999999999 109.177 -178.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -128.67 144.1 51.09 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-O 118.147 -0.93 . . . . 74.439999999999998 110.917 179.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.2 164.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.917 0 O-C-N 124.117 0.886 . . . . 60.229999999999997 111.1 177.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 3.6 mtt-85 -77.2 25.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 70.140000000000001 110.88 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.36 4.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.719 -0.753 . . . . 41.109999999999999 112.495 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.25 -76.0 0.58 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.343 . . . . 65.120000000000005 110.854 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -115.14 156.77 45.0 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.659 0.742 . . . . 53.340000000000003 110.913 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -79.48 178.47 7.34 Favored 'Trans proline' 0 C--N 1.365 1.404 0 O-C-N 118.454 -1.393 . . . . 51.210000000000001 110.194 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.8 mm -109.25 -57.16 4.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 CA-C-O 118.138 -0.934 . . . . 65.099999999999994 112.036 -172.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 77.9 p -103.54 176.18 5.24 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 117.767 -1.111 . . . . 74.430000000000007 110.047 -172.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -138.68 178.62 7.01 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-N 118.916 0.78 . . . . 63.119999999999997 112.208 -173.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -69.9 178.28 2.74 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-N 118.555 0.616 . . . . 71.430000000000007 110.557 -168.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.259 1.718 0 CA-C-O 118.169 -1.351 . . . . 30.109999999999999 109.876 176.484 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 110.202 -1.159 . . . . 55.240000000000002 110.202 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.03 -161.75 13.82 Favored Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.513 -1.16 . . . . 63.399999999999999 110.961 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.39 43.22 1.2 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.01 0.905 . . . . 53.109999999999999 109.393 178.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -150.24 3.0 Favored Glycine 0 C--N 1.352 1.457 0 CA-C-O 118.896 -0.947 . . . . 74.140000000000001 112.674 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.6 m170 -113.56 -22.33 10.36 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.32 0.648 . . . . 73.340000000000003 110.854 -171.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.2 t -111.67 136.36 21.1 Favored Pre-proline 0 C--N 1.362 1.116 0 O-C-N 119.264 -2.147 . . . . 64.349999999999994 106.632 -172.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.01 152.72 63.1 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 123.796 2.391 . . . . 73.439999999999998 112.865 -174.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -82.5 -43.64 16.93 Favored 'General case' 0 C--N 1.353 0.756 0 CA-C-O 118.715 -0.66 . . . . 74.310000000000002 109.52 178.143 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -143.68 176.48 9.19 Favored 'General case' 0 C--N 1.353 0.733 0 CA-C-O 117.592 -1.194 . . . . 71.510000000000005 109.02 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -131.69 143.62 50.41 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.164 -0.922 . . . . 72.129999999999995 110.872 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.41 165.08 3.55 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 O-C-N 124.019 0.824 . . . . 65.310000000000002 111.137 177.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.587 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp180 -76.9 25.71 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 73.530000000000001 110.903 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.437 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.14 -115.72 4.1 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.776 -0.726 . . . . 63.130000000000003 112.489 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -116.06 -76.15 0.58 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.875 0.369 . . . . 65.219999999999999 110.876 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -115.11 155.96 46.0 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.67 0.747 . . . . 72.329999999999998 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -78.85 179.69 6.26 Favored 'Trans proline' 0 C--N 1.366 1.478 0 O-C-N 118.53 -1.353 . . . . 70.040000000000006 111.108 -176.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 76.0 mt -107.8 -62.95 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 CA-C-O 118.07 -0.967 . . . . 53.409999999999997 111.257 -171.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 63.5 p -97.94 175.67 6.05 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.857 -1.068 . . . . 50.240000000000002 110.344 -172.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -136.9 176.15 8.97 Favored 'General case' 0 C--N 1.359 0.98 0 CA-C-O 118.718 -0.658 . . . . 74.340000000000003 111.711 -177.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -67.77 -177.09 0.73 Allowed 'General case' 0 C--N 1.353 0.746 0 CA-C-N 118.601 0.637 . . . . 71.319999999999993 110.305 -168.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.753 0 CA-C-O 117.763 -1.576 . . . . 64.450000000000003 109.751 179.069 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.7 0 N-CA-C 110.608 -0.997 . . . . 71.299999999999997 110.608 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -160.69 8.01 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-O 118.63 -1.095 . . . . 62.310000000000002 111.88 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -113.02 40.91 2.2 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 117.9 0.85 . . . . 53.0 109.907 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.13 -146.93 4.46 Favored Glycine 0 C--N 1.354 1.533 0 CA-C-O 118.55 -1.139 . . . . 65.430000000000007 112.928 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -113.82 -22.98 9.89 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-N 117.559 0.68 . . . . 74.200000000000003 110.848 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -110.15 135.69 20.54 Favored Pre-proline 0 C--N 1.361 1.108 0 O-C-N 119.145 -2.222 . . . . 72.099999999999994 106.865 -172.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.54 151.58 70.31 Favored 'Trans proline' 0 C--N 1.358 1.064 0 CA-C-N 123.709 2.36 . . . . 73.329999999999998 112.75 -174.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -83.39 -42.15 17.35 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 118.673 -0.68 . . . . 71.030000000000001 109.667 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -143.6 173.4 11.68 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.876 -1.059 . . . . 74.349999999999994 109.416 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -132.32 137.64 47.5 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-O 117.062 -1.447 . . . . 52.020000000000003 109.778 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -103.22 164.9 3.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-N 119.231 0.923 . . . . 73.409999999999997 111.172 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 56.7 mtp85 -76.74 29.51 0.13 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 75.140000000000001 110.911 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.65 4.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.743 -0.741 . . . . 70.209999999999994 112.463 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -116.11 -76.1 0.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 64.129999999999995 110.849 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -116.95 156.42 48.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.632 0.729 . . . . 74.430000000000007 110.915 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.79 178.26 7.48 Favored 'Trans proline' 0 C--N 1.365 1.428 0 O-C-N 118.133 -1.562 . . . . 74.040000000000006 110.238 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.5 mm -110.78 -57.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.909 0 CA-C-O 118.126 -0.94 . . . . 61.450000000000003 112.158 -172.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.1 p -100.86 176.31 5.33 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-O 117.79 -1.1 . . . . 62.43 110.017 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -140.3 -178.62 5.57 Favored 'General case' 0 C--N 1.358 0.948 0 CA-C-N 118.992 0.815 . . . . 73.209999999999994 112.178 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -70.15 -177.31 1.35 Allowed 'General case' 0 C--N 1.354 0.768 0 CA-C-N 118.587 0.63 . . . . 71.319999999999993 110.793 -168.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 109.986 -1.245 . . . . 70.239999999999995 109.986 175.584 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.662 0 N-CA-C 110.383 -1.087 . . . . 73.310000000000002 110.383 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.83 -164.56 5.56 Favored Glycine 0 C--N 1.354 1.541 0 C-N-CA 120.243 -0.979 . . . . 52.340000000000003 111.619 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.2 41.67 1.93 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 117.784 0.792 . . . . 71.109999999999999 109.367 178.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.09 -144.91 4.26 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.333 -1.26 . . . . 50.310000000000002 112.218 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.3 m80 -115.45 -22.33 9.36 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-N 117.781 0.79 . . . . 75.340000000000003 110.905 -170.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.7 t -110.14 136.87 20.45 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.175 -2.203 . . . . 63.329999999999998 106.872 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -70.05 150.54 66.59 Favored 'Trans proline' 0 C--N 1.356 0.964 0 CA-C-N 123.802 2.393 . . . . 74.319999999999993 112.743 -175.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -82.52 -41.03 20.2 Favored 'General case' 0 C--N 1.356 0.857 0 CA-C-O 118.68 -0.676 . . . . 74.540000000000006 109.771 177.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -144.79 173.98 11.38 Favored 'General case' 0 C--N 1.353 0.728 0 CA-C-O 117.869 -1.062 . . . . 74.329999999999998 109.417 -177.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -132.51 137.04 47.04 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-O 117.16 -1.4 . . . . 74.099999999999994 109.702 -178.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.57 164.91 3.1 Favored 'Isoleucine or valine' 0 C--N 1.357 0.928 0 CA-C-N 119.191 0.905 . . . . 73.430000000000007 111.096 175.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 74.9 mtm180 -76.92 29.41 0.13 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 61.240000000000002 110.866 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.438 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.85 -115.51 4.08 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.709 -0.757 . . . . 74.040000000000006 112.473 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.96 -76.24 0.58 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.868 0.366 . . . . 74.099999999999994 110.873 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -116.97 156.02 48.67 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.638 0.732 . . . . 75.409999999999997 110.903 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -78.79 174.46 12.22 Favored 'Trans proline' 0 C--N 1.366 1.466 0 O-C-N 118.524 -1.356 . . . . 65.430000000000007 110.561 -178.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.423 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -103.1 -64.41 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.911 0 CA-C-O 118.456 -0.783 . . . . 71.420000000000002 110.112 -172.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.0 p -98.15 178.36 5.1 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-O 117.75 -1.119 . . . . 73.019999999999996 110.606 -170.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -137.7 179.45 6.41 Favored 'General case' 0 C--N 1.36 1.037 0 CA-C-N 118.847 0.749 . . . . 74.319999999999993 112.053 -175.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.2 176.61 3.17 Favored 'General case' 0 C--N 1.354 0.767 0 CA-C-O 118.648 -0.692 . . . . 75.540000000000006 110.237 -169.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.82 0 CA-C-O 118.182 -1.344 . . . . 54.119999999999997 110.048 177.747 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.983 -1.247 . . . . 53.329999999999998 109.983 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.15 -161.03 12.52 Favored Glycine 0 C--N 1.354 1.557 0 CA-C-O 118.758 -1.023 . . . . 53.119999999999997 111.373 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.2 42.04 1.44 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 117.751 0.775 . . . . 75.319999999999993 109.938 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.56 -149.56 4.51 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-O 118.711 -1.049 . . . . 53.43 112.723 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -113.76 -22.41 10.21 Favored 'General case' 0 C--N 1.359 0.989 0 C-N-CA 123.235 0.614 . . . . 75.409999999999997 110.893 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.1 t -109.86 135.53 20.45 Favored Pre-proline 0 C--N 1.361 1.079 0 O-C-N 119.183 -2.198 . . . . 55.5 106.893 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.89 149.09 65.62 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.726 2.367 . . . . 43.439999999999998 112.49 -175.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -80.24 -44.8 19.08 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.715 -0.66 . . . . 63.299999999999997 109.542 177.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.4 p90 -140.98 173.93 11.0 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.973 -1.013 . . . . 71.109999999999999 109.41 -175.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -133.4 135.74 44.84 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.165 -1.398 . . . . 75.450000000000003 109.574 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.1 t -101.89 164.85 2.95 Favored 'Isoleucine or valine' 0 C--N 1.357 0.912 0 CA-C-N 119.2 0.909 . . . . 75.400000000000006 111.119 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp85 -76.83 29.91 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.201 -0.454 . . . . 72.519999999999996 110.887 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -104.04 -115.4 4.07 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.78 -0.724 . . . . 73.230000000000004 112.504 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -116.26 -75.34 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.856 0.36 . . . . 71.519999999999996 110.868 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -118.16 155.87 51.07 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.642 0.734 . . . . 73.319999999999993 110.855 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -79.49 174.29 12.05 Favored 'Trans proline' 0 C--N 1.366 1.489 0 O-C-N 118.403 -1.419 . . . . 70.310000000000002 110.883 -177.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.41 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -102.86 -64.54 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.904 0 CA-C-O 118.389 -0.815 . . . . 64.340000000000003 110.072 -172.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.1 p -98.26 176.22 5.79 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 117.792 -1.099 . . . . 63.219999999999999 110.866 -170.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -137.82 178.51 7.06 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.79 0.723 . . . . 74.010000000000005 112.125 -176.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -69.39 -178.36 1.36 Allowed 'General case' 0 C--N 1.353 0.723 0 CA-C-N 118.502 0.592 . . . . 74.140000000000001 110.571 -168.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.819 0 N-CA-C 110.029 -1.228 . . . . 33.520000000000003 110.029 176.048 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.61 0 N-CA-C 109.968 -1.253 . . . . 43.210000000000001 109.968 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.27 -162.18 8.47 Favored Glycine 0 C--N 1.353 1.509 0 C-N-CA 120.344 -0.932 . . . . 64.549999999999997 111.268 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -108.61 43.49 1.24 Allowed 'General case' 0 C--N 1.357 0.891 0 CA-C-N 117.823 0.811 . . . . 73.219999999999999 109.135 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.13 -148.73 3.77 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.611 -1.105 . . . . 51.450000000000003 112.177 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -114.07 -23.06 9.72 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 117.437 0.619 . . . . 73.140000000000001 110.84 -172.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.7 t -108.79 136.12 20.03 Favored Pre-proline 0 C--N 1.361 1.091 0 O-C-N 119.145 -2.222 . . . . 71.25 106.607 -172.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.56 148.45 59.95 Favored 'Trans proline' 0 C--N 1.357 1.023 0 CA-C-N 123.663 2.344 . . . . 75.099999999999994 112.265 -175.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -80.08 -42.05 24.42 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.539 -0.743 . . . . 73.530000000000001 109.514 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -142.58 174.54 10.54 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 118.017 -0.992 . . . . 62.119999999999997 109.662 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -133.25 136.9 45.84 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 117.14 -1.409 . . . . 71.239999999999995 109.62 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.56 164.86 3.11 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 CA-C-N 119.174 0.897 . . . . 62.049999999999997 111.145 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 59.3 mtp180 -77.06 29.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 73.049999999999997 110.85 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.92 -115.32 4.06 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.766 -0.73 . . . . 64.450000000000003 112.483 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -116.1 -75.74 0.58 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.85 0.357 . . . . 74.319999999999993 110.884 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -117.55 155.74 50.05 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.676 0.751 . . . . 72.439999999999998 110.891 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.16 173.51 13.29 Favored 'Trans proline' 0 C--N 1.366 1.484 0 O-C-N 118.508 -1.364 . . . . 72.329999999999998 111.009 -176.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.39 -64.88 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-O 118.39 -0.814 . . . . 61.409999999999997 110.004 -172.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.6 p -95.25 175.65 6.52 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.0 -1.0 . . . . 70.230000000000004 110.842 -170.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -136.6 177.8 7.57 Favored 'General case' 0 C--N 1.359 0.992 0 CA-C-O 118.661 -0.685 . . . . 65.519999999999996 111.542 -177.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -66.95 177.86 1.57 Allowed 'General case' 0 C--N 1.353 0.759 0 CA-C-N 118.824 0.738 . . . . 64.439999999999998 110.702 -169.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.775 0 CA-C-O 118.214 -1.326 . . . . 50.530000000000001 109.874 179.28 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.691 0 N-CA-C 110.429 -1.068 . . . . 42.399999999999999 110.429 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.88 -156.11 5.02 Favored Glycine 0 C--N 1.353 1.511 0 CA-C-O 118.581 -1.122 . . . . 74.209999999999994 111.293 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -120.1 42.17 3.01 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 118.225 1.013 . . . . 72.230000000000004 109.541 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.09 -143.74 3.23 Favored Glycine 0 C--N 1.353 1.522 0 CA-C-O 118.233 -1.315 . . . . 72.140000000000001 111.916 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 -114.63 -22.42 9.76 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-N 117.934 0.867 . . . . 70.129999999999995 110.817 -170.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -109.76 136.82 20.31 Favored Pre-proline 0 C--N 1.361 1.089 0 O-C-N 119.465 -2.022 . . . . 70.109999999999999 106.474 -172.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -72.07 150.91 55.06 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.677 2.349 . . . . 74.519999999999996 112.498 -175.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -81.8 -39.76 23.57 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.603 -0.713 . . . . 64.120000000000005 109.637 178.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 p90 -145.78 175.71 10.2 Favored 'General case' 0 C--N 1.353 0.726 0 CA-C-O 117.491 -1.243 . . . . 73.230000000000004 109.385 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -130.14 145.29 51.69 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-O 118.106 -0.95 . . . . 73.329999999999998 110.929 177.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.47 164.99 3.92 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.159 0.912 . . . . 71.310000000000002 111.109 177.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.584 ' N ' HG12 ' A' ' 11' ' ' VAL . 26.1 mtt85 -77.23 25.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.456 . . . . 62.329999999999998 110.893 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.08 -115.81 4.11 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.742 -0.742 . . . . 71.430000000000007 112.474 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -116.06 -76.43 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.35 . . . . 75.5 110.863 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.6 m-85 -113.44 155.91 44.05 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.634 0.73 . . . . 73.239999999999995 110.876 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -78.74 173.56 13.45 Favored 'Trans proline' 0 C--N 1.364 1.384 0 O-C-N 118.609 -1.311 . . . . 65.129999999999995 110.542 -177.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.422 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.9 mp -102.07 -64.69 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.907 0 CA-C-O 118.62 -0.705 . . . . 65.540000000000006 109.75 -173.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.0 p -90.75 177.6 6.28 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 118.058 -0.972 . . . . 62.43 111.076 -170.279 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -137.51 177.14 8.1 Favored 'General case' 0 C--N 1.358 0.955 0 CA-C-O 118.64 -0.695 . . . . 71.140000000000001 111.495 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -71.57 169.35 15.69 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.87 0.759 . . . . 75.230000000000004 111.098 -168.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.811 0 C-N-CA 119.858 -1.163 . . . . 53.200000000000003 111.404 174.281 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 110.577 -1.009 . . . . 71.340000000000003 110.577 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.5 -158.36 6.02 Favored Glycine 0 C--N 1.353 1.497 0 CA-C-O 118.662 -1.077 . . . . 55.43 111.557 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.87 41.8 2.64 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.032 0.916 . . . . 72.510000000000005 109.644 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.99 -144.4 3.38 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 118.323 -1.265 . . . . 72.310000000000002 112.111 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.2 m80 -114.92 -23.02 9.31 Favored 'General case' 0 C--N 1.358 0.973 0 CA-C-N 117.83 0.815 . . . . 65.230000000000004 110.872 -170.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.5 t -109.64 136.8 20.27 Favored Pre-proline 0 C--N 1.362 1.117 0 O-C-N 119.325 -2.109 . . . . 61.25 106.612 -172.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.1 151.31 61.29 Favored 'Trans proline' 0 C--N 1.357 1.019 0 CA-C-N 123.6 2.321 . . . . 51.399999999999999 112.643 -175.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.89 -41.68 17.17 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-O 118.765 -0.636 . . . . 72.209999999999994 109.728 178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -145.27 174.71 10.86 Favored 'General case' 0 C--N 1.353 0.736 0 CA-C-O 117.502 -1.237 . . . . 63.32 109.196 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -130.24 145.09 51.71 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 118.139 -0.934 . . . . 63.329999999999998 110.927 178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.98 165.03 3.74 Favored 'Isoleucine or valine' 0 C--N 1.358 0.935 0 O-C-N 124.212 0.945 . . . . 72.129999999999995 111.125 177.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.581 ' N ' HG12 ' A' ' 11' ' ' VAL . 41.1 mtp85 -76.97 26.23 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 71.530000000000001 110.89 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.436 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.37 -116.02 4.14 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 60.130000000000003 112.519 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -116.27 -76.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.8 0.334 . . . . 73.519999999999996 110.908 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -113.93 156.1 44.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.634 0.731 . . . . 75.219999999999999 110.911 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -79.7 174.48 11.67 Favored 'Trans proline' 0 C--N 1.365 1.441 0 O-C-N 117.96 -1.653 . . . . 53.399999999999999 110.602 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.7 mp -100.64 -63.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.913 0 CA-C-O 118.632 -0.699 . . . . 60.409999999999997 110.058 -172.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 28.0 p -98.46 177.22 5.41 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 117.941 -1.028 . . . . 63.350000000000001 110.802 -169.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -136.16 -179.64 5.79 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.649 -0.691 . . . . 74.109999999999999 111.73 -175.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -70.24 171.08 10.4 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 118.828 0.74 . . . . 71.010000000000005 111.357 -168.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.741 0 CA-C-O 117.989 -1.451 . . . . 12.35 111.386 176.245 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.644 0 N-CA-C 110.101 -1.2 . . . . 61.299999999999997 110.101 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.7 -164.73 15.87 Favored Glycine 0 C--N 1.353 1.52 0 C-N-CA 120.342 -0.932 . . . . 71.400000000000006 111.652 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -105.2 45.44 0.96 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 117.559 0.68 . . . . 61.340000000000003 109.712 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -84.78 -150.0 11.49 Favored Glycine 0 C--N 1.354 1.54 0 CA-C-O 118.469 -1.184 . . . . 74.530000000000001 113.077 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 45.3 m170 -113.3 -23.27 10.0 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.46 0.63 . . . . 73.120000000000005 110.862 -173.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 91.9 t -111.15 132.24 21.81 Favored Pre-proline 0 C--N 1.362 1.139 0 O-C-N 119.08 -2.263 . . . . 72.340000000000003 106.988 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -68.96 153.17 72.97 Favored 'Trans proline' 0 C--N 1.356 0.965 0 CA-C-N 123.631 2.333 . . . . 62.409999999999997 112.9 -172.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -83.46 -46.87 11.99 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 118.82 -0.61 . . . . 73.140000000000001 109.429 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.2 p90 -141.66 168.29 20.11 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 117.669 -1.158 . . . . 75.420000000000002 109.09 -177.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -123.92 144.87 49.52 Favored 'General case' 0 C--N 1.356 0.885 0 CA-C-O 118.257 -0.878 . . . . 74.329999999999998 110.49 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.31 164.98 3.87 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 O-C-N 124.237 0.961 . . . . 73.340000000000003 111.138 177.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 22.5 mtp180 -77.16 25.68 0.16 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 72.010000000000005 110.918 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.28 -115.83 4.12 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 52.119999999999997 112.525 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -116.18 -76.22 0.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 65.420000000000002 110.88 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -113.7 156.27 43.86 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.681 0.753 . . . . 62.210000000000001 110.845 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -77.85 -177.72 4.07 Favored 'Trans proline' 0 C--N 1.366 1.463 0 O-C-N 118.261 -1.494 . . . . 61.43 110.517 -178.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mp -110.78 -64.26 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 118.429 -0.795 . . . . 75.310000000000002 110.69 -173.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 34.6 p -100.09 176.42 5.41 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.686 -1.15 . . . . 74.230000000000004 109.976 -172.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -176.78 4.8 Favored 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.004 0.82 . . . . 75.209999999999994 112.707 -176.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -68.77 -174.24 0.55 Allowed 'General case' 0 C--N 1.353 0.748 0 CA-C-O 119.136 -0.459 . . . . 73.140000000000001 110.428 -169.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.547 -1.421 . . . . 53.130000000000003 109.547 176.981 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 N-CA-C 110.259 -1.136 . . . . 51.200000000000003 110.259 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.66 -157.34 9.07 Favored Glycine 0 C--N 1.353 1.488 0 CA-C-O 118.439 -1.201 . . . . 53.399999999999999 111.146 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.66 42.63 1.81 Allowed 'General case' 0 C--N 1.356 0.883 0 CA-C-N 118.115 0.957 . . . . 73.200000000000003 109.846 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.85 -147.89 3.91 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-O 118.609 -1.106 . . . . 61.299999999999997 112.572 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.3 m80 -113.97 -22.73 9.94 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.452 0.626 . . . . 71.319999999999993 110.887 -171.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.9 t -110.46 135.64 20.65 Favored Pre-proline 0 C--N 1.361 1.085 0 O-C-N 119.437 -2.039 . . . . 55.240000000000002 106.529 -171.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.49 150.5 57.81 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.593 2.319 . . . . 65.219999999999999 112.603 -174.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -81.25 -41.86 21.58 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.564 -0.732 . . . . 75.340000000000003 109.448 177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -143.38 175.57 9.81 Favored 'General case' 0 C--N 1.353 0.745 0 CA-C-O 117.699 -1.143 . . . . 74.319999999999993 109.255 -176.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -130.9 144.4 51.43 Favored 'General case' 0 C--N 1.357 0.902 0 CA-C-O 118.274 -0.87 . . . . 74.219999999999999 110.757 177.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.65 164.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.358 0.956 0 O-C-N 124.054 0.846 . . . . 63.310000000000002 111.103 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.579 ' N ' HG12 ' A' ' 11' ' ' VAL . 25.5 mtp85 -77.25 25.16 0.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 64.340000000000003 110.904 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.07 -115.66 4.09 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 62.109999999999999 112.444 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -116.1 -76.63 0.57 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 75.530000000000001 110.871 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -113.36 155.86 44.02 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.675 0.75 . . . . 72.109999999999999 110.904 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -78.68 -179.88 5.86 Favored 'Trans proline' 0 C--N 1.366 1.482 0 O-C-N 118.47 -1.384 . . . . 52.009999999999998 110.897 -176.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 78.9 mt -108.36 -63.67 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.895 0 CA-C-O 118.303 -0.856 . . . . 72.409999999999997 111.142 -171.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 54.4 p -98.3 175.29 6.11 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.918 -1.039 . . . . 72.209999999999994 110.058 -173.097 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -136.32 177.02 8.17 Favored 'General case' 0 C--N 1.359 0.995 0 CA-C-O 118.63 -0.7 . . . . 52.420000000000002 111.652 -176.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -67.3 171.73 5.57 Favored 'General case' 0 C--N 1.353 0.727 0 CA-C-N 118.728 0.695 . . . . 72.409999999999997 111.029 -168.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.799 0 C-N-CA 119.938 -1.125 . . . . 41.350000000000001 111.624 174.869 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.649 0 N-CA-C 110.328 -1.109 . . . . 50.219999999999999 110.328 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -71.37 -164.09 5.96 Favored Glycine 0 C--N 1.353 1.527 0 CA-C-N 118.214 1.007 . . . . 63.530000000000001 111.408 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.53 41.56 2.0 Favored 'General case' 0 C--N 1.355 0.826 0 CA-C-N 117.906 0.853 . . . . 54.350000000000001 109.367 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.33 -144.69 3.69 Favored Glycine 0 C--N 1.353 1.49 0 CA-C-O 118.47 -1.183 . . . . 73.409999999999997 112.088 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 42.4 m80 -115.46 -23.4 8.84 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 117.701 0.75 . . . . 72.219999999999999 110.831 -169.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.2 t -110.02 136.8 20.41 Favored Pre-proline 0 C--N 1.361 1.106 0 O-C-N 119.364 -2.085 . . . . 64.239999999999995 106.655 -172.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -70.94 151.45 62.37 Favored 'Trans proline' 0 C--N 1.358 1.026 0 CA-C-N 123.666 2.345 . . . . 74.019999999999996 113.05 -174.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -82.9 -40.44 20.19 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.525 -0.75 . . . . 60.450000000000003 109.612 177.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 18.5 p90 -145.46 174.55 11.05 Favored 'General case' 0 C--N 1.354 0.769 0 CA-C-O 117.594 -1.193 . . . . 51.229999999999997 109.419 -178.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -130.01 144.54 51.39 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-O 118.05 -0.976 . . . . 73.439999999999998 110.889 178.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.95 164.91 4.11 Favored 'Isoleucine or valine' 0 C--N 1.359 0.98 0 O-C-N 124.136 0.898 . . . . 74.430000000000007 111.15 177.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 30.8 mtp180 -77.21 25.3 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 74.209999999999994 110.864 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.48 4.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.784 -0.722 . . . . 62.299999999999997 112.479 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -116.24 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 72.329999999999998 110.821 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -114.25 156.27 44.52 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.656 0.741 . . . . 65.25 110.861 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -78.95 177.73 8.36 Favored 'Trans proline' 0 C--N 1.365 1.413 0 O-C-N 118.532 -1.352 . . . . 62.219999999999999 110.421 -178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -108.83 -58.6 3.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-O 118.144 -0.932 . . . . 32.420000000000002 111.798 -172.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.5 p -97.41 177.2 5.61 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-O 117.808 -1.092 . . . . 71.109999999999999 110.206 -173.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -138.78 178.6 7.03 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-N 118.746 0.703 . . . . 64.120000000000005 111.73 -177.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -69.71 178.98 2.33 Favored 'General case' 0 C--N 1.354 0.774 0 CA-C-N 118.694 0.679 . . . . 74.040000000000006 109.927 -170.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.751 0 CA-C-O 117.832 -1.538 . . . . 62.329999999999998 109.934 178.097 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.626 0 N-CA-C 110.302 -1.119 . . . . 62.219999999999999 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.6 -158.65 5.29 Favored Glycine 0 C--N 1.353 1.487 0 CA-C-O 118.864 -0.964 . . . . 24.120000000000001 111.308 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -117.57 42.29 2.63 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-N 118.007 0.903 . . . . 62.350000000000001 109.341 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.71 -143.46 2.93 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.31 -1.272 . . . . 40.140000000000001 111.906 179.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.8 m170 -115.47 -23.26 8.9 Favored 'General case' 0 C--N 1.358 0.975 0 CA-C-N 117.93 0.865 . . . . 73.120000000000005 110.911 -170.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -109.14 136.27 20.13 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.405 -2.059 . . . . 71.010000000000005 106.433 -172.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -71.52 150.97 58.42 Favored 'Trans proline' 0 C--N 1.358 1.034 0 CA-C-N 123.598 2.321 . . . . 72.25 112.471 -175.363 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -82.74 -40.06 21.06 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 118.604 -0.712 . . . . 73.450000000000003 109.721 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.1 p90 -143.75 174.66 10.61 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-O 117.589 -1.196 . . . . 65.200000000000003 109.498 -178.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -129.69 144.44 51.29 Favored 'General case' 0 C--N 1.356 0.874 0 CA-C-O 118.058 -0.973 . . . . 71.120000000000005 110.711 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.578 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.3 t -105.56 164.8 4.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 O-C-N 124.104 0.878 . . . . 71.349999999999994 111.16 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.578 ' N ' HG12 ' A' ' 11' ' ' VAL . 10.0 mtt85 -77.47 25.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 60.350000000000001 110.893 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.43 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.02 -115.46 4.07 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.739 . . . . 31.300000000000001 112.491 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -116.13 -76.18 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 62.530000000000001 110.864 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -113.91 155.76 44.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 74.230000000000004 110.874 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -77.54 178.12 8.0 Favored 'Trans proline' 0 C--N 1.365 1.438 0 O-C-N 118.84 -1.189 . . . . 75.230000000000004 110.569 -177.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 73.8 mt -105.64 -61.27 2.55 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 CA-C-O 118.509 -0.757 . . . . 55.020000000000003 111.077 -171.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 p -99.92 178.02 4.93 Favored 'General case' 0 C--N 1.354 0.78 0 CA-C-O 117.942 -1.027 . . . . 62.039999999999999 110.257 -171.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -137.1 178.44 7.08 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-O 118.751 -0.642 . . . . 63.340000000000003 111.435 -176.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -69.49 169.93 11.57 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-N 118.776 0.717 . . . . 64.439999999999998 111.118 -168.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.802 0 CA-C-O 118.216 -1.324 . . . . 63.020000000000003 111.184 177.717 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.653 0 N-CA-C 110.748 -0.941 . . . . 71.219999999999999 110.748 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.1 -161.58 5.35 Favored Glycine 0 C--N 1.353 1.517 0 CA-C-O 118.82 -0.989 . . . . 63.100000000000001 111.512 -179.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.04 42.02 2.28 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.95 0.875 . . . . 74.109999999999999 109.236 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.97 -143.08 3.48 Favored Glycine 0 C--N 1.353 1.512 0 CA-C-O 118.334 -1.259 . . . . 72.140000000000001 112.062 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.2 m80 -116.58 -22.67 8.57 Favored 'General case' 0 C--N 1.359 0.999 0 CA-C-N 117.855 0.827 . . . . 61.520000000000003 110.851 -169.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -109.75 136.08 20.36 Favored Pre-proline 0 C--N 1.361 1.082 0 O-C-N 119.131 -2.231 . . . . 71.420000000000002 106.607 -173.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -70.12 151.19 66.88 Favored 'Trans proline' 0 C--N 1.358 1.078 0 CA-C-N 123.662 2.343 . . . . 60.329999999999998 112.167 -175.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -83.91 -39.14 20.19 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-O 118.483 -0.77 . . . . 74.150000000000006 109.947 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -145.62 174.08 11.49 Favored 'General case' 0 C--N 1.353 0.72 0 CA-C-O 117.888 -1.053 . . . . 72.420000000000002 109.533 -178.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -132.73 136.25 46.26 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-O 117.167 -1.397 . . . . 74.209999999999994 109.676 -178.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -102.43 164.91 3.06 Favored 'Isoleucine or valine' 0 C--N 1.357 0.921 0 CA-C-N 119.152 0.887 . . . . 74.329999999999998 111.168 175.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.9 mtp180 -76.64 29.64 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.219999999999999 110.852 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.83 -115.25 4.05 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.742 -0.742 . . . . 65.340000000000003 112.492 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -116.1 -75.49 0.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.873 0.368 . . . . 72.340000000000003 110.887 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -118.89 156.08 52.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.695 0.76 . . . . 75.409999999999997 110.862 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -78.04 178.54 7.47 Favored 'Trans proline' 0 C--N 1.365 1.433 0 O-C-N 118.572 -1.331 . . . . 71.230000000000004 110.702 -177.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.5 mt -107.35 -60.57 2.84 Favored 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-O 118.268 -0.872 . . . . 71.340000000000003 111.242 -171.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 70.6 p -105.2 176.69 5.08 Favored 'General case' 0 C--N 1.353 0.743 0 CA-C-O 117.84 -1.076 . . . . 54.43 109.938 -171.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -136.63 179.65 6.24 Favored 'General case' 0 C--N 1.358 0.953 0 CA-C-N 118.65 0.659 . . . . 71.010000000000005 111.584 -173.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -67.9 173.12 4.71 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 118.642 0.655 . . . . 63.210000000000001 110.678 -169.187 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.778 0 CA-C-O 118.361 -1.244 . . . . 31.23 110.833 178.29 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.69 0 N-CA-C 110.79 -0.924 . . . . 63.399999999999999 110.79 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.98 -163.65 7.65 Favored Glycine 0 C--N 1.352 1.462 0 CA-C-N 118.179 0.989 . . . . 72.400000000000006 111.878 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.03 40.08 2.01 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-N 117.677 0.738 . . . . 73.239999999999995 109.756 178.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.49 -146.05 3.64 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-O 118.604 -1.109 . . . . 52.020000000000003 112.889 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -114.89 -22.95 9.36 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 117.53 0.665 . . . . 75.439999999999998 110.802 -170.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -110.86 135.77 20.78 Favored Pre-proline 0 C--N 1.362 1.129 0 O-C-N 119.161 -2.212 . . . . 74.400000000000006 106.872 -172.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.96 151.99 68.1 Favored 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.767 2.381 . . . . 53.399999999999999 112.877 -174.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -83.93 -41.68 17.11 Favored 'General case' 0 C--N 1.356 0.86 0 CA-C-O 118.618 -0.706 . . . . 73.109999999999999 109.701 178.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -145.95 172.33 13.52 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.657 -1.163 . . . . 61.32 109.248 -178.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -127.77 143.97 51.11 Favored 'General case' 0 C--N 1.357 0.91 0 CA-C-O 118.226 -0.892 . . . . 73.349999999999994 110.684 179.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.24 164.97 3.85 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 O-C-N 124.139 0.9 . . . . 74.209999999999994 111.138 177.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.58 ' N ' HG12 ' A' ' 11' ' ' VAL . 13.9 mtp85 -76.83 25.85 0.14 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 73.230000000000004 110.898 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.06 -115.55 4.08 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 54.039999999999999 112.473 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.3 -76.2 0.57 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.816 0.341 . . . . 74.129999999999995 110.822 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -114.94 156.45 45.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.602 0.715 . . . . 71.409999999999997 110.895 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -78.42 179.22 6.7 Favored 'Trans proline' 0 C--N 1.366 1.462 0 O-C-N 118.798 -1.212 . . . . 73.340000000000003 110.577 -177.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 77.9 mt -106.43 -59.97 3.12 Favored 'Isoleucine or valine' 0 C--N 1.355 0.839 0 CA-C-O 118.415 -0.802 . . . . 71.519999999999996 111.28 -171.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.3 p -108.0 177.2 4.88 Favored 'General case' 0 C--N 1.353 0.753 0 CA-C-O 117.755 -1.117 . . . . 74.340000000000003 109.934 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -138.33 179.55 6.39 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 118.943 0.792 . . . . 72.030000000000001 112.196 -172.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -69.47 179.1 2.18 Favored 'General case' 0 C--N 1.352 0.715 0 CA-C-N 118.449 0.568 . . . . 55.32 110.576 -168.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.773 0 CA-C-O 118.235 -1.314 . . . . 62.149999999999999 109.882 177.193 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.684 0 N-CA-C 110.965 -0.854 . . . . 72.140000000000001 110.965 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.83 -163.01 8.49 Favored Glycine 0 C--N 1.352 1.471 0 CA-C-N 118.083 0.941 . . . . 73.140000000000001 111.947 -178.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.09 40.68 1.88 Allowed 'General case' 0 C--N 1.356 0.881 0 CA-C-N 117.647 0.723 . . . . 50.439999999999998 109.678 178.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.48 -146.66 3.85 Favored Glycine 0 C--N 1.353 1.499 0 CA-C-O 118.531 -1.149 . . . . 62.549999999999997 112.771 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -114.64 -22.77 9.58 Favored 'General case' 0 C--N 1.359 1.001 0 CA-C-N 117.524 0.662 . . . . 74.340000000000003 110.839 -171.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.4 t -111.45 136.3 21.0 Favored Pre-proline 0 C--N 1.362 1.112 0 O-C-N 119.282 -2.136 . . . . 41.119999999999997 106.701 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.49 153.26 65.68 Favored 'Trans proline' 0 C--N 1.358 1.062 0 CA-C-N 123.706 2.359 . . . . 54.450000000000003 113.185 -174.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -85.14 -42.57 14.64 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 118.665 -0.683 . . . . 73.400000000000006 109.653 178.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -145.8 172.14 13.76 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 117.583 -1.199 . . . . 73.349999999999994 109.145 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -127.57 143.77 51.14 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-O 118.04 -0.981 . . . . 71.329999999999998 110.824 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.585 HG12 ' N ' ' A' ' 12' ' ' ARG . 21.9 t -105.44 165.17 3.84 Favored 'Isoleucine or valine' 0 C--N 1.357 0.931 0 O-C-N 124.138 0.899 . . . . 64.5 111.135 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.585 ' N ' HG12 ' A' ' 11' ' ' VAL . 12.6 mtp180 -76.88 25.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 72.510000000000005 110.865 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.45 4.07 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 34.520000000000003 112.514 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 16.0 t0 -116.15 -76.24 0.57 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.898 0.38 . . . . 65.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -115.34 156.2 46.03 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.647 0.737 . . . . 53.130000000000003 110.929 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -78.15 174.73 12.04 Favored 'Trans proline' 0 C--N 1.365 1.437 0 O-C-N 118.771 -1.226 . . . . 71.340000000000003 110.74 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.413 HD12 ' N ' ' A' ' 17' ' ' ILE . 1.6 mp -100.0 -61.75 2.23 Favored 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-O 118.677 -0.677 . . . . 72.209999999999994 110.093 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 67.0 p -106.64 177.25 4.91 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 117.737 -1.125 . . . . 71.430000000000007 110.564 -169.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -137.93 -179.88 6.03 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 118.907 0.776 . . . . 64.030000000000001 112.391 -173.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.08 -179.83 2.07 Favored 'General case' 0 C--N 1.354 0.775 0 CA-C-N 118.505 0.593 . . . . 64.209999999999994 110.63 -168.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.755 0 CA-C-O 118.153 -1.359 . . . . 72.209999999999994 109.968 176.313 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 N-CA-C 110.787 -0.925 . . . . 64.409999999999997 110.787 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -73.53 -162.16 7.42 Favored Glycine 0 C--N 1.353 1.484 0 CA-C-O 118.834 -0.981 . . . . 55.100000000000001 111.851 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -111.94 39.83 2.3 Favored 'General case' 0 C--N 1.356 0.866 0 CA-C-N 117.804 0.802 . . . . 71.439999999999998 109.753 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.1 -145.52 3.17 Favored Glycine 0 C--N 1.354 1.545 0 CA-C-O 118.549 -1.14 . . . . 61.140000000000001 112.751 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 59.5 m80 -114.99 -23.05 9.26 Favored 'General case' 0 C--N 1.359 0.993 0 CA-C-N 117.572 0.686 . . . . 74.109999999999999 110.893 -169.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.2 t -110.76 136.47 20.7 Favored Pre-proline 0 C--N 1.361 1.096 0 O-C-N 119.306 -2.121 . . . . 73.340000000000003 106.694 -172.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.44 152.63 65.92 Favored 'Trans proline' 0 C--N 1.358 1.077 0 CA-C-N 123.776 2.384 . . . . 72.450000000000003 112.839 -174.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -83.95 -41.33 17.46 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 118.687 -0.673 . . . . 74.299999999999997 109.794 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -146.46 173.8 11.96 Favored 'General case' 0 C--N 1.353 0.738 0 CA-C-O 117.566 -1.207 . . . . 72.109999999999999 109.177 -178.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -128.67 144.1 51.09 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-O 118.147 -0.93 . . . . 74.439999999999998 110.917 179.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -105.2 164.97 3.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.917 0 O-C-N 124.117 0.886 . . . . 60.229999999999997 111.1 177.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.582 ' N ' HG12 ' A' ' 11' ' ' VAL . 3.6 mtt-85 -77.2 25.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 70.140000000000001 110.88 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.16 -115.36 4.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.719 -0.753 . . . . 41.109999999999999 112.495 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -116.25 -76.0 0.58 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.343 . . . . 65.120000000000005 110.854 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -115.14 156.77 45.0 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.659 0.742 . . . . 53.340000000000003 110.913 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -79.48 178.47 7.34 Favored 'Trans proline' 0 C--N 1.365 1.404 0 O-C-N 118.454 -1.393 . . . . 51.210000000000001 110.194 -179.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.8 mm -109.25 -57.16 4.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 CA-C-O 118.138 -0.934 . . . . 65.099999999999994 112.036 -172.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 77.9 p -103.54 176.18 5.24 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 117.767 -1.111 . . . . 74.430000000000007 110.047 -172.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -138.68 178.62 7.01 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-N 118.916 0.78 . . . . 63.119999999999997 112.208 -173.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -69.9 178.28 2.74 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-N 118.555 0.616 . . . . 71.430000000000007 110.557 -168.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.259 1.718 0 CA-C-O 118.169 -1.351 . . . . 30.109999999999999 109.876 176.484 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 110.202 -1.159 . . . . 55.240000000000002 110.202 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.03 -161.75 13.82 Favored Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.513 -1.16 . . . . 63.399999999999999 110.961 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.39 43.22 1.2 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.01 0.905 . . . . 53.109999999999999 109.393 178.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -150.24 3.0 Favored Glycine 0 C--N 1.352 1.457 0 CA-C-O 118.896 -0.947 . . . . 74.140000000000001 112.674 179.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.6 m170 -113.56 -22.33 10.36 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.32 0.648 . . . . 73.340000000000003 110.854 -171.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.2 t -111.67 136.36 21.1 Favored Pre-proline 0 C--N 1.362 1.116 0 O-C-N 119.264 -2.147 . . . . 64.349999999999994 106.632 -172.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.01 152.72 63.1 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 123.796 2.391 . . . . 73.439999999999998 112.865 -174.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -82.5 -43.64 16.93 Favored 'General case' 0 C--N 1.353 0.756 0 CA-C-O 118.715 -0.66 . . . . 74.310000000000002 109.52 178.143 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -143.68 176.48 9.19 Favored 'General case' 0 C--N 1.353 0.733 0 CA-C-O 117.592 -1.194 . . . . 71.510000000000005 109.02 -176.201 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -131.69 143.62 50.41 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.164 -0.922 . . . . 72.129999999999995 110.872 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 12' ' ' ARG . 22.0 t -104.41 165.08 3.55 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 O-C-N 124.019 0.824 . . . . 65.310000000000002 111.137 177.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.587 ' N ' HG12 ' A' ' 11' ' ' VAL . 61.2 mtp180 -76.9 25.71 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 73.530000000000001 110.903 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.437 ' H ' ' C ' ' A' ' 11' ' ' VAL . . . -103.14 -115.72 4.1 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.776 -0.726 . . . . 63.130000000000003 112.489 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -116.06 -76.15 0.58 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.875 0.369 . . . . 65.219999999999999 110.876 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -115.11 155.96 46.0 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.67 0.747 . . . . 72.329999999999998 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -78.85 179.69 6.26 Favored 'Trans proline' 0 C--N 1.366 1.478 0 O-C-N 118.53 -1.353 . . . . 70.040000000000006 111.108 -176.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 76.0 mt -107.8 -62.95 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 CA-C-O 118.07 -0.967 . . . . 53.409999999999997 111.257 -171.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 63.5 p -97.94 175.67 6.05 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.857 -1.068 . . . . 50.240000000000002 110.344 -172.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -136.9 176.15 8.97 Favored 'General case' 0 C--N 1.359 0.98 0 CA-C-O 118.718 -0.658 . . . . 74.340000000000003 111.711 -177.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -67.77 -177.09 0.73 Allowed 'General case' 0 C--N 1.353 0.746 0 CA-C-N 118.601 0.637 . . . . 71.319999999999993 110.305 -168.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.26 1.753 0 CA-C-O 117.763 -1.576 . . . . 64.450000000000003 109.751 179.069 . . . . . . . . 0 0 . 1 stop_ save_